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ABSTRACT 
Since the first cases were reported over thirty years ago, great strides have been 
made to control disease progression in people living with HIV/AIDS. However, current 
estimates report that there are about 34 million individuals infected with HIV worldwide. 
Critical in the ongoing fight against this pandemic is the continuing development of 
highly active anti-retroviral therapies, ideally those with novel mechanisms of action. 
Currently, there are no medications approved for use that exploit the HIV-1 MA protein, 
despite its central role in multiple stages of the virus life cycle.  
This thesis sought to examine whether a highly conserved glutamate residue at 
position 99 in the understudied C-terminal helix of MA is required for HIV-1 replication. 
I characterized a panel of mutant viruses that contain different amino acid substitutions at 
this position using viral infectivity studies, virus-cell fusion assays, and immunoblotting. 
In doing so, I found that substitution of this glutamate with either a valine (E99V) or 
lysine (E99K) residue disrupted Env incorporation into nascent HIV particles, and 
abrogated their ability to fuse with target-cell membranes. In determining that the strain 
of HIV could affect the magnitude of E99V-associated defects, I identified a 
compensatory substitution at MA residue 84 that rescued both E99V- and E99K-
associated impairments.  
I further characterized the MA E99V and E99K mutations by truncating HIV Env 
and pseudotyping with heterologous envelope proteins in an attempt to overcome the Env 
incorporation defect. Unexpectedly, I found that facilitating fusion at the plasma 
membrane was not sufficient to reverse the severe impairments in virus infectivity. Using 
vi 
 
quantitative PCR, I determined that an early post-entry step is disrupted in these particles 
that contain the E99V or E99K MA substitutions. However, allowing entry of mutant 
virus particles into cells through an endosomal route conferred a partial rescue in 
infectivity. As the characterization of this post-entry defect was limited by established 
virological methods, I designed a novel technique to analyze post-fusion events in 
retroviral infection. Thus, I present preliminary data regarding the development of a 
novel PCR-based assay that monitors trafficking of the viral reverse transcription 
complex (RTC) in an infected cell.  
The data presented in this thesis indicate that a single residue in MA, E99, has a 
previously unsuspected and key role in multiple facets of HIV-1 MA function. The 
pleiotropic defects that arise from specific substitutions of this amino acid implicate a 
hydrophobic pocket in MA in Env incorporation and an early post-entry function of the 
protein. These findings suggest that this understudied region of MA could be an 
important target in the development of a novel antiretroviral therapy. 
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CHAPTER I: INTRODUCTION 
1.1 The Identification of HIV and the Development of Therapeutics  
In the spring of 1981, physicians in New York and California identified rare 
illnesses in previously healthy gay men (33, 83, 125). It was determined that the immune 
deficiencies exhibited in these patients correlated with a severe depletion of CD4+ T 
lymphocytes and was given the title Gay-Related Immune Deficiency, or GRID, by the 
Centers for Disease Control (CDC) (11, 33). However, this term quickly stigmatized the 
gay community as carriers of the disease even as it became apparent that individuals 
beyond the male homosexual population were also at a heightened risk, such as 
intravenous drug users, hemophiliacs and heterosexuals. The following year, the disease 
was linked to blood, and was renamed Acquired Immune Deficiency Syndrome, or 
AIDS, by the CDC. 
In 1983, Luc Montagnier’s team from the Pasteur Institute in France identified a 
retrovirus as the causative agent of AIDS (9). Soon after, Robert Gallo’s group at the 
National Institute of Health (NIH) published more evidence confirming the link between 
this novel human retrovirus and AIDS (78). The virus was given the name Human 
Immunodeficiency Virus (HIV). The first diagnostic blood test was developed and 
approved in 1985, enabling hospitals to screen the blood supply for HIV (132). As the 
disease- now an epidemic- continued to spread, a glimmer of hope finally appeared in 
1987 when the first anti-HIV therapeutic, a nucleoside analog called AZT, was developed 
and approved for use. Unfortunately, optimism faded when doctors quickly recognized 
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that AZT monotherapy was futile, as AZT-resistant strains emerged soon after patients 
took the drug (156). 
Things began to improve again in 1995, when Saquinavir- the first of a new 
antiretroviral drug class, the Protease Inhibitors, was developed. The following year, the 
first non-nucleoside reverse transcriptase inhibitor, Nevirapine, was approved for use in 
the US. Physicians soon recognized that the prognosis of HIV-infected patients rapidly 
improved when the new classes of drugs were used in combination. Thus, a new era in 
HIV treatment began when doctors recommended that patients receive a cocktail of three 
antiretroviral drugs, in a regimen referred to as Highly Active Antiretroviral Therapy 
(HAART) (156). This new approach proved to be very efficacious, and its significance 
became evident in 1997 when the CDC reported that for the first time since the early 
1980’s, the incidence of HIV and annual AIDS deaths had declined in the US (156). 
Globally, however, the pandemic was still on the rise, as 22 million people around the 
world were living with HIV and 3.2 million individuals were newly infected in that year 
alone (196).  
By 2001, AIDS was determined to be the leading cause of death in sub-Saharan 
Africa (135, 196). Of the 21 million deaths that were attributed to AIDS around the 
globe, 17 million were from this region of Africa (196). In an effort to bring some relief 
to this area of the world, European drug companies began to manufacture and distribute 
less expensive, generic versions of HIV medications. Despite the impact made through 
this relief effort, scientists recognized that the real breakthrough in combating the AIDS 
pandemic would be in the development of an anti-HIV vaccine. Efforts to develop an 
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effective vaccine were underway, but unfortunately the first large-scale clinical trial of an 
AIDS vaccine, AIDSVAX, failed in 2003. Studies revealed that it did not reduce the 
incidence of HIV infection in more than 2,000 intravenous drug users who volunteered 
for the trial (112, 187).  
The next big advancement in HIV therapy came in 2006 with the approval of 
Atripla, the first once-a-day HIV treatment option. Atripla consisted of three medications 
from two different classes of anti-retrovirals in a single pill, and its use eased the burden 
of complicated drug regimens that many patients previously had to endure. However, 
progress in HIV vaccine development continued to stall when testing for another major 
HIV vaccine candidate, the STEP trial, was abruptly terminated (199). The data revealed 
that administration of the vaccine conferred no benefit, and that unfortunately the 
adenovirus vector used to deliver the HIV antigens might have even enhanced 
susceptibility to HIV infection in some of the trial participants (185). Nonetheless, 
promising findings regarding an HIV vaccine candidate finally came in 2009 with the 
RV114 trial conducted in Thailand. This vaccine utilized a canary pox vector expressing 
HIV genes in conjunction with a recombinant HIV envelope glycoprotein. Modest 
efficacy was observed after three years, as participants receiving the vaccine were found 
to have a lowered rate of HIV infection by 31.2% compared to unvaccinated control 
subjects (112, 169). 
Amazingly, recent reports suggest that a blood stem cell transplant may have 
cured the first person ever of AIDS (121). This approach utilizes a rare mutation 
(CCR5∆32) in the human gene that encodes a co-receptor required by HIV for entry into 
  
4 
host cells. This mutation, present in only 1% of Caucasians, is believed to provide a 
natural resistance to HIV infection (96). San Francisco native Timothy Ray Brown lived 
for 11 years with HIV before he was diagnosed with Leukemia in 2006. The following 
year, doctors located an individual who was not only a tissue match for Brown, but who 
also had this rare CCR5 mutation. Brown underwent a risky blood stem cell transplant, 
and although his cancer came back a year later, his HIV did not. Today, Brown no longer 
receives any antiretroviral treatment and HIV has not been detected in any of his tissues. 
While this method would be impractical in widespread use, it is a remarkable proof of 
concept that may be used to manage disease in those living with HIV, or possibly even 
lead to a cure (121). 
This past June marked the 30th anniversary of the first reported cases of AIDS. 
Considerable progress has been made, as the use of HAART has enabled HIV patients to 
live for decades before developing AIDS, and mother to child transmission has been 
reduced from 25% thirty years ago, to less than 3% today (196). However, the HIV/AIDS 
pandemic has taken the lives of nearly 30 million people worldwide, and there are about 
34 million individuals that currently live with the disease (196). Patients continue to 
endure devastating side effects that are associated with existing medications and drug-
resistant strains often emerge in those unable to tolerate the strict drug adherence 
protocols. Thus, without an effective vaccine in sight, the development of new anti-HIV 
drugs remains critical. 
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1.2  HIV Infection and Disease Progression 
Two types of HIV exist in the world, HIV-1 and HIV-2. HIV-2 is concentrated in 
West Africa, and appears to be less easily transmitted than HIV-1 (37). HIV-1, on the 
other hand, is the predominant strain and associated with a shorter time between initial 
infection and illness. Despite these differences, the overall pattern of virus replication 
kinetics and CD4+ T-cell depletion is similar in infected individuals, and both types 
cause clinically indistinguishable AIDS (85). The immunologic and virologic events that 
are associated with the acute, chronic and AIDS phases of an average HIV infection is 
illustrated in Figure 1.1. 
The acute phase of an HIV infection refers to the period between primary 
exposure to the virus and completion of the initial immune responses. Upon entry into a 
host, the virus is quickly disseminated throughout the body and seeds the lymphoid 
tissues. The number of virus particles circulating in the bloodstream is usually highest 
between 2 and 4 weeks post-exposure, and patients are highly infectious during this phase 
(85). This massive viremia induces a rapid CD4+ T lymphocyte depletion, with immune 
cells of the mucosa being the most affected target (130). While approximately 70% of 
patients develop a flu-like illness, routine tests for HIV antibodies often fail during this 
time (85).  Consequently, most cases are either undiagnosed or misdiagnosed in the acute 
phase. The length of this phase varies, depending on the individual and HIV strain. 
Normally, symptoms resolve between a week and a few months (85).  
Once an immune response is generated, the infection enters the clinical latency 
period. During this time, CD4+ T cell counts increase and although they may rebound to 
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80-90% of its original level, gut-associated CD4+ T-cell depletion never fully recovers 
(85, 130). Still, patients may be asymptomatic during the latency phase since the overall 
immune system remains sufficiently intact to prevent most other infections. The viremia 
is also resolved to some extent, as plasma levels can drop below the limit of detection. 
However, immune responses do not suppress viral replication completely; HIV continues 
to persist in the lymphoid organs and other reservoirs even in the presence of high 
antibody titers (3, 85). The extent of viremia associated with this asymptomatic phase is 
referred to as the viral set point, and oftentimes disease progression parallels that of the 
viral load after the immune response (85).  
The ability of the virus to evade host immune responses is in part a consequence 
of its high mutation rate. Indeed, recombination events and mistakes made by the reverse 
transcriptase enzyme cause many different variants, or quasi-species, of HIV to develop 
in an individual. Since long-lived cells are infected, these variants persist throughout the 
course of infection. It has been estimated that billions of new HIV virions are produced 
and destroyed daily (85). In an attempt to keep virus replication at bay, the immune 
system produces CD4+ cells at 10 to 100 times the normal rate (85). Such chronic 
immune activation imposes a significant strain on the maintenance of new CD4+ cells. In 
many patients, this latent phase lasts for 7 to 11 years (37).  
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Figure 1.1 Kinetics of immunologic and virologic events associated with HIV 
infection during the acute, chronic and AIDS phases. (85) A schematic 
representation of changes in mucosal (purple) and blood (blue) CD4+ T-cells, 
virus levels in the blood (green), and immune activation (red) over the course of 
an average HIV infection. During the acute phase, mucosal CD4+ T-cells are 
rapidly lost and virus titers rise sharply. The immune system becomes activated 
and controls viremia to some extent to mark entry into the chronic phase. Blood-
associated CD4+ T-cell counts recover moderately during the chronic phase. The 
immune system remains in a highly active state throughout the course of 
infection. As viremia continues to rise, the regenerative capacity of CD4+ T-cells 
declines and clinical AIDS develops.  
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Eventually, the immune system becomes overwhelmed by the high levels of viral 
replication. The collapse of the immune system leads to the development of clinical 
AIDS, the most advanced stage of disease. AIDS is diagnosed once CD4+ T-cell counts 
have fallen substantially, and is associated with opportunistic infections or cancers that 
do not usually affect healthy individuals (37). Patients can also display a range of 
neurological problems depending on the extent of infection in the brain. Most patients 
diagnosed with clinical AIDS ultimately succumb to the disease within months if not 
treated (3).  
1.3 Overview of HIV-1 Replication 
The replication cycle of HIV-1 is a complex multi-step process, regulated by both 
viral and cellular proteins. Events in the viral life cycle can be divided into early and late 
stages, based on when they occur in relation to viral DNA integration. The HIV 
replication cycle is depicted in Figure 1.2.  
Early events begin with an interaction between the viral surface envelope 
glycoprotein gp120 and the cellular receptor CD4. This CD4 binding induces a 
subsequent interaction with the host CCR5 or CXCR4 co-receptor. A membrane fusion 
reaction is triggered by co-receptor binding, whereby conformational changes in both 
gp120 and the transmembrane glycoprotein gp41 promote fusion of the viral lipid 
envelope and the host plasma membrane (PM) (36, 70). This fusion event delivers the 
viral core into the cytoplasm of the target cell. The HIV core is composed of a capsid 
protein shell that encases the single-stranded, dimeric viral RNA genome and several 
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viral and host proteins (8, 129, 131). The core then associates with cortical actin 
microfilaments of the host cell cytoskeleton, which then promotes core migration through 
the cytoplasm (21). It is believed that further advancement of the complex toward the 
cell’s nucleus occurs through subsequent transfer to the microtubule network (7, 129). 
Dissociation of the capsid shell takes place during an uncoating step and exposes a 
reverse transcription complex (RTC) made up of the genomic RNA, and the viral proteins 
nucleocapsid (NC), reverse transcriptase (RT), integrase (IN), viral protein R (Vpr) and 
matrix (MA) (19, 25, 59). Inside the RTC, genomic RNA is reverse transcribed by RT 
into a double-stranded proviral DNA. The resulting high-molecular weight complex, now 
referred to as the preintegration complex (PIC), is transported across the nuclear envelope 
using the components of the cellular nuclear transport machinery (24, 113). Once in the 
nucleus, IN catalyzes integration of the viral DNA into the host cell genome (57). This 
integration step assures that the proviral HIV-1 endures for the lifetime of the infected 
host cell. 
After the integration step are late events, which begin with transcription of 
integrated proviral DNA. Cellular RNA Polymerase II synthesizes HIV transcripts 
expressed from the promoter located in the 5′ long terminal repeat (LTR) of the proviral 
template. The rate and processivity of transcription is greatly enhanced by the viral 
regulatory protein, Tat (144). There are three classes of viral RNAs- fully spliced, 
partially spliced or unspliced. The latter two forms of mRNAs contain the cis-acting Rev 
Response Element (RRE) that is recognized and bound by the viral Rev protein. By 
shuttling between the nucleus and cytoplasm, Rev mediates the nuclear export of partially 
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spliced or unspliced mRNAs through the cellular nuclear export machinery to the 
cytoplasm (144). HIV-1 particle formation is directed by the expression of viral Gag 
proteins, and requires components of host adaptor protein complexes that control 
endocytic trafficking (12, 51). It has been proposed that full-length viral genomic RNA 
may act as a scaffold along which Gag molecules align and pack (103, 176). Gag 
coordinates the incorporation of each of the viral protein components and viral genomic 
RNA dimers into the assembling particle (64). In most cell types, the components are 
transported to the PM for assembly. However, in macrophages and dendritic cells, viral 
assembly is thought to take place within membranes of an intracellular compartment (13, 
98, 160). Nascent virions are then thought to engage with lipid raft-rich regions of the 
PM before budding into the extracellular environment (15, 29, 95). Release is facilitated 
by a sequence in the p6 domain of Gag, which interacts with host machinery that 
normally functions in membrane fission events (65, 66, 80, 99, 123, 186). During or 
shortly after virus release, the immature spherical virus particle undergoes a morphologic 
change known as maturation. This final step involves proteolytic processing of the Gag 
and Gag-Pol polyproteins by the viral protease to form the condensed, conical core that is 
characteristic of mature infectious HIV-1 virions (39, 166).  
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Figure 1.2 The HIV-1 replication cycle. (81) Events of the HIV-1 life cycle are 
described as early or late, depending on when they occur in relation to the 
integration step. The early steps are depicted in the left panel and include virus 
attachment and entry into a host cell, uncoating of the capsid core, reverse 
transcription of the viral genomic RNA into DNA, its nuclear import, and then 
integration of the viral DNA into the host’s genome. Late events, shown in the 
panel on the right, consist of viral gene transcription, export of fully spliced, 
partially spliced and unspliced mRNA into the cytoplasm, translation, nascent 
particle assembly, budding and release into the extracellular environment and 
finally, particle maturation. A more detailed description of each of these events in 
HIV replication is included in the text. 
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1.4 Overview of HIV-1 Genes 
The genome of HIV-1 is about 9.7 kilobases (Kb) in length and exists as two 
copies of positive, single-stranded RNAs in a typical virus particle. Downstream from a 
5’ long terminal repeat (LTR) are nine open reading frames (ORFs), which encode fifteen 
distinct proteins. A schematic representation of the DNA form of the HIV-1 genome is 
depicted in Figure 1.3. Exhibiting a multitude of activities, these proteins can be 
categorized into four groups based on their individual functions: structural, enzymatic, 
regulatory, and accessory proteins.  
1.4.1 The Structural Proteins 
Gag and Envelope (Env) are the HIV-1 structural proteins and are initially 
expressed as polyproteins in an infected cell. Proteolytic cleavage of these precursors 
occurs through different mechanisms, and are necessary events in the production of 
infectious particles. The Pr55gag polyprotein (Gag) is comprised of distinct structural and 
functional domains that are essential in the virus life cycle (reviewed in ref. 64). During 
late events, Gag exists in the 55 kilodalton (kDa) precursor form and is cleaved by the 
viral protease upon particle maturation. This processing step yields the matrix (MA/p17), 
capsid (CA/p24), and nucleocapsid (NC/p7) proteins, as well as p6 and two additional 
spacer peptides, p1 and p2.  
My thesis research focuses on MA, which is encoded by the N-terminal 132 
residues of Gag, and later processed into a mature 17 kDa form. MA is best characterized 
by its roles in assembly, where it directs Gag to the cellular membrane and facilitates the 
incorporation of envelope glycoproteins into nascent virions. Upon cleavage, a small 
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subset of MA molecules is selectively phosphorylated, and is though to participate in 
early events. A more in depth analysis of MA structure and functions is included in 
section 1.5. 
Downstream of MA is the CA domain of Gag. CA is critical in virus assembly by 
its contribution to Gag-Gag interactions, and packaging of Gag-Pol precursors and host 
cyclophilin A (CypA) proteins into nascent particles. By forming a protective shell 
around the viral RNA genome (gRNA) and core-associated proteins, CA molecules 
facilitate optimal delivery of the HIV-1 genome into target cells and promote efficient 
reverse transcription. 
The next Gag domain is the NC sequence, which has several important functions 
in virus assembly. By associating with gRNA, NC directs its dimerization and 
incorporation into particles. As part of Gag, it also promotes the tight packing of Gag 
molecules, membrane binding, and virus release. Following cleavage from the Gag 
precursor, NC is released from the other structural proteins and participates in early 
events by stimulating reverse transcription and stabilizing the PIC (64). 
P6 makes up the C-terminal portion of Gag and participates in assembly by 
incorporating the accessory protein Vpr into virus particles. A Pro-Thr-Ala-Pro-Pro 
(PTAP) sequence near the N-terminus of the domain promotes virus release into the 
extracellular environment by engaging with Tsg101 and other host proteins (65). 
Env is the other main structural gene of HIV-1, and it is synthesized as a 160 kDa 
precursor (gp160) on ribosomes associated with the endoplasmic reticulum (ER) 
(reviewed in ref. 70). The envelope polyproteins are co-translationally glycosylated, and 
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then oligomerized into trimers before transport from the ER to the Golgi complex. Once 
in the Golgi, gp160 is proteolytically cleaved by a cellular enzyme, which generates the 
mature glycoproteins gp120 and gp41. This processing step is essential for transport to 
the PM, however little is known about how Env is transported from the Golgi network to 
the cell surface (15). Both gp120 and gp41 are maintained in the assembled Env trimers 
through non-covalent interactions. 
The surface glycoprotein gp120 is responsible for receptor and co-receptor 
binding onto the target cell. The protein has five variable regions (V1 through V5) that 
are well exposed on the surface of the molecule (70, 162). Interspersed between these 
variable loops are five conserved regions that fold into the gp120 core. While elements 
from both the core and surface domains contribute to CD4 binding, the attachment to 
chemokine receptors is mainly governed by sequences in the gp120 V3 region. 
The gp41 glycoprotein catalyzes virus-cell membrane fusion events. It is made up 
of an ectodomain that is largely responsible for trimerization and fusion, a membrane-
spanning anchor (TM), and a cytoplasmic tail domain (CT). A striking feature of 
lentiviruses is the extended length of the gp41 CT, which is generally about five times 
longer than those of avian and murine retroviruses (64, 90). The CT of HIV-1 gp41 is 
necessary for recruitment by the MA region of Gag during particle assembly (40, 53, 71, 
115, 153). Some evidence also suggests that the CT is important in virus infectivity, 
however, this function appears to be cell-type dependent (70, 162.)  
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1.4.2 The Enzymatic Proteins 
The pol gene resides downstream of the gag gene, and a negative ribosomal 
frameshift error which occurs during 5% of all Gag translation events, leads to its 
synthesis as part of a Gag-Pol precursor protein (Pr160). Encoded in the pol gene are 
three viral enzymes: protease (PR), reverse transcriptase (RT) and integrase (IN). All of 
these proteins provide essential enzymatic functions, and therefore, each of their 
activities has been used as targets for anti-HIV therapies (reviewed in ref. 94). 
Structural studies of PR reveal that it must dimerize to form the protein’s active 
site (143). Dimerization of the identical PR subunits is concentration dependent and 
favored during virion assembly. The first substrate of PR is likely to be itself so that it 
can be released and continue cleaving the Gag and Gag-Pol precursors. Processing of 
these polyproteins by PR is the main event in virion maturation, and precipitates a 
morphological change in the particle that is required for virus infectivity.  
The RT gene comes after the protease domain in pol, and encodes an RNA-
dependent DNA polymerase (reviewed in ref. 82). During the early stages of the viral life 
cycle, RT generates double-stranded proviral DNAs from the single-stranded viral RNA 
genomes. The active form of HIV-1 RT is made up of two chains, referred to as p51 and 
p66. While p51 has a mainly structural function, p66 contains the catalytic site for DNA 
polymerization. For reverse transcription to occur, the RNA template, primer, two 
divalent cations, and dNTPs must localize to a cavity within p66, formed by the protein’s 
fingers, palm, and thumb subdomains (82). The p66 chain also has an RNase H activity 
that cleaves the genomic RNA template while it is still hybridized to DNA during double-
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stranded DNA synthesis. HIV-1 RT is regarded as an error prone polymerase, as it 
exhibits no exonucleolytic proofreading activity. 
Integrase (IN) makes up the C-terminal region of the Gag-Pol proteins (reviewed 
in ref. 57). During maturation, IN is cleaved into its 32 kDa mature form and associates 
with the viral core. Following nuclear import, IN carries out the first two steps required 
for integration of the double-stranded viral DNA into the host genome. First, IN cleaves 
the blunt ends of the viral DNA to form an active intermediate. Next is the strand-transfer 
step, where the processed ends of the viral DNA are inserted into one of the cell’s 
chromosomes. This step is also carried out by IN, and assisted by LEDGF/p75, which 
tethers IN to chromatin, and several other host cofactors (182). Finally, host machinery 
fills the gaps at the 5’-ends of the viral DNA to complete the integration process. 
1.4.3 The Regulatory Proteins 
Two regulatory proteins, Tat and Rev, make up the next class of HIV-1 gene 
products. The efficient expression of most viral proteins is dependent on these two 
proteins, and therefore both factors are indispensable in HIV-1 replication. 
The transcriptional transactivator (Tat) is one of the earliest viral proteins 
expressed in an infected cell, and is essential for synthesis of full-length transcripts from 
the HIV-1 provirus (reviewed in ref. 144). By binding to the transactivation response 
(TAR) element at the 5′ end of nascent HIV-1 mRNAs, Tat recruits a host factor called P-
TEFb. This interaction then signals a cyclin T1/CDK9 complex to hypo-phosphorylate 
the C-terminal domain of RNA polymerase II (Pol II), stimulating LTR-directed 
transcriptional elongation.  
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The regulatory Rev protein encodes two functional domains, an arginine-rich 
nuclear localization signal (NLS) and a leucine-rich nuclear exporting signal (NES) 
(144). These regions are essential for the protein’s nucleocytoplasmic shuttling activity. 
Rev binds to the Rev responsive element (RRE) present in unspliced and partially spliced 
viral transcripts through its arginine rich motif. Using an interaction with Ran GTP, Rev 
directs the export of gag-pol and env mRNAs from the nucleus to the cytoplasm. 
1.4.4 The Accessory Proteins  
The final category of HIV-1 gene products include the “accessory” proteins, a 
term given because their absence in proviral clones has little bearing on viral replication 
in cell cultures. However, recent studies have uncovered that, in vivo, they are key 
determinants for HIV virulence (194). These proteins are called viral infectivity factor 
(Vif), viral protein u (Vpu), viral protein r (Vpr) and negative factor (Nef).  
Vif is a late gene product present in most lentiviruses that counteracts the antiviral 
effects of the human restriction factor, apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide-like 3G (APOBEC3G) (178). APOBEC3G is a cytosine deanimase that, in 
the absence of Vif, is incorporated into nascent virus particles. If packaged, this host 
protein converts cytosine (C) residues in minus-strand reverse transcripts of the viral 
genome into uracil (U) residues. During reverse transcription, RT registers this change as 
a thymine (T), resulting in guanine (G) to adenine (A) hypermutations in the viral 
genome. Vif effectively antagonizes the antiviral effects of APOBEC3G in the majority 
of wild-type viral infections, through the recruitment of a ubiquitin ligase that induces the 
polyubiquitylation and degradation of both APOBEC3G and Vif.  
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The Vpu gene product is translated from a bicistronic mRNA that also contains 
the env open reading frame. As an integral membrane phosphoprotein, it associates 
mainly with the internal membranes of the cell and carries a dual function. First, it down-
regulates intracellular CD4 expression, which is thought to increase the infectivity of 
HIV-1 virions by enhancing the intracellular transport and maturation of Env. Second, 
Vpu is reported to counteract the antiviral activity of host protein B cell stromal factor 2 
(BST-2) or tetherin (54). In the absence of Vpu, tetherin prevents virus egress, and as a 
result, particles accumulate at the exterior of the cell or are transported to endosomes.  
The mechanism by which tetherin prevents virion release is not yet clear, but it has been 
suggested to involve linking cholesterol-rich lipid rafts together on the PM (54). It has 
been proposed that Vpu counteracts this restriction factor by altering tetherin trafficking 
between different cytoplasmic sites (54, 117). By interfering with the antiviral activity of 
tetherin, Vpu enhances the release of budded particles from the surface of HIV-1 infected 
cells. 
Nef is a myristoylated protein that is a critical determinant of pathogenicity and 
disease progression in vivo (reviewed in ref. 117). One of the first viral proteins to be 
expressed following infection, Nef enhances virus infection with at least three activities. 
First, it triggers the rapid endocytosis and lysosomal degradation of CD4 and major 
histocompatibility complex I (MHC-I). Reducing the surface expression of these 
molecules may diminish Env interference with CD4, and help infected cells evade 
detection by the host immune system, respectively. Second, Nef alters T-cell activation 
pathways, possibly to safeguard against host immunity, which could extend virus 
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production and long-term persistence. Lastly, minimal amounts of Nef are detected in 
HIV-1 particles, where they are thought to enhance the initial phases of infection. Its 
precise roles in early events have yet to be defined, but Nef may assist the core 
penetrating in the cortical actin network, and stimulate proviral DNA synthesis during 
reverse transcription.  
Finally, Vpr is thought to promote virus replication by altering various factors in 
the cellular environment. Vpr is packaged into HIV-1 particles through an interaction 
with the p6 region of Gag, potentially facilitating the infection of macrophages (117). 
This mechanism might involve connecting the PIC with the cell nuclear-import pathway, 
or by stimulating transcription from some cellular promoters. Also, Vpr arrests cells in 
the G2 phase of the cell cycle, which may enhance viral transcription by exploiting the 
phase associated with the most active host machinery (117). However, this activity has 
been linked to an enhancement of cell death, and could simply be a consequence of the 
destruction of an unidentified host protein. 
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Figure 1.3 Genomic map of HIV-1. (41) The HIV-1 genome comprises nine 
genes and is flanked by long terminal repeat sequences (LTRs) in its proviral 
form. Fifteen different proteins are expressed from these nine genes, and each is 
necessary for HIV disease pathogenesis. gag and env make up the structural 
genes. pol encodes the enzymatic genes. tat and rev comprise the regulatory 
proteins. And the remaining genes vif, vpr, vpu and nef, encode the HIV-1 
accessory proteins. The individual roles of these gene products are described in 
the text.  
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1.5 MA in the HIV-1 Life Cycle 
Although variable in sequence, Gag proteins of most retroviruses encode a matrix 
domain that functions to anchor the viral Gag to the PM at a step during particle assembly 
(reviewed in ref. 90). Certain retroviruses, referred to as type C, form and bud 
simultaneously at the membrane. Lentiviruses such as HIV, and mammalian and avian 
retroviruses, are examples of type C viruses. Other retroviruses, referred to as type B and 
D, fully assemble as a core particle within the cytoplasm before budding from the 
membrane. Such examples include the mouse mammary tumor virus (MMTV) and the 
Mason-Pfizer monkey virus (M-PMV), respectively. Interestingly, the sequences within 
matrix domains that determine assembly localization are very subtle, since a single point 
mutation is able to change the assembly of a type D virus into that of a type C virus 
(171).  
The structures of retroviral Matrix proteins (MA) are predominantly composed of 
closely packed α-helices (39). Many retroviral Gag proteins are co-translationally 
myristoylated at its N-terminal glycine. Myristic acid is a 14-carbon saturated fatty acid 
that anchor into the PM and plays a key role in Gag trafficking. However, MA regions of 
some retroviral Gag proteins, such as Rous sarcoma virus (RSV), Visna virus, caprine 
arthritis-encephalitis virus (CAEV) and equine infectious anemia virus (EIAV), are not 
myristoylated. Instead, the high membrane affinity of Gag is conferred by an exposed 
patch of basic amino acids situated within the MA domain that interacts with membrane-
associated acidic phospholipids. Nonetheless, the membrane targeting and binding 
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properties of most retroviral Gag proteins are coordinated by both a myristoyl moiety and 
polybasic motif in MA.   
The HIV-1 MA protein is synthesized as part of a 55 kDa precursor protein 
encoded by the HIV-1 gag gene. As a domain of Gag, MA is critical in coordinating late 
events in the virus replication cycle. Gag proteins are processed during virus maturation, 
and MA is released as a mature 17 kDa protein that can interact with the viral core and 
potentially participate in early events. Both Nuclear Magnetic Resonance (NMR) and X-
ray crystallographic approaches have been used to determine the three-dimensional 
structure of the 17 kDa HIV-1 MA protein (39, 93, 124). These studies have revealed that 
of the 132 residues in MA, the first 95 make up of four major α-helices and a three-
stranded mixed β-sheet that come together, forming a compact globular core domain. 
Residues 96 through 121 create a fifth, C-terminal helix that projects away from the 
globular head (93, 124). The remaining C-terminal residues are relatively unstructured 
and likely serve as a spacer region between the MA and CA domains of Gag (93). 
Interestingly, the helical topology of HIV-1 MA shares a striking similarity to the 
immune modulator interferon gamma (IFN-γ), and it has been suggested that MA may act 
as a viral cytokine in vivo (44, 62, 126). A ribbon diagram depicting the structure of HIV-
1 MA, is shown in Figure 1.4A. The many roles of HIV-1 MA, during late and early 
events of the HIV-1 life cycle, and also as a potential virokine, are outlined in the 
following sections. 
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Figure 1.4 Ribbon diagrams of HIV-1 MA. (93) (A) A depiction of the MA 
monomer. The structure of MA consists of five major α-helices and a mixed β-
sheet. The first four helices (1-4, shown in magenta, green, blue and red, 
respectively) come together to form a compact globular core domain that is 
capped by the mixed β-sheet (maroon). The fourth helix, buried within the 
hydrophobic core, is important in maintaining the overall structure of the core 
domain. The C-terminal fifth α-helix (shown in yellow), projects away from the 
others. (B) An HIV-1 MA trimer and its proposed orientation on the plasma 
membrane. MA favors the trimer formation when expressed in the context of the 
Gag polyprotein. An N-terminal myristate moiety (shown in red) acts in concert 
with essential basic residues (magenta) to promote membrane binding of MA 
trimers. Additional basic residues not required for membrane binding (shown in 
green) are distributed throughout the protein.  
B 
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1.5.1 HIV-1 MA in Late Events  
As in many other retroviruses, the N-terminal MA domain of HIV-1 Gag provides 
the membrane-targeting signals that are critical for late events of the virus life cycle. The 
high membrane affinity of HIV-1 Gag is conferred by a bipartite signal consisting of a 
myristoyl moiety and a polybasic region located on one side of the MA globular head 
domain. The myristic acid is covalently attachment to the N-terminal glycine residue of 
MA during translation. The positively charged motif is formed by a highly basic domain, 
encoded by MA residues 18 through 32, that comes together with other basic amino acids 
of MA in the tertiary structure of the protein (93). MA molecules trimerize in solution to 
form a large membrane-binding surface, whereby the bipartite signals is able to facilitate 
interactions between Gag and the PM. This association of MA trimers with the PM, as 
depicted in Figure 1.4B, is necessary for HIV-1 particle production in most cell types (64, 
138). The importance of this bipartite signal in HIV-1 has been demonstrated by several 
mutational studies. For example, substitutions of MA residues required for 
myristoylation, namely 2G, 3A, 4R, or 5A, (20, 84, 136, 184), as well as mutating the 
basic amino acids K18, R20, K26, K27 or K30 (69, 72, 150, 177) which are part of the 
protein’s positively charged motif, each cause a marked decrease in HIV-1 particle 
production. However, it is likely that specific trafficking machineries are also responsible 
for Gag transport within cellular compartments. This involvement is likely because HIV-
1 viral assembly takes place at the limiting membrane of an intracellular compartment in 
macrophages and dendritic cells, rather than at the PM (13, 51, 146, 147, 160). Thus, the 
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cooperative membrane targeting by the myristate moiety and basic domain of HIV-1 MA 
might be cell-type specific.  
It has been proposed that some of the basic residues in MA may dictate the 
specificity of the bound lipid, since particular substitutions have resulted in a re-targeting 
of Gag to other intracellular membranes (147, 175). Such aberrant Gag trafficking also 
occurs in HIV-1 infected cells when membrane-bound PI(4,5)P2 is depleted by the over-
expression of proteins involved in phospholipid metabolism (4). PI(4,5)P2 is an acidic 
phospholipid that is predominantly localized on the inner leaflet of the PM and likely 
associates with MA during HIV assembly. Direct interactions between HIV-1 MA and 
PI(4,5)P2 have been observed in vitro by both NMR spectroscopy (175) and mass 
spectrometric protein footprinting (181). The MA residues involved in the PI(4,5)P2 
interaction have been previously implicated in RNA binding during assembly, however it 
was also observed that PI(4,5)P2 was the only lipid that could remove nucleic acids 
bound to basic residues on recombinant HIV-1 MA proteins (5).  
Mutations in MA other than basic amino acid substitutions have also been shown 
to re-target Gag to different membranes in the cell. For example, single amino acid 
substitutions at positions 85 through 89 have been associated with the re-direction of 
particle assembly from the PM to intracellular compartments, such as the Golgi or Golgi-
derived vesicles (72).  Also, deletion of a large region in MA re-targeted virus formation 
to the ER (58, 77). It is believed that these mutations may act by specifically disrupting a 
PM targeting signal, or by creating a novel re-targeting signal (90).   
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In general, any mutation that prevents the correct folding or multimerization of 
MA is also likely to inhibit particle assembly (30). For example, substitutions of residues 
at the proposed trimer interface of HIV-1 MA (L64, T70, E74) resulted in inefficient 
assembly (30, 39, 137). Particle production was also disrupted when MA residues 56 
through 60 were mutated, and is likely related to a diminution in the half-life of Gag 
proteins (72). However, a most intriguing observation was that particles were still 
generated when the entire MA sequence was replaced with a heterologous membrane-
binding domain (168). In this study, assembly was observed at both the plasma and 
intracellular membranes. One explanation for this phenomenon is that certain MA 
mutations might exert a dominant-negative effect on the function of Gag that is not seen 
in the absence of MA (150).  
Besides Gag targeting, MA is also involved in the incorporation of particular viral 
components into nascent virions during assembly. For example, an RNA binding region 
in the MA basic domain can facilitate packaging of genomic viral RNA into particles in 
the absence of NC (64). In addition, the incorporation of Env glycoproteins into newly 
assembled virus is dependent on MA. Results from several different studies have 
demonstrated that HIV-1 Env packaging is mediated through an interaction between MA 
and the cytoplasmic tail (CT) of gp41. First, MA mutants that impaired Env incorporation 
could be rescued by compensatory changes in the gp41 CT (69, 118, 141, 204). Second, 
the expression of HIV-1 Env in trans targeted HIV-1 budding to the basolateral surfaces 
of polarized epithelial cells. This selective budding site was dependent on the gp41 CT 
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and could be blocked by mutations in MA (115, 153). Finally, an in vitro study detected a 
direct interaction between HIV-1 MA and gp41 (40).  
However, in an apparent contradiction, truncation of the entire gp41 cytoplasmic 
tail does not block Env incorporation, and heterologous retroviral glycoproteins can be 
efficiently incorporated into HIV-1 particles (reviewed in ref. 70). This discrepancy has 
been resolved in part by the observation that single amino substitutions in MA which 
block the incorporation of full length HIV-1 Env into particles do not inhibit the 
packaging of truncated HIV-1 Env glycoproteins (69, 118). Thus, it appears that while 
the inclusion of virus envelopes with short cytoplasmic tails occurs independently of MA, 
incorporation of full length HIV-1 Env into HIV-1 particles requires a specific interaction 
with, or at least a modification by MA. It has been suggested that during assembly, MA 
trimers form a lattice structure containing an arrangement of spaces large enough to 
accommodate the cytoplasmic tails of gp41 (93, 165). In line with this model, several 
point mutations within MA that disrupt Env incorporation reside within these putative 
holes that could potentially interact with the cytoplasmic domains of Env (69, 71).  
Most of the single amino acid substitutions that abrogate Env incorporation into 
particles, namely G11R, L13E, W16A, L30E, V34E or A37P, are located at N-terminal 
residues of MA (14, 31, 68, 69, 111, 141, 150, 155, 207, 214). However, functional 
analyses of viruses with in-frame MA deletions suggest that regions throughout the 
protein are involved in Env incorporation, not just N-terminal sequences. For example, 
deletion of MA residues 27 through 30, 63 through 65, 77 through 80, or 98 through 100, 
results in the production of Env-deficient particles (52). Also, in a recent study, 
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researchers found that the L50D substitution in MA conferred a selective reduction in 
particle-associated gp120, without diminishing the levels of incorporated gp41 (43). 
Altogether, these findings suggest that regions throughout the entire globular core of MA 
are involved in HIV-1 Env incorporation, and that some might be required for stabilizing 
gp41-gp120 complexes.  
Currently, the initial site of this putative MA-Env interaction is unknown. It is 
widely believed that cellular cofactors help facilitate HIV-1 Env incorporation, and that 
identification of such cofactors could provide insight into the cellular location hosting the 
initial MA-Env encounter (51, 90). TIP47 is a cytosolic protein required for the 
retrograde transport of certain proteins from late endosomes to the trans-Golgi network 
(TGN), and has been shown to form a ternary complex with the MA domain of Gag and 
the TM of Env (16, 49, 116). The TIP47-MA interaction was abolished by mutations of 
MA residues W15 and E16, which interestingly, also impaired Env incorporation into 
HIV-1 particles (116). These particular MA residues are located within a region of MA 
previously implicated to associate with the AP3 adaptor complex (51). AP3 is host 
trafficking machinery that localizes to the TGN and peripheral endosomal compartments. 
Disruption of the MA-AP3 interaction has been shown to drastically diminish particle 
assembly (47, 51). These results suggest that Gag could associate with Env and TIP47 on 
endosomal compartments (90).  
During assembly, both Gag and Env associate with concentrated microdomains of 
specific lipids on membranes called lipid rafts (50, 114). Often made up of cholesterol, 
sphingolipids and membrane proteins, these domains may be platforms for signal 
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transduction and cell activation (6). HIV-1 particles bud preferentially through these raft 
microdomains of the PM, and HIV-1 viral membranes have an unusually high cholesterol 
and sphingomeylin content (6, 29, 89, 146, 148, 149). Other studies have shown that 
cholesterol depletion from producer cell membranes impairs Gag multimerization, and 
significantly reduces the production of HIV-1 viral particles (86, 147, 152, 175, 181). It 
has been proposed that the initial docking of Gag at the PM is followed by lateral 
transport to lipid rafts, since lipid raft targeting appears to be a slower process than 
membrane association (149). Although recent findings suggest that Gag might be 
necessary for Env to associate with lipid rafts, whether MA actively aggregates these 
membrane microdomains or binds to pre-formed platforms, is not yet known (15, 90).  
1.5.2 HIV-1 MA in Early Events 
In addition to the key roles of MA as a domain of Gag, several lines of evidence 
suggest that the mature 17 kDa form of MA functions in early events of the HIV-1 life 
cycle. During HIV-1 maturation, the viral protease cleaves the 132-residue domain of 
MA from other Gag structural proteins. The majority of these cleaved MA proteins form 
a protective shell that is attached to the inner surface of the viral membrane (84, 145). 
However, a small subset of the 17 kDa MA molecules dissociates from the membrane 
and interacts with the viral core (28, 76, 131, 189, 203). These MA proteins enter the new 
host cell as part of the RTC, and several studies have even detected them in the viral PIC 
(23, 74, 131).  These observations suggest a role for MA following membrane fusion, and 
indeed, MA mutations have been reported that impair virus replication without affecting 
Env incorporation, assembly or release (31, 104, 166, 167, 213) 
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For a subset of mature MA molecules to interact with the viral core, the protein 
must somehow reduce its membrane affinity. Early on, it was proposed that the 
membrane binding property of MA might be regulated by a “myristoyl switch” 
mechanism that alters the accessibility of its N-terminal myristoyl group (217). In this 
model, MA can adopt a “relaxed” or “tense” state that facilitates myristate exposure or 
sequestration, respectively. Thus, burial of the myristoyl group inside a hydrophobic 
pocket of the MA globular domain might diminish the membrane affinity of MA, and 
permit an association with the viral core. The structures of both myristoylated and 
unmyristoylated HIV-1 MA have been resolved, and findings from the studies suggest 
that MA does not undergo a dramatic conformational change when switching between 
states (93, 124, 127, 191). Recent data indicate that conversion between the two 
conformations is entropically regulated and several factors, such as MA concentration 
and proximity to RNA or PI(4,5)P2, might influence which of the myristate-exposed or –
sequestered states is favored (90, 191, 206). It has also been speculated that Gag 
processing during particle maturation might promote sequestration of the myristoyl 
moiety (90, 174). Thus far, only a few MA residues (V7, L8, S9, G10 and G11) have 
been implicated in regulating the myristoyl switch (174, 191). 
It has also been proposed that the membrane affinity of MA might be reduced 
through specific phosphorylation events inside the virus particle (22, 75, 76, 189). Such 
modifications might induce structural changes that promote the myristoyl switch. 
Alternatively, the negative charge conferred by the addition of phosphate groups to a MA 
protein might counteract electrostatic interactions with acidic phospholipids of the lipid 
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bilayer (22, 26, 75, 76, 212). Indeed, this post-translational modification has previously 
been associated with regulating the functions and affinities of other myristoylated 
proteins. For example, it has been demonstrated that interactions between members of the 
myristoylated, alanine-rich C kinase substrate (MARCKS) family of proteins and the PM 
can be reversed through specific phosphorylation events (193).  
Although many laboratories have attempted to identify which, if any, phospho-
acceptor sites on HIV-1 MA are required for an early post-entry step, they generated 
conflicting results that suggest a complexity behind MA phosphorylation events (22, 67, 
75, 76, 189). For example, studies from one group indicated that a membrane-associated 
tyrosine kinase is incorporated into budding virions, and phosphorylates the C-terminal 
tyrosine residue (Y132) of MA (75, 76). This group proposed that this phosphorylation 
event could promote the membrane dissociation of MA and even facilitate nuclear import 
through a MA-IN interaction. However, other groups found that phosphorylation of MA 
Y132 did not prevent infection in primary macrophages, and was therefore dispensable 
(22, 67). Nonetheless, it was noted that mutation of Y132 resulted in differential 
phosphorylation of another tyrosine residue in MA (22).  
Another group reported that phosphorylation of MA residue S111 was essential 
for the membrane-binding properties of MA (212). Yet, this requirement could not be 
subsequently confirmed using site-directed mutagenesis analyses and subcellular 
fractionation experiments (217). It was later suggested that an additive effect of multiple 
phosphate acceptor sites in MA, particularly at residues S38, S67, S77, and S111, is 
required to facilitate MA dissociation from the negatively charged PM (22). In direct 
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opposition to this hypothesis, however, was the observation by another group that both 
free and membrane-bound MA molecules are phosphorylated to an equivalent degree 
(183). In support of single MA residues regulating membrane affinity, yet another study 
indicates that individual mutations at residues S9, S67, S72 and S77 inhibited a post-
entry MA function (101). However, additional findings indicate that these mutations 
reduced Env incorporation and likely diminish the fusion capacity of virus particles (14). 
The authors of the latter study proposed that instead of reducing membrane affinity, 
abrogation of the phosphorylation sites inhibited the ability of MA to recruit Env to the 
sites of viral assembly. Nevertheless, they speculated that some of these mutant particles 
might have had an additional post-entry block to replication, since restoring fusion failed 
to completely rescue infectivity.  
Also implicated in early events of the HIV-1 replication cycle is the C-terminal 
helix of MA. An early study reported that C-terminal deletions in MA reduced particle 
infectivity without affecting assembly (213). However, recent findings attribute the 
impaired infectivity of these viruses to reductions in Env incorporation (14). It has been 
suggested that large deletions in the extended fifth helix could modify the conformation 
of Gag precursors, disrupting protein-protein interactions necessary for Env 
incorporation. Nonetheless, the C-terminal helix of MA has been shown to reduce 
liposome binding in vitro, and this behavior was also reflected in vivo (217). The authors 
of this study hypothesized that the fifth helix in MA exerts a negative effect on the 
membrane binding of MA, and might regulate the exposure of myristate.  
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Since MA has been detected inside reverse transcription and preintegration 
complexes, it has been suggested that MA might act as a karyophilic agent, promoting 
nuclear migration of these viral complexes. Indeed, two short stretches of basic amino 
acids, encompassing residues 24 through 31 (NLS-1) and 110 through 114 (NLS-2), have 
been identified in MA that could potentially act as nuclear localization signals (NLS) 
(24). Initial findings suggested that the NLSs were functional, since disruptions of these 
sequences in viruses imposed infectivity blocks that correlated to a reduction in nuclear 
import (24, 23, 35, 38, 88, 92, 124, 127, 198). However, subsequent studies revealed that 
MA displayed very low kariophilicity (48, 63, 120, 209). It has since been established 
that the discrepancies concerning the role of MA sequences in nuclear import might be 
due to redundant nuclear import signals, since IN, Vpr, and the central DNA flap 
remaining on viral DNA after reverse transcription (cPPT-CTS) also displays 
kariophilicity (17, 73, 92, 198, 215). In a recent study, HIV-1-based viruses were 
analyzed in which all but one of the possible kariophilic entities were removed (172). 
Among the viral elements analyzed, the cPPT-CTS was reported to provide the most 
significant nuclear import signal. However, the importance of this element varied in 
different cell types and was independent of the dividing status of the cell. The current 
consensus appears to be that MA does not function in this regard, or contains a weak 
signal that acts cooperatively with other elements of the viral core (73, 92, 168). 
Lastly, it has been proposed that MA molecules are involved in HIV-1 
integration. An early study reported that the EED protein, an IN-binding partner, interacts 
with HIV-1 MA, and that the IN-EED-MA complex might be critical for directing the 
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PIC to host chromatin inside the nucleus (161). EED is normally involved in reducing the 
accessibility of DNA to maintain the silent state of chromatin, and it was later suggested 
that this putative MA-EED interaction could trigger transcriptional activation (197). A 
subsequent study indicates that although substitutions in the putative MA NLS-1 (K27I, 
K28I) did not significantly alter the nuclear import of the viral PIC, they could reduce 
viral infectivity by affecting late post-chromatin binding events (120). The authors 
proposed that MA might have a crucial function in mediating interactions between 
chromatin-bound PICs and host machinery involved in HIV-1 DNA integration and 
circularization. Taken together, these findings suggest a potential function of the MA 
protein in virus integration.  
1.5.3 HIV-1 MA is a Potential Virokine 
It has been previously demonstrated that viruses may encode virokines, which are 
cytokine homologues capable of acting as agonists or antagonists that can trigger or 
prevent specific biological responses, respectively (reviewed in ref. 109). A 1994 study 
revealed that the helical topology of the HIV-1 MA protein shares a striking similarity 
with the immune modulator interferon gamma (IFN-γ) (126). Although mature MA did 
not seem to oligomerize with, or mimic the biological properties of IFN-γ (3), it binds to 
a cell surface receptor constitutively expressed on peripheral B cells (44, 45). This 
receptor, termed p17R, is also expressed on T-cells in PBMC cultures at the very early 
stages of T-cell activation (45). The authors of this study reported that while exogenous 
MA did not induce any biologically relevant effect on resting T-cells, it increased the T-
cell proliferative response even at very weak doses of IL-2. These results suggested that 
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at least in culture, exogenous MA might have immunomodulatory activities that could 
promote target cell proliferation, and possibly enhance viral replication. Consistent with 
this hypothesis, HIV-1 infected PBMCs cultured in the presence of IL-2 and exogenous 
MA together released higher amounts of virus than infected cells that were cultured in the 
presence of IL-2 alone (45).  
Recent evidence has indicated that in vitro, HIV-1 infected cells are able to 
release a significant amount of MA (51). A later study demonstrated that extracellular 
MA is abundant in the lymph nodes of HIV-1 infected patients, and even accumulates in 
the lymph nodes of patients on HAART with undetectable viral loads (164). Multiple 
groups have reported that MA-specific neutralizing antibodies are produced in vivo (44, 
157). In cell culture, these anti-MA antibodies inhibited the interaction between MA and 
its putative p17R receptor, and abolished the exogenous MA cytokine-like activity (44). 
The p17R receptor-binding region of MA was mapped to the protein’s N-terminus, 
however the authors noted that other sites might contribute to the MA-p17R interaction 
(44). Collectively, these findings suggest that exogenous MA might exert biological 
activities in vivo and possibly act as a virokine in infected individuals (164). 
1.6 Scope of Thesis 
The findings presented in this thesis demonstrate that a highly conserved residue 
within the C-terminal helix of HIV-1 MA has multiple, essential roles in the function of 
the protein. I determined that substitutions of this residue, a glutamate at position 99 
(E99), abolish virus infectivity in multiple cell lines. Further characterization of the 
defects associated with MA E99 substitutions was achieved using a variety of approaches 
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designed to analyze individual steps in the virus life cycle. Specifically, I examine Env 
incorporation, particle production, and Gag processing, and determine that particles 
bearing specific E99 substitutions are generated at normal levels yet have a reduction in 
Env packaging. Through virus-cell membrane fusion studies, I functionally link the Env 
incorporation defect with a diminished capacity to fuse with target cells. A genetic 
approach was used to identify a compensatory mutation at MA position 84, and although 
the extent of rescue conferred by this second site change varies in different viral clones, it 
is specific for rescuing the defects associated with E99 substitutions. Multiple strategies 
were employed to restore virus-cell fusion in particles bearing the E99 substitutions. 
Further analyses reveal that these particles remain defective at an early, post-entry step. 
Finally, preliminary results are presented for the development of a novel method that 
might be used to identify trafficking defects that are critical for early steps in the HIV-1 
life cycle. Such methods could be used to further characterize the post-entry defect 
exhibited by particles bearing mutations at MA E99. Collectively, the data presented here 
indicate that the C-terminal hydrophobic pocket of MA, which encompasses both 
positions 84 and 99, has a previously undiscovered and key role in multiple functions of 
the protein. These findings may provide new insights that can advance the development 
of novel anti-HIV therapeutics.  
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CHAPTER II: MATERIALS AND METHODS 
2.1 Tissue Culture Cell-Lines 
HeLa, 293-T or TZM-bl were grown in 1X Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS) and 1% Penicillin-Streptomycin 
(Pen-Strep). TZM-bl cells are derived from a HeLa clone that express relatively high 
surface levels of CD4, CCR5, and CXCR4. They contain stably integrated reporter genes 
that encode the Escherichia coli β-Galactosidase (β-Gal) and Renilla Firefly Luciferase. 
Expressions of both proteins are driven by the HIV-1 LTR, and are thus, Tat-dependent 
(202). This reporter cell line is susceptible to infection by both R5 and X4 HIV-1 isolates 
(190). The MAGI cells are also a HeLa-CD4-LTR-β-gal indictor cell line, and were 
maintained in DMEM with 10% FCS and 1% Pen-Strep that was supplemented with 0.1 
mg of hygromycin B and 0.15 mg of G418 per ml (105). MT-4, M8166, and C8166 cells 
were grown in RPMI 1640 medium supplemented with 10% FCS, and 1% Pen-Strep.  All 
cell lines were grown at 37°C in a 5% CO2 atmosphere.  
2.2 DNA Constructions 
HIV-1 MA mutations were created with the Quikchange II Site-Directed 
Mutagenesis Kit (Stratagene) as previously described (211), using the pLAI or pNL4.3 
proviral clones (1, 158). These proviral clones were obtained from the AIDS Reagent 
Program of NIAID, NIH.  
The proviral clone pLAI-Gag(-) encodes a nonfunctional gag gene, and was 
created by introducing two stop codons proximal to the start of the gag reading frame, as 
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previously described (119). The pLAI-∆Env proviral clone encodes a nonfunctional env 
gene, due to removal of the 582-nt Bgl2/ Bgl2 fragment (bases 6638-7220) located early 
in the env coding sequence. Truncations of the HIV-1 gp41 CT were made by introducing 
two consecutive stop codons into the gp41 coding sequences, as described previously 
(119). The relative locations of each of these changes made in the HIV-1 genome is 
represented in Figure 2.1A. The gp41 proteins generated from transfection of the LAI-
∆144 proviral clones contain an abbreviated CT that is six residues in length, instead of 
the normal 150 amino acids. The truncated Env protein is depicted in Figure 2.1B. 
Mutagenic primers were designed to introduce changes in pLAI and pNL4.3 
proviral clones. The primer sequences are written in the 5’ to 3’ direction: L13E/f: GTA 
TTA AGC GGG GGA GAA GAA GAT CGA TGG GAA AAA ATT C; L13E/r: G 
AAT TTT TTC CCA TCG ATC TTC TTC TCC CCC GCT TAA TAC; L21K/f: GA 
TGG GAA AAA ATT CGG AAA AGG CCA GGG GGA AAG; L21K/r: CTT TCC 
CCC TGG CCT TTT CCG AAT TTT TTC CCA TC; K32E/f: G AAA AAA TAT AAA 
TTA GAA CAT ATA GTA TGG GCA AGC; K32E/r: GCT TGC CCA TAC TAT ATG 
TTC TAA TTT ATA TTT TTT C; LAI-E99V/f: G ATA AAA GAC ACC AAG GTA 
GCT TTA GAC AAG ATA G; LAI-E99V/r: C TAT CTT GTC TAA AGC TAC CTT 
GGT GTC TTT TAT C; E99A/f: G ATA AAA GAC ACC AAG GCA GCT TTA GAC 
AAG ATA G; E99A/r: C TAT CTT GTC TAA AGC TGC CTT GGT GTC TTT TAT C; 
E99G/f: G ATA AAA GAC ACC AAG GGA GCT TTA GAC AAG ATA G; E99G/r: 
C TAT CTT GTC TAA AGC TCC CTT GGT GTC TTT TAT C; E99D/f: G ATA AAA 
GAC ACC AAG GAC GCT TTA GAC AAG ATA G; E99D/r: C TAT CTT GTC TAA 
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AGC GTC CTT GGT GTC TTT TAT C; E99K/f: G ATA AAA GAC ACC AAG AAA 
GCT TTA GAC AAG ATA G; E99K/r: C TAT CTT GTC TAA AGC TTT CTT GGT 
GTC TTT TAT C; LAIdel84/f: C ATT ATA TAA TAC AGT AGC AGT CCT CTA 
TTG TGT GCA TC; LAIdel84/r: GA TGC ACA CAA TAG AGG ACT GCT ACT 
GTA TTA TAT AAT G; NL43del84/f: CAT TAT ATA ATA CAA TAG CAA CCC 
TCT ATT GTG TGC ATC; NL43del84/r: GAT GCA CAC AAT AGA GGG TTG CTA 
TTG TAT TAT ATA AT; NL-E99V/f: GTA AAA GAC ACC AAG GTA GCC TTA 
GAT AAG ATA G; NL-E99V/r: C TAT CTT ATC TAA GGC TAC CTT GGT GTC 
TTT TAC; LAIdelGAG/f: G AGA GCG TCA GTA TAA AGC GGG TGA GAA TTA 
GAT CGA TG; and LAIdelGAG/r: CA TCG ATC TAA TTC TCA CCC GCT TTA 
TAC TGA CGC TCT C. 
Sanger sequencing of both DNA strands confirmed nucleotide changes in the 
HIV-1 mutant proviral clones. All mutations created in the MA domain are named based 
on their proximity to the initial methionine in the Gag coding sequence. 
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Figure 2.1 Relative locations of changes made to LAI proviral clones. (A) An 
early stop codon was introduced at the beginning of the gag gene to generate the 
Gag(-) clone. To generate the LAI-∆Env clones, a 582 nucleotide fragment (Bgl2-
Bgl2 site) within the env gene was removed. To generate the LAI-∆144 proviral 
clones, two consecutive stop codons were introduced into the env gene that 
removed the C-terminal 144 amino acids from the cytoplasmic tail of gp41. Note: 
Gag(-), LAI-∆Env, and LAI-∆144 proviral clones had only one of the three 
changes shown (adapted from 41). (B) Truncated Env proteins synthesized from 
the pLAI-∆144 proviral clones has a gp41 cytoplasmic tail of six amino acids 
instead of the normal 150. The site of the last amino acid in the truncated 
glycoprotein is indicated in the diagram (70). 
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2.3 Expression Vectors 
pHCMV-G expresses the vesicular stomatitis virus envelope glycoprotein G 
(VSV-G) from a human cytomegalovirus (CMV) promoter (210). pSV-A-MLV expresses 
the amphotropic Murine Leukemia Virus strain 4070 A env (a-MLV-Env) coding 
sequence expressed from the MLV-LTR promoter (154). The pBLaM-Vpr plasmid 
expresses β-lactamase (BLaM) fused to the amino terminus of HIV-1 Vpr, under the 
control of the CMV promoter (32).  
2.4 Virus Production 
Wild-type (WT) and mutant virus stocks were produced by transient transfection 
of proviral clones into 293T cells using TransIT-LTI (Mirus Corp.). Fresh media was 
added six hours post-transfection. HIV-1 particles carrying β-lactamase proteins were 
produced by co-transfection of an individual proviral clone and pBLaM-Vpr at a ratio of 
3:1. VSV-G pseudotyped particles were generated by co-transfection the Env deficient 
proviral clone and pHCMV-G at a ratio of 6:1. A-MLV-env pseudotyped particles were 
generated by co-transfection the Env deficient proviral clone and pSV-A-MLV at a ratio 
of 1:2. Pseudotyped particles were harvested after 24 and 48 hours. Fresh media was 
added to the cultured cells after the 24-hour harvest. All other viruses were harvested 
after 48 hours. Viruses were clarified through a 0.45 µm filter (Millipore) immediately 
after harvesting and aliquotted for storage at -80° C. Stocks were normalized for Reverse 
Transcriptase (RT) activity using the enzymatic assay described below. For immunoblot 
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analysis, HeLa cells were transiently transfected with the individual proviral clones and 
viral lysates prepared as previously described (119). 
2.5 Reverse Transcriptase (RT) Activity Assays 
HIV-1 RT activity was measured as previously described (163). For each sample, 
5 µL of filtered culture supernatant was mixed with 10 µL Solution A (100mM Tris-HCl 
pH 7.9, 300 mM KCl, 10 mM DTT, 0.1% NP-40) and incubated for 15 minutes at 37° C. 
Viral lysates were then combined with 25 µL Solution B (50 mM Tris-HCl pH 7.9, 150 
mM KCl, 5 mM DTT, 15 mM MgCl2, 0.05% NP-40, 10 µg/ml poly A, 0.250 U/ml oligo 
dTTP, 10 µCi/ ml 3H-TTP), and incubated overnight at 37°C. Reaction products were 
precipitated using Stop solution (100% trichloroacetic acid, 0.5M Na4P2O7 -10H2O) and 
RT activity determined as previously described (211).  
2.6 p24 ELISA 
Equal volumes of supernatants from 293T cells, obtained 48 hours post-
transfection of the indicated proviral clones, were diluted in complete media in a 96-well 
plate and then added to micro-titer plates coated with α-p24 antibody. A 1:10 or 1:20 
dilution of supernatants generally resulted in readings within the range of the assay. Viral 
titers were determined according to the HIV-1 p24 ELISA kit from Perkin Elmer 
(NEK050B). 
2.7 Immunoblot Analyses 
Transfected cells were lysed in RIPA buffer with a cocktail tablet of protease 
inhibitors (Complete, Roche). Cell or viral lysates were resolved on 12% SDS-
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polyacrylamide gels and transferred to Hybond-C Extra Nitrocellulose membranes (NC; 
Amersham Biosciences) using a semi-dry blotter. NC membranes were blocked with 5% 
dry milk in 1X TBST buffer (25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4, and 0.1% 
Tween-20) at room temperature for 1 hour, then incubated with primary monoclonal 
antibodies directed against HIV-1 gp41 (Chessie-8, diluted 1:250), HIV-1 Gag (183-H12-
5C, NIH AIDS Reagent Program, diluted 1:500), human β-Actin (AC-15, Sigma, diluted 
1:4400) or GAPDH (ab8245, Abcam, diluted 1:5000), or polyclonal antibodies directed 
against Sam68 (ab26803, Abcam, diluted 1:600), Nup62 (sc-25523, Santa Cruz 
Biotechnology, diluted 1:200), pyruvate kinase (ab38237, Abcam, diluted 1:200) or 
HSP90 (sc-7947, Santa Cruz Biotechnology, diluted 1:200). Following three 10-minutes 
washes in 1X TBST buffer, membranes were incubated with goat α-mouse or mouse α-
rabbit secondary antibodies conjugated to horseradish peroxidase (Sigma, diluted 
1:10:000). Bands were detected and visualized using enhanced chemiluminescence 
(SuperSignal West Pico, Thermo Scientific) with Kodak X-Omat Blue film.  
2.8 Virus-Cell Fusion Assays 
HIV particles are generated through the co-transfection of proviral clones and an 
expression plasmid encoding a β-lactamase (BLaM)-Vpr chimeric protein. BLaM-Vpr is 
packaged into particles as a result of the interaction between Vpr and the p6 domain of 
Gag. Infected cells are loaded with a dye that is a substrate for the BLaM enzyme. 
BLaM-mediated cleavage of the dye causes cells to turn blue, whereas cells will fluoresce 
green in the absence of BLaM. Thus, intracellular BLaM activity can be quantified with a 
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fluorometer to monitor virus-cell fusion events. A schematic overview and images of 
cells used in this fusion assay are shown in Figure 2.2. 
The procedure for the fusion assay is as follows: TZM-bl cells, seeded at 10 x 104 
cells per well, were inoculated with virus using spinoculation (2100 x g) at room 
temperature for 30 minutes in a total volume of 50 µL. Cells were incubated for up to 3 
hours at 37°C. The BLaM substrate, CCF2-AM dye (20 µM, Invitrogen LiveBLAzer 
FRET-B/G Loading Kit), was prepared according to the manufacturer’s standard 
substrate loading protocol, with the exception that Solution C was diluted 1:6 in 1X 
HBSS++ [Hanks’ Balanced Salt Solution, 20 µM Hepes, 2 mM Glutamine]. The CCF2-
AM solution was added to cells and the cultures were incubated overnight in the dark at 
room temperature. Cells were washed in cold 1X PBS (Phosphate Buffered Saline) and 
fluorescence emission was measured at 447 nm or 520 nm following excitation at 409 nm 
using a fluorometer (BioTek Synergy 2). Intracellular BLaM activity was measured and 
normalized as previously described (133). 
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Figure 2.2 Virus-cell membrane fusion assay. (A) Schematic overview of the 
fusion assay. HIV particles are generated through the co-transfection of proviral 
clones and an expression plasmid encoding a BLaM-Vpr chimeric protein. The 
resulting particles are used to infect target cells, which are then incubated with 
CCF2/AM dye. This dye, a substrate for BLaM, passively diffuses into cells. In 
the absence of BLaM-Vpr, the cells will fluoresce green. However, if a virus 
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particle containing BLaM-Vpr chimeras fuses with a cell, then the BLaM enzyme 
will cleave the dye and the cell will fluoresce blue. The relative quantities of blue 
or green cells in a given culture can then be quantified using a fluorometer. (32) 
(B) Images from the virus-cell membrane fusion assay. Either LAI-WT (left 
panel) or LAI-∆Env (right panel) particles, both containing BLaM-Vpr 
chimeras, were incubated with TZM-bl cells for three hours. Cells were then 
washed and loaded with CCF2/AM dye. After time was allowed for substrate 
cleavage, the cells were washed in PBS and pictures were taken under the 
microscope. LAI-WT particles successfully fused with TZM-bl cells, enabling the 
BLaM enzyme to cleave the dye inside target cells, resulting in a blue color (left 
panel). However, the LAI-∆Env particles could not deliver the BLaM enzyme 
into target cells, and cells remained green (right panel).  
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2.9 Beta Glo  Assays of Viral Infectivity 
The Beta-Glo assay system (Promega) provides a highly sensitive, quantitative 
analysis of viral infectivity with a wide range of HIV-1 isolates (91). The TZM-bl cells 
used in this assay contain separately integrated copies of the β-galactosidase and firefly 
luciferase reporter genes, whose expressions are driven by the HIV-1 LTR and thus, are 
Tat-dependent (202). The Beta-Glo reporter assay utilizes a coupled enzyme reaction 
system that employs a single reagent, luciferin-galactoside. In living cells, this substrate 
is cleaved by β-galactosidase to galactose and luciferin, the latter being used by firefly 
luciferase to generate a luminescent signal that is proportional to the amount of β-
galactosidase. Following HIV-1 infection, the enzymatic activity of luciferase in TZM-bl 
cells can be quantified in terms of relative luminescence units (RLU). The RLU values 
obtained are directly proportional to the number of infectious virus particles in the viral 
inoculum. The procedure for this assay was carried out per the manufacturer’s 
instructions. Briefly, TZM-bl cells were seeded at 10 x 104 cells per well of a 96-well 
plate. Duplicate wells were infected with equal amounts of virus, and incubated for 24 or 
48 hours at 37° C. Cells were lysed at room temperature by the addition of Beta Glo 
substrate (Promega). Luciferase activity was quantified using a luminometer and 
normalized as previously described (91). 
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2.10 Quantification of HIV-1 Reverse Transcription Products 
Total cellular DNA was extracted using the DNAeasy kit (Qiagen), as directed by 
the manufacturer. A single-step, real-time PCR was used to quantify EPs and 2-LTRs 
from DNA extracts in a 30 µl PCR reaction mix containing 15 µL TaqMan Universal 
PCR Master Mix (Applied Biosystems) and a fluorescence Taqman probe that targeted 
the HIV-1 sequence being amplified (2nr4nr: 5′-
AGCCTCAATAAAGCTTGCCTTGAGTGC-3′). Amplification reactions were 
performed using an Applied Biosystems 7000 real-time PCR system with the following 
program: 95°C for 20 s, then 35-45 cycles of 95°C for 30 s and 60°C for 30 sec. The EP 
and 2-LTR values were normalized relative to CCR5 gene copy number. 
2LTR circles were amplified from 10 µL DNA with 45 cycles using primers C1/f 
(5′-CTAACTAGGGAACCCACTGCT-3′) and C4/r (5′-
GTAGTTCTGCCAATCAGGGAAG-3′). Copy numbers were based on a standard curve 
generated with a plasmid that harbors the HIV LTR-LTR junction. Early products were 
amplified from 5 µL DNA with 40 cycles using primers M667/f (5’-GGC TAA CTA 
GGG AAC CCA CTG C-3’) and AA55/r (5’-CTG CTA GAG ATT TTC CAC ACT 
GAC-3’). Copy numbers were based on a standard curve generated with a plasmid that 
harbors the LAI early product sequence between U5 and R. CCR5 gene copies were 
amplified from 10 µL DNA with 40 cycles using CCR5 specific primers and a CCR5 
specific probe. CCR5 copy numbers were based on a standard curve generated with a 
plasmid that harbors the human CCR5 gene. 
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2.11 RTC Trafficking Assay  
Several variations of this protocol were performed and are described in Chapter 6. 
A brief overview of the methods is outlined in Figure 6.1. The relative targets of each of 
the primers used in the PCR steps of this assay are shown in Figure 6.2. Included here is 
the optimized procedure used to carry out the experiments, and consists of four main 
steps: virus infection, cell harvesting and fractionation, RT-PCR of viral genomes, and 
quantification of viral genomes by qPCR. 
2.11.1 Infection Protocol 
MAGI cells were added to a T-25 flask in MAGI media, and incubated 2-3 days 
until cells were about 80% confluent. For AZT controls, cells were incubated with 10 µM 
AZT for two hours at 37° C prior to infection. All viruses were treated with DNase I 
(Boehringer Mannheim) for 30 minutes at 37° C before added to cells. Media was 
removed from flasks and 750,000 RT units of virus diluted in cold MAGI media were 
added. Flasks were incubated at 4° C for one hour, and manually rocked every five 
minutes to assure that media and virus covered all cells. After an hour, virus was 
removed from each flask and prewarmed 0.45 M sucrose media was added to cells. Cells 
were incubated at 37° C for 20 more minutes. Media was again removed from each flask 
and prewarmed media was added. Infections were incubated further at 37° C until pre-
determined time points.  
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2.11.2 Cell Harvesting and NP-40 Fractionation 
Media was removed from each flask and cold 1X PBS was added to wash the 
cells. PBS was aspirated, and exposed to trypsin-EDTA. Flasks were incubated at 37° C 
for three minutes, and then gently tapped to detach cells. MAGI media was added to 
neutralize the trypsin. Cells were transferred to eppendorf tubes and pelleted by 
centrifugation at 3500 RPM for five minutes at 4° C. Culture supernatants were removed 
and cells were resuspended in cold PBS. Half of the cell suspensions were transferred to a 
new tube and frozen at -80° C for subsequent total DNA extraction. The remaining tubes 
were centrifuged for three minutes at 3500 RPM at 4° C. The PBS was aspirated and cells 
were resuspended in cold hypotonic Buffer A (0.01 M Hepes pH 7.9, 0.01 M KCl, 0.1 
mM EDTA, 1 mM DTT). Cells were left on ice for 15 minutes to swell. NP-40 was 
added to cells at a final concentration of 0.6% and then vortexed vigorously. The tubes 
were centrifuged for three minutes at 6500 RPM at 4° C. After the spin, the supernatants 
(cytoplasmic fractions) were transferred to clean tubes. Nuclei pellets were resuspended 
in Buffer A and spun for 3 minutes further at 6500 RPM at 4° C. After the spin, the 
supernatants were aspirated, and the nuclei were resuspended in Buffer B (0.01 M Hepes 
pH 7.9, 0.05 M NaCl, 0.1 mM EDTA, 25% glycerol) and stored at -80° C.  
2.11.3 RNA Extraction and RT-PCR 
Each of the tubes were thawed and total RNA was extracted with RNeasy kit 
(Qiagen), as directed. The Applied Biosystems Reverse Transcription kit (Superscript, 
Invitrogen) was used to perform reverse transcription, as directed. For this procedure, 8 
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µL of RNA from each sample was added to 2 µL of a 1:1 dNTP: primer BB (sequence 5'-
GGATTAACTGCGAATCGTTC-3') solution and kept on ice. Tubes were incubated in a 
65° C water bath for five minutes to denature RNA secondary structure. Tubes were then 
quickly spun, and placed back on ice for one minute. A mastermix solution was prepared 
so that each reaction could occur with 2 µL 10X RT buffer, 4 µL of 25 mM MgCl2, 2 µL 
of 0.1 M DTT and 1 µL of RNase OUT (all components of the kit). 9 µ L of the 
Mastermix was added to each tube, centrifuged, and added to a 42° C water bath. 1 µL of 
the Superscript II RT enzyme was added to each tube and reactions were kept in the 42° 
C water bath for 50 minutes. The tubes were then transferred to a 70° C water bath for 15 
minutes to stop the reactions, and then chilled on ice until further analysis. 
2.11.4 Quantitative PCR to Analyze cDNA Copy Number 
Real-time PCR was used to quantify copy numbers of 1 µL of the HIV-1 cDNA 
in a 30 µl PCR reaction mix containing 15 µL TaqMan Universal PCR Master Mix 
(Applied Biosystems), the C1/f primer (5'-GTAGTTCTGCCAATCAGGGAAG -3'), the 
LA17/r primer (5’-AACTGATCGCCTCCGATCTTCCTCT-3’), and a fluorescence 
Taqman probe that targeted the HIV-1 sequence being amplified (2nr4nr: 5′-
AGCCTCAATAAAGCTTGCCTTGAGTGC-3′). Amplification reactions were 
performed using an Applied Biosystems 7000 real-time PCR system with the following 
program: 95°C for 20 sec, then 45 cycles of 95°C for 30 sec and 60°C for 30 sec. Copy 
numbers were based on a standard curve generated with a plasmid that harbors the LTR-
Gag sequence being amplified (the last part of the 2nd strand). cDNA copies were 
normalized relative to CCR5 gene copy number, quantified from total cellular DNA. 
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CHAPTER III: CHARACTERIZATION OF HIV-1 VIRUSES 
ENCODING SUBSTITUTIONS AT MA RESIDUE 99  
3.1 Introduction 
Previously, several groups have analyzed single amino acid substitutions within 
MA at highly conserved positions. In doing so, they were able to identify residues 
involved in a specific MA function. For example, an L13E substitution is one of several 
individual MA mutations that abrogates incorporation of full length HIV-1 Env into virus 
particles (72). An L21K substitution in the basic domain of MA enhances membrane 
binding of Gag and accelerates Gag processing, resulting in a post-entry defect in virus 
particles (104). Finally, a K32E substitution in MA abolishes viral infectivity in Jurkat 
cells without significantly affecting virus assembly and release, or Env incorporation 
(111).  
A PCR-based mutagenesis scheme was used in a previous study to generate 
proviral clones containing different mutations in the MA coding sequence (55). These 
clones were then screened for defects in nuclear import and export using direct immuno-
fluorescence microscopy. Of the MA mutants generated for subsequent study, one such 
mutant contained a single amino acid substitution, a glutamate to valine change at residue 
99 in the LAI background (LAI-E99V). An amino acid sequence alignment of over 1100 
HIV-1 isolates in the Los Alamos HIV sequence database (subtypes A through K of 
group M) reveals a striking degree of conservation at this residue 99 in MA. In fact, 99% 
of the sequences analyzed had glutamate at residue 99, with aspartate accounting for most 
other known changes. Figure 3.1 shows a schematic representation of the E99V 
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substitution relative to MA functional domains and previously characterized MA single 
amino acid substitutions. 
3.2 Results 
3.2.1 Virus production and Gag processing is normal in LAI-derived 
particles bearing the E99V MA mutation 
 
Since assembly is an important function of MA, I determined whether the LAI 
proviral clone containing the E99V mutation in MA (pLAI-E99V) could produce viral 
particles. 293T cells were transiently transfected with either a WT proviral clone (pLAI-
WT) or pLAI-E99V, using cationic liposomes. After 48 hours, cell supernatants were 
collected and particle production levels were monitored using an enzymatic assay for 
HIV-1 p24 ELISA quantification and RT activity (Figure 3.2). Results from these assays 
indicate that production of LAI-E99V particles (LAI-E99V) was comparable to that of 
LAI-WT.   
Certain mutations in MA have previously been shown to affect the efficiency of 
Gag processing (84, 100, 104), so next, I decided to examine whether Gag processing is 
affected in LAI-E99V particles. HeLa cells were transfected with pLAI-WT, pLAI-
E99V, an LAI proviral clone encoding either the L21K or K32E mutations in MA (pLAI-
L21K or pLAI-K32E), or an LAI proviral clone with a nonfunctional env gene (pLAI-
ΔEnv). After 48 hours, transfected HeLa cells or virus particles in cell supernatants were 
harvested and virus was normalized based on RT activity as described above. Equal 
amounts of virus or cells were resuspended in RIPA buffer, resolved on an SDS-
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polyacrylamide gel and analyzed for Gag processing through immunoblotting with an 
anti-HIV-1 p24 monoclonal antibody (mAb). In both viral (Left Panel) and cellular 
(Right Panel) lysates, I found that the level of Gag processing was comparable for LAI-
WT and LAI-E99V viruses (Figure 3.3). By contrast, and consistent with previous 
studies, I found that Gag processing was enhanced in the LAI-L21K viral lysates (Left 
Panel), as evidenced by the appearance of a strong band corresponding to p41, a 
processing intermediate composed of p17 and p24 (104).  
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Figure 3.1 Functional domains and single amino acid substitutions in HIV-1 
MA. A schematic representation of previously defined functional domains in 
HIV-1 MA, and the relative locations of single amino acid substitutions, also 
characterized in earlier studies. The novel E99V MA substitution analyzed in this 
study is located at the beginning of the C-terminal helix of the protein. 
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Figure 3.2 Effect of the MA E99V mutation on LAI particle production. 
Transient transfection of 293T cells with proviral clones pLAI-WT and pLAI-
E99V. Particle yield was determined by both p24 ELISA (A) and RT analysis (B) 
as described in Methods and Materials. The data represent the average of two 
independent transfections. 
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3.2.2 LAI-derived particles bearing the E99V or E99K MA mutations have 
severe infectivity defects 
Next, to determine whether an early step in the viral life cycle might be disrupted 
in LAI-E99V, I analyzed a single-cycle of virus infection in TZM-bl cells using the Beta-
Glo assay system. This reporter system provides a highly sensitive, quantitative 
analysis of viral infectivity with a wide range of HIV-1 isolates (91). TZM-bl cells have a 
firefly luciferase gene stably integrated into their genomes, and expression of the reporter 
gene is driven by the HIV-1 LTR (202). Following HIV-1 infection, the enzymatic 
activity of luciferase is quantified in cells and is directly proportional to the number of 
infectious virus particles in the viral inoculum.  
Virus particles were produced in 293T cells by transfection with pLAI-WT, 
pLAI-E99V, pLAI-L21K, pLAI-K32E, pLAI-ΔEnv, or an LAI proviral clone encoding 
either the L13E mutation in MA (pLAI-L13E). Virus from each culture supernatant was 
harvested and normalized by RT content.  Equal amounts of each virus were then added 
to TZM-bl cells cultured in 96-well plates. 
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Figure 3.3 Western blot analysis of Gag processing in LAI-derived virus. 
Equal RT units of virus particles (Left Panel) or transfected HeLa cells (Right 
Panel) were harvested, and then resuspended in RIPA buffer, as previously 
described (119). Gag processing was analyzed by SDS-PAGE and 
immunoblotting using monoclonal antibodies directed against HIV-1 Gag. 
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After 24 hours, Beta-Glo substrate was added to the cells and luciferase activity in 
each well was quantified using a luminometer. The RLU value from each infection was 
normalized using the LAI-WT value, which represents 100% infectivity. Figure 3.4 
shows that LAI-WT, but not LAI-ΔEnv, was highly competent for viral infection in this 
assay.  Similar to previous reports, I found that the L13E, L21K and K32E mutations in 
MA reduce viral infectivity by approximately 29-fold, 1.5-fold and 3.5-fold, respectively. 
Most striking, I observed a 100-fold reduction in infectivity in cells incubated with LAI-
E99V. These data suggest that LAI-E99V particles are defective at an early step in the 
virus life cycle. 
Because LAI-E99V was markedly less infectious than the other viruses tested, I 
analyzed the functional significance of glutamate at residue 99 using specific amino acid 
substitutions at this position in MA. I selected an alanine or a glycine substitution (E99A, 
E99G) because of their neutral side chain groups compared to glutamate. An aspartate 
substitution (E99D) was chosen based on its charge similarity and slightly larger mass. 
Lastly, a lysine substitution (E99K) was selected because it places a negative, rather than 
a positive charge at this position. LAI proviral clones encoding these single amino acid 
substitutions at residue 99 were generated using PCR-based site-directed mutagenesis and 
individually transfected into 293T cells to produce virus. The levels of viral infectivity 
were monitored in TZM-bl cells as in the previous section. These results indicate that 
exchanging glutamate for an alanine, glycine, or aspartate at residue 99 of MA had no 
discernible effect on viral infectivity (Figure 3.4). By contrast, a lysine substitution at this 
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position led to a 100-fold decrease in viral infectivity, a level comparable to that observed 
for the E99V substitution. 
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Figure 3.4 Single-cycle infectivities of LAI-derived MA mutants. Virus stocks 
generated in 293T cells with the indicated pLAI molecular clones were 
normalized based on RT activity and used to infect TZM-bl cells. Single-cycle 
infectivity was determined 24 hours post-infection using the Beta-Glo reporter 
assay and a luminometer. The assessment of infectivity is based on the level of 
LAI-WT, which represents 100% infectivity. The data shown is representative of 
four independent experiments performed in duplicate. 
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Although I did not detect virus infection in cells inoculated with LAI-E99V using 
single-cycle reporter assays, it was possible that infection was occurring at a level below 
the detection limit of the assay. Alternatively, the observed infectivity defect might be an 
anomaly of TZM-bl cells. As a complementary approach for determining viral infectivity, 
I examined whether LAI-E99V retained the ability to initiate a spreading infection in a 
human T-cell line. MT-4 cells were inoculated with LAI-WT, LAI-E99V or LAI-ΔEnv. 
Four hours post-infection, cells were washed and re-plated in fresh media, and incubated 
further for fifteen days. An aliquot of each culture supernatant was obtained every other 
day and stored at -20°C. On day seven, one-half of the culture volume was replaced with 
an equal volume of fresh cell: media suspension (1:1 ratio). The level of RT activity in 
each aliquot was measured using a standard enzymatic assay, as described in Materials 
and Methods. Robust levels of viral replication were detected in the cultures incubated 
with LAI-WT, but not LAI-ΔEnv. However, LAI-E99V was unable to replicate in these 
MT-4 cells (Figure 3.5A). I also saw similar results with C8166 and M8166 cell lines 
(Figures 3.5B and C, respectively). Taken together, these results indicate that LAI-E99V 
has a marked defect in viral infectivity. 
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Figure 3.5 Replication kinetics of LAI-derived virus in Human T-cell lines. 
Virus stocks generated in 293T cells by transfection with the indicated pLAI 
molecular clones were normalized based on RT activity and used to infect MT-4 
(A), C8166 (B) or M8166 (C) cells. Fresh cells and media were added to each 
culture on day seven. RT activities in cell culture supernatants were monitored 
every other day for two weeks. The data shown is representative of two 
independent experiments performed in duplicate. 
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3.2.3 LAI-derived particles bearing the E99V or E99K MA mutations have a 
severe defect in Env incorporation 
 
Because certain amino acid substitutions in MA have been shown to disrupt Env 
incorporation in nascent particles (68, 69, 72, 111, 150), I next examined whether this 
process might be impaired in viruses lacking a glutamate at position 99 in MA. HeLa 
cells were transfected with the proviral clones pLAI-WT, pLAI-E99V, pLAI-E99A, 
pLAI-E99K, pLAI-E99D, pLAI-E99G, pLAI-K32E, pLAI-L21K, pLAI-L13E, and 
pLAI-ΔEnv, or an LAI proviral clone with two stop codons proximal to the start of the 
gag reading frame [pLAI-Gag(-)]. After 48 hours, transfected cells were harvested and 
culture supernatants were normalized based on RT activity. Cellular and viral lysates 
were prepared and analyzed for Env expression and particle incorporation, respectively, 
by immunoblotting with an anti-HIV-1 Env mAb as previously described (52). 
The data shown in Figure 3.6 (Top Panel) indicate that Env precursor proteins 
were expressed in all cultures transfected with a proviral clone containing an intact env 
open reading frame. The bottom panel of Figure 3.6 shows results from the immunoblot 
analysis of Env proteins of the corresponding viral lysates. The absence of Env in the 
LAI-Gag(-) culture confirms that the signals detected represent virus-associated Env, and 
not viral glycoproteins trapped in intracellular vesicles. Similar to a previous study, LAI-
L13E was found to be completely devoid of Env proteins, a result consistent with a defect 
in Env incorporation (72). Also as previously reported, the level of Env incorporated into 
L21K particles was comparable to that of LAI-WT (104). On the other hand, I observed a 
  
67 
marked reduction in the amount of Env in LAI-K32E particles, a finding that does not 
agree with the initial characterization of this virus (111). Of the mutations at E99, I found 
the amount of Env in LAI-E99A, LAI-E99D, or LAI-E99G particles was comparable to 
that in LAI-WT particles. However, I found that the LAI-E99V and LAI-E99K particles 
were devoid of viral glycoproteins. Given that cells transfected with pLAI-E99V or 
pLAI-E99K expressed wild-type levels of Env (Figure 3.6, Top Panel), I conclude that 
the E99V and E99K MA mutations disrupt incorporation of Env into nascent particles. 
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Figure 3.6 Effects of MA mutations on HIV-1 Env incorporation in LAI-
derived virus. Transfected HeLa cells (Top Panel) or virus particles (Bottom 
Panel) were harvested, and cellular or viral lysates were prepared as previously 
described (119). The levels of Env proteins in lysates were analyzed by SDS-
PAGE and immunoblotting using monoclonal antibodies directed against HIV-1 
p24, HIV-1 gp41 and β-actin, or against HIV-1 p24 and HIV-1 gp41.  
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3.2.4 LAI-derived particles bearing the E99V or E99K MA mutations are 
markedly impaired for fusion with target cells 
 
Although the immunoblotting results were consistent with a severe disruption in 
Env incorporation for LAI-E99V and LAI-E99K, I considered that some Env 
glycoproteins could still be incorporated into particles at a level below the detection limit 
of this assay, which could facilitate some target-cell fusion events. Indeed, a previous 
study has demonstrated that striking reductions in Env incorporation do not always 
correlate with a proportional defect in fusion capacity (43). Therefore, I examined 
whether LAI-E99V and LAI-E99K are also defective in their ability to fuse with target-
cell membranes. I used a recently modified fusion assay that measures β-lactamase 
(BLaM) activity as an indicator of virus-cell fusion events in living TZM-bl cells after 
fusion with virus containing chimeric BLaM-Vpr proteins (32, 133). In parallel, I 
monitored single-cycle infectivity of WT or mutant viruses using the Beta-Glo assay. 
Representative data from virus-cell fusion assays and the corresponding viral infectivity 
studies, using LAI-E99V, LAI-E99K, LAI-L13E, and LAI-K32E are shown in Figures 
3.7A and B. At 80 minutes and later times, I observed high levels of BLaM activity in 
cells incubated with LAI-WT. In contrast, minimal BLaM activity was detected in mock- 
or LAI-ΔEnv-treated cells, even at late times (180 minutes). Overall, there was a direct 
correlation between the fusion capacity of each virus and its level of infectivity. Notably, 
few discernable fusion events were detectable at each sampling time for cells incubated 
with LAI-E99V, LAI-E99K or LAI-L13E particles, each of which is devoid of Env 
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proteins. These results suggest that similar to LAI-L13E, the LAI-E99V and LAI-E99K 
viruses are defective in membrane fusion and infectivity due to a disruption in Env 
incorporation. 
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Figure 3.7 Effects of MA mutations on virus-cell membrane fusion capacity 
in LAI-derived virus. Equal amounts of virus were added to TZM-bl cells grown 
in 96-well plates. The plates were centrifuged at room temperature for 30 minutes, 
and then incubated further at 37°C for 50, 100 or 150 minutes, or 24 hours. The 
data shown are representative of three independent experiments performed in 
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duplicate. (A) Virus-cell fusion events. Cells were washed with 1X PBS at the 
indicated times post-infection and the BLaM substrate was added to the culture 
media. Plates were incubated overnight at room temperature to allow cleavage of 
the loaded substrate. Cellular BLaM activity was monitored as an indicator ofvirus-­‐cell fusion events using a fluorometer. (B) Single-cycle infectivities of 
LAI-derived MA mutants from the virus-cell fusion assay. Relative infectivities 
of the indicated viruses were assayed 24 hours post-infection as described in 
Figure 3.4. The assessment of infectivity is based on the level of LAI-WT.  
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3.2.5 Defects associated with the E99V MA mutation are mitigated when 
expressed in the NL4.3 strain 
 
Although particle production and Gag processing was normal in LAI-E99V 
particles, these results indicate that these mutant particles had pronounced defects in Env 
incorporation, membrane fusion, and infectivity. To determine whether the E99V 
mutation affects similar processes in a different strain of HIV, I introduced the E99V 
mutation into an NL4.3 proviral clone (pNL4.3-E99V). 
As described for Figure 3.2, HeLa cells were transfected with either pNL4.3-WT 
or pNL4.3-E99V. Transfected cell supernatants were collected 48 hours later, and then 
equal volumes were analyzed for virus production by p24 ELISA and RT assay (Figure 
3.8). There was a slight reduction in particle production from the pNL4.3-E99V 
transfection when compared to that generated from transfection of pNL4.3-WT. Although 
this modest difference was observed in both the p24 quantification and in RT activity of 
transfected cell supernatants, it seemed that NL4.3-E99V particles were efficiently 
produced by transfection.  
I also compared Gag processing of the NL4.3-derived viruses. Equal RT units of 
LAI- or NL4.3-, wild-type or E99V viruses were pelleted, resuspended in RIPA buffer, 
and then resolved on an SDS-polyacrylamide gel. Gag processing was analyzed by 
immunoblotting using an anti HIV-1 p24 mAb. Shown in Figure 3.9, I observed a slight 
difference in Gag processing between the two viruses. Levels of fully processed p24 were 
high in all lanes, while immature Gag, running at 55 kDa, was slightly greater in NL4.3-
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WT. Interestingly, the stronger signal corresponding to a MA-CA processing 
intermediate (p41) was observed in the NL4.3-WT particle analysis, similar to that 
detected earlier in L21K-containing particles (Figure 3.3). I reasoned that although Gag 
processing may be slightly enhanced with NL4.3-WT, fully processed p24 was similar to 
levels detected with LAI-WT, and therefore the significance of such a processing 
difference might be low. Overall, it seems that the E99V MA mutation does not cause 
significant differences in Gag processing for NL4.3 virus.   
Next, single-cycle infectivity for LAI-WT, LAI-E99V, NL4.3-WT, NL4.3-E99V, 
and LAI-ΔEnv was monitored at 24 and 48 hours using the Beta-Glo assay, as 
described in Figure 3.4. In the LAI-E99V infection, I observed a major defect in 
infectivity at both the 24- and 48-hour time points, specifically a 32- and 22-fold 
reduction, respectively. However, while a 23-fold reduction in infectivity was observed at 
24 hours with NL4.3-E99V, the infection improved significantly by 48 hours to a modest 
2.3-fold reduction compared to NL4.3-WT (Figure 3.10A). Replication of LAI-ΔEnv was 
undetectable, confirming the specificity of the assay (data not shown). Thus, the 
infectivity defect associated with the E99V mutation appears to be mitigated in NL4.3-
derived particles when compared to the defects seen in LAI.   
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Figure 3.8 Effect of the E99V MA mutation on NL4.3 particle production. 
Virus was generated by transient transfection of 293T cells with proviral clones 
pNL4.3-WT and pNL4.3-E99V. Particle yield was determined by both p24 
ELISA (A) and RT analysis (B). The data represent the average of two 
independent transfections.  
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Figure 3.9 Western blot analysis of Gag processing in NL4.3- and LAI-
derived viruses. Equal RT units of the indicated virus particles were harvested 
and then resuspended in RIPA buffer, as previously described (119). Gag 
processing was analyzed by SDS-PAGE and immunoblotting using monoclonal 
antibodies directed against HIV-1 Gag, as in Figure 3.3. 
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Next, I examined whether NL4.3-E99V could initiate a spreading infection in 
MT-4 cells. Cells were inoculated with NL4.3-WT, NL4.3-E99V or LAI-ΔEnv and 
incubated for fifteen days. An aliquot of each culture supernatant was obtained every 
other day and the level of RT activity in each aliquot was measured using the RT assay. 
Figure 3.10B shows the results from this viral infectivity study. Robust levels of viral 
replication were detected in cultures incubated with NL4.3-WT, but not LAI-ΔEnv.  
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Figure 3.10 Effects of the E99V MA mutation in LAI- and NL4.3-derived 
particles. (A) Single-cycle infectivities of LAI- and NL4.3-derived viruses, with 
and without the E99V MA mutation, were assayed at 24 or 48 hours post-
infection as described in Figure 3.4.  The assessment of infectivity was based on 
the level of LAI-WT determined at 24 hours post-infection. The data is 
representative of three independent experiments performed in duplicate. (B) 
Replication kinetics of NL4.3-E99V in the MT-4 cell line. Virus stocks were 
generated in 293T cells by transient transfection, normalized based on RT activity 
and then used to infect MT-4 cells, as in Figure 3.5. A representative graph of two 
independent experiments is shown. (C) Effects of the E99V MA mutation on Env 
incorporation in LAI- and NL4.3-derived particles. Lysates from transfected 
HeLa cells (Top Panel) or virus particles (Bottom Panel) were prepared and 
analyzed as described in Figure 3.6.  
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Interestingly, I did not detect replication in the NL4.3-E99V infected culture until 
day 13. Supernatant from the NL4.3-E99V infected culture was added to fresh MT-4 
cells and permitted to incubate for longer. After a week’s time, only minimal RT activity 
was detected in this new culture, and the cells were harvested. Total DNA was extracted 
and primers specific for HIV-1 MA were used to amplify MA from proviral DNA. Upon 
sequencing, I found that the E99V mutation was still present and had not reverted back to 
E99. Thus, consistent with the data from single-cycle infectivity assays, I observed a 
significant reduction in NL4.3-E99V infectivity. However, instead of being abolished, 
virus replication may have been delayed.   
I also examined whether Env incorporation might be disrupted in NL4.3-E99V 
particles. HeLa cells were transfected with pNL4.3-WT, pNL4.3-E99V, pLAI-WT, or 
pLAI-E99V. At 48 hours, virus and the transfected cells were harvested and analyzed for 
Env incorporation and expression, respectively, as described in Figure 3.6. Immunoblot 
analyses show that Env precursor proteins were expressed at comparable levels in the 
transfected cell cultures (Figure 3.10C, Top Panel). The corresponding viral lysates 
indicate that NL4.3-E99V, but not LAI-E99V particles, contained a detectable amount of 
Env proteins (Figure 3.10C, Bottom Panel). Repeatedly, I found that while the level of 
Env incorporation was markedly reduced in NL4.3-E99V particles compared to that of 
NL4.3-WT, it was substantially higher than that of LAI-E99V particles. 
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3.3 Discussion 
In this chapter, I examined whether a highly conserved glutamate at MA position 
99 is required for the function of the protein in HIV-1 replication. I found that both 
production and processing of LAI-E99V particles were comparable to that in the wild-
type virus. However, analyses of single-cycle and spreading infection showed a 
significant infectivity defect. After introducing additional substitutions at this position, I 
discovered that a lysine for glutamate change (E99K) also imposed a similar reduction in 
infectivity. I observe a severe disruption of Env incorporation into LAI-E99V and LAI-
E99K particles through immunoblotting analyses, and then correlated this assembly 
defect to a marked reduction for fusion capacity. Next, the role for E99 in another HIV-1 
strain was analyzed, and I found that in the context of NL4.3, the E99V substitution 
imposed somewhat mitigated defects compared to those observed in LAI. Interestingly, 
the infectivity defect observed in NL4.3-E99V was consistent with a possible delay 
compared to the course of an NL4.3-WT infection. The results described here are 
summarized in Table 3.1. 
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Table 3.1 Summary of Results from Chapter 3
Single-cycle infectivities of eleven different viruses were analyzed in this chapter, 
and additional assays were performed to further characterize those defective for 
virus replication. Viruses are listed in the left hand column. The assays performed 
are given in the top row, and the findings relative to results of WT virus are 
shown. Single-cycle infectivity was determined in TZM-bl cells 24 hours post-
infection, unless indicated otherwise. Relative Env incorporation was 
approximated by Western blot using anti-gp41 mAb (Chessie 8). Spreading 
infection results refer to analysis in MT-4 cells. ND = assay not done. NS = assay 
performed but results not shown. * = infectivity results from 48 hours post-
infection. 
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To validate my findings, viral mutants with substitutions at residue 99 were 
compared to other single amino acid substitutions in MA that had been previously 
characterized. For example, a slight enhancement in Gag processing was observed in the 
L21K mutant, consistent with results from an earlier study (104). Similarly, the 
significant reduction in Env incorporation previously reported for HIV-1 particles 
containing the L13E MA mutation was also observed in my studies (72). These findings 
were substantiated by directly correlating the impairments in Env incorporation with 
marked reductions in virus-cell fusion capacity. Although several earlier studies had 
demonstrated significant MA-imposed Env incorporation defects, the corresponding 
virus-cell fusion capacities were not always analyzed. I, and others have found that oddly, 
such reductions in Env incorporation do not always correlate with an equally severe 
defect in virus-cell fusion (14, 43). Because of this phenomenon, it seems that virus-cell 
fusion assays should be directly analyzed to accurately validate a correlation between 
disrupted Env incorporation and compromised fusion.  
While most of my results using previously characterized mutants were consistent 
with earlier reports, I observed a different phenotype of the K32E MA mutant that had 
been published previously. In contrast to the 1997 study published by Lee et al., I 
observed a reduction in Env incorporation in particles generated from a K32E-containing 
clone (111). A modest defect in virus-cell fusion, observed with my LAI-K32E virus, was 
consistent with such a disruption in Env incorporation. I believe that the discrepancy 
between my findings and those from the previous report might be attributed to several 
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differences between the two studies. First, I analyzed the K32E substitution in the context 
of an LAI background, whereas the previous study examined the mutation in an HXB2R3 
clone. Second, I evaluated virus produced in HeLa cells, rather than COS-7 cells. Third, 
the Lee study did not include a Gag(-) control, which is necessary to determine whether 
the Env detected is virion associated, or from cellular vesicles pelleted along with the 
virus. And fourth, an α-gp120 Ab had been used to detect Env in the Lee study, while I 
used Chessie 8, an α-gp41 Ab. In spite of these differences, it is worth noting that my 
results are consistent with an Env incorporation defect associated with a different 
substitution in MA residue 32 (14, K32I mutant). 
NMR and X-ray crystallographic studies have determined that this highly 
conserved glutamate at MA residue 99 resides in the protein’s C-terminal helix, a domain 
that encompasses residues 96 through 121 (93, 124). Although substitutions of residue 99 
have not been previously examined, several groups have observed various defects caused 
by other mutations in this region. One study reported that transfection of an HIV-1 clone 
encoding an A100E MA point mutation failed to produce virus (72). Later, the same 
group produced a K98E MA mutant and although virus particles were produced, there 
was an increase in membrane bound Gag in producer cells and replication was delayed 
(150). Other studies have suggested that MA residues T97 and K98 may both be involved 
in PI(4,5)P2 binding at the cell membrane (150, 174). Finally, an Env incorporation 
defect was associated with an HIV-1 mutant containing a deletion in MA amino acids 98-
100. Taken together, these findings suggest that the beginning of the C-terminal helix is 
involved in Gag targeting and assembly.  
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My studies indicate that MA E99 might specifically be involved in the Env 
incorporation step during virus assembly. One possibility is that E99 is necessary for 
maintaining the overall structure of MA, and certain substitutions at this position might 
indirectly affect Env incorporation by preventing the correct folding of the MA protein. 
Conversely, E99 may have a direct function in Env incorporation via a specific 
interaction with viral glycoproteins. It has been suggested that during assembly, MA 
trimers form a lattice structure containing an arrangement of spaces large enough to 
accommodate the cytoplasmic tails of gp41 trimers (93, 124, 165). Additionally, others 
have speculated that the C-terminal tail of gp41 might bind to several different MA 
protein surfaces within the hexameric lattice (124). Although the crystal structure of MA 
in the context of Gag has not yet been deciphered, antibody-mapping studies have 
suggested that E99 in Gag is solvent-exposed (124, 157). Therefore, E99 might be 
considered as a potential binding site for the C-terminal tail of gp41. Alternatively, E99 
might interact with cellular or other viral proteins that stabilize Gag: Env complexes 
required for the retention of Env in virus particles. The human protein TIP47 has been 
previously reported to be involved in Gag: Env interactions (116). Although this study 
identified MA residues L12, W15 and E16 to interact with TIP47, the authors note that 
this association might involve other portions of MA as well. Therefore, TIP47 might be a 
cellular factor that selectively binds to E99. 
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CHAPTER IV: IDENTIFICATION OF A COMPENSATORY 
MUTATION AT MA RESIDUE 84 
4.1 Introduction 
When characterizing viral mutants containing single amino acid substitutions, 
several groups have identified second-site changes that can rescue the phenotype 
conferred by the original mutation. The identification of compensatory changes can offer 
valuable insight into the relationship between protein structure and function by defining 
possible inter- and intra-molecular interactions. There are several ways a second-site 
change can offset the original mutation when the two residues occur in the same protein. 
First, the two amino acids may directly interact in the context of a single functional or 
structural domain, and one mutation may restore the association that was disrupted by the 
other. In this case, the two residues may be close to one another in the primary sequence 
of the protein, or they could be distant in primary structure but proximal in the tertiary 
structure. Alternatively, the residues may be distant in the tertiary structure of the 
molecule, but interact in the quaternary structure of the functional protein, possibly 
through an interface between monomers. The second way a mutation might compensate 
for the original defect is if it falls within a domain that is separate from, but functionally 
linked to the region containing the primary-site mutation. For example, the two residues 
may interact with a common host or viral factor, and the second-site change may restore 
this interaction. In the third way, the compensatory mutation may offset a global 
conformational change brought about by the first substitution, restoring the original 
function of the protein. 
  
87 
By isolating and sequencing emergent viruses, previous groups have identified 
second-site compensatory changes in MA that specifically reverse a primary defect in 
Env incorporation. For example, one study determined that the impairment in Env 
incorporation imposed by the MA L13E mutation is reversed by a V35I substitution in 
the same protein (69). Similarly, the phenotype of a different substitution at MA residue 
35 (V35E), which also abrogated Env incorporation into virus particles, could be offset 
by the single amino acid change Q63R (150). Interestingly, neither the V35E nor the 
Q63R secondary substitutions alone abrogated Env incorporation. Such observations 
suggest the possibility that second-site mutational analyses can also reveal residues in the 
protein with more subtle involvements in a particular process, as their role may only be 
evident in the context of the primary site mutation.  
I used a molecular genetic approach to identify a residue that compensates for the 
defects associated with substitutions at MA E99 in LAI. With the identification of this 
second-site mutation, located at MA position 84, I was able to broaden my initial 
hypothesis that implicated the MA C-terminal helix in Env incorporation. Here, I present 
evidence that also associates a C-terminal hydrophobic pocket of MA in facilitating HIV-
1 Env incorporation.  
4.2 Results 
4.2.1 Identification of MA residue 84 in potentially modulating E99V-
associated defects 
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In the previous chapter, I showed that the E99V MA mutation, when introduced 
into an LAI-WT proviral clone, causes severe defects in Env incorporation, virus-cell 
fusion and infectivity. However, I found that the E99V-associated Env incorporation and 
infectivity defects appeared to be mitigated in the context of the NL4.3 strain. Therefore, 
I considered whether the phenotypic discrepancies observed between the two viruses 
(LAI-E99V and NL4.3-E99V) might be due to an inherent amino acid difference in their 
respective MA proteins.  
I aligned the amino acid sequences of the LAI- and NL4.3-MA proteins, and 
found non-conservative changes at four positions: 28, 84, 124, and 125 (Figure 4.1A). 
Using PyMOL, I then established the positions of these residues on a published 3-
dimensional structure of HIV-1 MA [PDB ID code 1UPH, (191)], and examined their 
positions relative to residue E99 (Figure 4.1B). My studies revealed that of these four 
amino acids, residue 84, a threonine in LAI and a valine in NL4.3, lies in close proximity 
to the glutamate at position 99.  
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Figure 4.1 Amino acid differences between the LAI and NL4.3 MA proteins 
and their locations relative to E99. (A) Alignment of the LAI and NL4.3 MA 
protein sequences showing four non-conservative amino acid differences, 
highlighted in red. Conservative differences are highlighted in blue, and the 
common glutamate at residue 99 is shown in green. (B) A ribbon diagram of the 
HIV-1 MA structure [PDB ID code 1UPH, (191)] showing that residue 84, a 
threonine in LAI and a valine in NL4.3, has closest proximity to residue 99, 
compared to the positions of the three other non-conservative changes.  
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4.2.2 MA V84 modulates the E99V-associated defects 
Because of its relative proximity, I considered whether the amino acid difference 
at position 84 might affect the degree to which the E99V substitution imposes its defects 
in these two HIV-1 strains. To test this possibility, I use PCR-based site-directed 
mutagenesis to introduce a T84V mutation into pLAI-WT and pLAI-E99V, or the 
reciprocal mutation, V84T, into pNL4.3-WT and pNL4.3-E99V. Each mutant proviral 
clone, pLAI-WT, or pNL4.3-WT, were individually transfected into 293T or HeLa cells. 
After 48 hours, virus in culture supernatants and the HeLa producer cells were harvested. 
The viruses were then subjected to analyses by the single-cycle infectivity assay, Western 
blot or the virus-cell fusion assay. 
Figure 4.2 shows results from Beta-Glo infectivity assays in TZM-bl cells using 
the indicated viruses. On its own, the threonine to valine change at MA position 84 in 
LAI (LAI-T84V) resulted in particles that were slightly more infectious than those 
containing the wild-type protein (upper graph). Conversely, the level of infectivity for 
NL4.3-derived particles with the solo mutation at position 84 in MA (NL4.3-V84T) was 
somewhat lower than that for NL4.3-WT (lower graph). These data suggest that in the 
context of an otherwise wild-type MA protein, a valine rather than threonine at position 
84 might be more conducive for virus infectivity.  
Examination of viruses with changes at both positions 84 and 99 in MA revealed 
that inclusion of the V84T substitution in NL4.3-E99V particles (NL4.3-V84T/E99V) 
completely ablated viral infectivity (lower graph). Strikingly, the addition of the 
reciprocal T84V MA mutation into LAI-E99V particles (LAI-T84V/E99V) restored 
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infectivity to wild-type levels (upper graph). These data strongly suggest that a valine at 
position 84 in MA is sufficient to rescue the infectivity defect associated with the E99V 
MA mutation in both of these HIV-1 strains, although to varying extents.   
Immunoblot analyses of the indicated viral lysates using an anti-Env mAb are 
shown in Figure 4.3A. No disruption in Env incorporation was observed for the LAI- or 
NL4.3-derived viruses with a single amino acid substitution at MA residue 84. By 
contrast, NL4.3-V84T/E99V particles were nearly devoid of Env proteins (lower panel). 
Consistent with the infectivity data, Env incorporation into LAI-T84V/E99V particles 
was indistinguishable from that of LAI-WT (upper panel). Env precursor proteins were 
expressed at comparable levels in the corresponding transfected HeLa cell lysates (Figure 
4.3B). 
Results from the corresponding membrane fusion assays are shown in Figure 4.4. 
I found that amino acid substitutions in residue 84 of MA in LAI- or NL4.3-derived 
viruses had no discernible effect on their ability to fuse with cell membranes. Similar to 
LAI-E99V and NL4.3-E99V, BLaM activity was deficient in cells incubated with NL4.3-
V84T/E99V (lower graph). Most important, cells treated with LAI-T84V/E99V 
contained levels of BLaM activity comparable to those produced with LAI-WT (upper 
graph). Thus, a valine at residue 84 in MA is sufficient to restore membrane fusion 
capability in LAI- or NL4.3- derived particles containing an E99V substitution. 
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Figure 4.2 Single-cycle infectivities of LAI- or NL4.3-derived viruses bearing 
single or double mutations at MA positions 84 and 99. TZM-bl cells were 
infected with LAI- (upper graph) or NL4.3- (lower graph) derived viruses. 
Single-cycle infectivities were monitored 48 hours post-infection, using the Beta-
Glo reporter assay, as described in Figure 3.4. The assessment of infectivity for 
each mutant virus was based on the level of LAI-WT (upper graph) or NL4.3-
WT (lower graph), which represented 100% infectivity. The amino acid 
identities at positions 84 and 99 in each virus are indicated above the bars of both 
graphs. The data shown is representative of two independent experiments 
performed in duplicate.  
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Figure 4.3 Effects of mutations at MA position 84 on Env incorporation in 
LAI- and NL4.3-derived particles bearing the E99V MA substitution. Lysates 
from LAI- (upper panel) or NL4.3- (lower panel) derived viruses (A), and their 
corresponding transfected HeLa cell lysates (B), were prepared and analyzed as in 
Figure 3.6.  
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4.2.3 MA V84 modulation is specific for MA E99 mutations 
From the data presented in Figure 4.2, I showed that valine, rather than threonine, 
at position 84 of MA was more favorable for virus infectivity in the context of both LAI 
and NL4.3 strains. However, the improvement observed in infectivity in an otherwise 
wild-type MA protein was far less dramatic than what I had observed in the context of 
E99V.  Therefore I considered whether the rescue by the T84V mutation was specific for 
changes at E99, or whether it was a more general phenomenon that could dramatically 
rescue defects imposed by substitutions of other MA residues.  
To determine the specificity of rescue for residue 99 by T84V, I next investigated 
whether the T84V mutation in LAI could similarly rescue the defects observed with 
E99K, L13E or K32E MA mutations. Using PCR-based site-directed mutagenesis, the 
T84V MA mutation was introduced into pLAI-E99K, pLAI-K32E, and pLAI-L13E to 
generate pLAI-T84V/E99K, pLAI-T84V/K32E and pLAI-T84V/L13E proviral clones, 
respectively. Each LAI-based clone encoding the double amino acid substitutions were 
individually transfected into 293-T in parallel to their counterparts containing the single 
MA mutations. At 48 hours post-transfection, virus in culture supernatants were 
harvested and normalized for subsequent analysis as in previous experiments. 
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Figure 4.4 Effects of single and double MA substitutions on virus-cell 
membrane fusion capacity in LAI- and NL4.3-derived viruses. Virus-cell 
fusion events in TZM-bl cells, using LAI- (upper graph) or NL4.3- (lower 
graph) derived viruses, were assayed as described in Figure 3.7. The data shown 
is representative of three independent experiments performed in duplicate.  
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Single-cycle infectivity was monitored in TZM-bl cells 24 hours after inoculation 
with each virus. The results were assessed with the Beta-Glo reporter assay and are 
presented in Figure 4.5. I found that in addition to enhancing infectivity of LAI 
containing an otherwise wild-type MA protein, the threonine to valine change at position 
84 also improved infectivity of viruses bearing each of the E99K, L13E or K32E MA 
mutations. Aside from virus encoding the E99V substitution, the T84V mutation most 
significantly enhanced infection of the LAI-E99K virus, which improved from about 2% 
to 40% of WT levels. In contrast to the considerable augmentation of infectivity in the 
context of the E99V or E99K substitutions, the T84V mutation only modestly boosted 
virus replication in the context of the L13E or K32E MA mutations.  
To determine whether the degree of rescue in infectivity by the T84V mutation is 
a function of virus titer, I performed similar Beta-Glo assays across four, two-fold 
dilutions of virus. The specific fold-increase in infectivity conferred by the T84V 
mutation was calculated in the context of each primary MA substitution, and the data 
across different viral inputs is presented in Table 4.1.  
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Figure 4.5 Effects on infectivity by the T84V MA mutation on LAI- derived 
particles bearing primary MA mutations. LAI-derived viruses bearing primary 
MA mutations in the presence or absence of the T84V MA substitution were used 
to infect TZM-bl cells. Single-cycle infectivities were monitored 24 hours post-
infection using the Beta-Glo reporter assay. The assessment of infectivity for 
each mutant virus is based on the level of LAI-WT, which represents 100% 
infectivity. Data is the average of four independent experiments performed in 
duplicate. 
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Table 4.1 Fold enhancement in relative infectivity of LAI-derived viruses 
bearing the T84V MA substitution 
 
The data is presented as fold improvement between viruses with primary MA 
mutations (as indicated in the top row) with, and without, the additional T84V 
change, at four serial dilutions (indicated in the left column as RT units of virus 
per well). Data shown are the averages of four independent Beta-­‐Glo infectivityassays analyzed 24 hours post-infection, performed in duplicate.  
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Overall, I did not observe any changes in relative infectivities that corresponded 
to viral titer. At each virus dilution, I observed a 1-2-fold enhancement in infectivity 
when the T84V MA mutation was expressed in the context of an otherwise wild-type MA 
protein. Similarly, I observed a modest 1-3-fold enhancement in viral infectivity when 
T84V was expressed alongside either of the L13E or K32E mutations. However, when 
presented in this way, the significance of T84V-imposed enhancements in the contexts of 
E99V or E99K MA substitutions was quite evident. Specifically, the relative luciferase 
units (RLU) of infections with LAI-E99K/T84V were improved by 20- to 43-fold when 
compared to TZM-bl infections with LAI-E99K. These findings were similar to the E99V 
rescues, which ranged from a 31- to 35-fold enhancement at each titer. In general, I found 
that a valine at residue 84 confers a modest improvement in infectivities in most MA 
contexts. However, these data strongly suggest that the rescue observed alongside an 
E99V or E99K MA mutation is unique and specific.  
Next, to determine whether the T84V mutation specifically improves Env 
incorporation in Env-deficient MA mutants, pLAI-WT, pLAI-E99V, pLAI-E99K, pLAI-
L13E pLAI-K32E, pLAI-T84V, pLAI-T84V/E99V, pLAI-T84V/E99K, pLAI-
T84V/L13E, pLAI-T84V/K32E and pLAI-Gag(-) were transfected into HeLa cells. The 
viral supernatants and producer cells were individually collected 48 hours later and 
processed as described previously (52).  
Immunoblot analyses of the corresponding viral and cellular lysates are shown in 
Figure 4.6. Again, Env precursor proteins were expressed at comparable levels in each of 
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the corresponding transfected HeLa cell lysates (bottom panel). In the vial lysate blots 
shown in the top panel, slight differences in viral content were demonstrated by the anti-
p24 mAb blot, despite equal amounts of virus loaded in each lane. For example, it 
appeared as though more virus was present in the LAI-E99V/T84V lane, compared to the 
virus in LAI-T84V or LAI-WT lanes. Overall, less virus RT units were used per lane in 
this blot, compared to the viral RT units loaded in the immunoblot from Figure 3.6, 
which might explain why Env was not detected in this LAI-K32E lane. Nevertheless, a 
distinct band at 41 kDa was detected in both the LAI-WT and LAI-E99V/T84V viral 
lysates, demonstrating the efficient processing and packaging of gp41 in these particles. 
Although not at levels equal to the LAI-E99V/T84V lysate, gp41 was clearly detected in 
LAI-E99K/T84V particles. This demonstrates a partial, but significant rescue in Env 
incorporation by the T84V mutation in the context of an E99K MA mutation, and agrees 
with the partial, but significant rescue observed in the infectivity studies. Interestingly, a 
similar band was observed in the LAI-K32E/T84V virus, and might represent a slight 
improvement in Env incorporation over the LAI-K32E particles. However, loading 
differences in the LAI-K32E and LAI-K32E/T84V lanes may also account for this 
observation. It is interesting to note that the similar gp41 bands observed in the LAI-
K32E/T84V and LAI-E99K/T84V lanes mimicked the comparable infectivities of these 
viruses that were demonstrated in Figure 4.5A. By contrast, Env was not detected in the 
LAI-L13E/T84V virus, again suggesting that the T84V mutation does not rescue the Env 
incorporation defect conferred by the L13E MA mutation. Taken together, these results 
agree with the infectivity data, demonstrating that while a T84V mutation confers a 
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modest improvement in defects associated with many MA mutations, a quite significant 
recovery is observed in the context of E99 substitutions. 
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Figure 4.6 Effects of the T84V MA substitution on Env incorporation in LAI-
derived particles containing WT MA or other MA mutations. Lysates from 
virus particles (top panel), or transfected HeLa cells (bottom panel) were 
prepared and analyzed by Western blotting, as in Figure 3.6. 
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Lastly, to determine whether the T84V mutation could rescue fusion defects in 
various MA mutants, pLAI-WT, pLAI-E99V, pLAI-E99K, pLAI-L13E, pLAI-K32E, the 
corresponding T84V double mutants, and pLAI-∆Env were individually transfected into 
293T cells, along with the pBLaM-Vpr expression plasmid. Viruses were harvested and 
processed as previously described, and equal amounts were used to infect TZM-bl cells 
for the fusion assay.  
Results from this fusion experiment are shown in Figure 4.7. Similar to the 
infectivity data, a valine at residue 84 appears to improve the capacity for membrane 
fusion in cells incubated with each virus tested. However, the degree of improvement 
varied, and was most evident in the context of the E99V and E99K mutations. Fusion of 
LAI-E99K/T84V particles with cells was significantly greater than that in the LAI-∆Env 
infection, improving to levels of about 50% that in the LAI-T84V infection, and 
demonstrates a greatly improved fusion capacity compared to that with LAI-E99K 
particles (fusion of LAI-E99K was presented in Figure 3.5). Only a slight enhancement 
of fusion was observed between LAI-L13E/T84V virus and target cells, when compared 
to that with LAI-∆Env, which corresponded to the minor improvement observed in the 
infectivity results. Lastly, although fusion appeared to be completely rescued in the LAI-
K32E/T84V infection, only a modest fusion defect was observed in the original LAI-
K32E virus infection, and therefore the improvement may only be about 2-fold (fusion of 
LAI-K32E was presented in Figure 3.5). 
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Figure 4.7 Effects of single and double MA substitutions on virus-cell 
membrane fusion capacity in LAI-derived viruses. Virus-cell fusion events in 
TZM-bl cells were assayed as described in Figure 3.7. The data shown is 
representative of three independent experiments performed in duplicate.  
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4.3 Discussion 
Using a molecular genetic approach, I identify a substitution at MA residue 84 
that counteracts the E99V-imposed defects in the LAI HIV-1 strain. Introduction of this 
T84V change in the context of the original E99V mutation caused a significant 
improvement in Env incorporation, virus-cell fusion and single-cycle infectivity assays. 
These findings indicate that T84V is sufficient to reverse the defects imposed by the 
original E99V amino acid change in LAI. I also demonstrated that in the NL4.3 
background, a valine at residue 84 only partially compensates for the severe infectivity 
defects imposed by the T84, V99 combination in MA. Finally, analyzing the T84V 
mutation in the context of individual MA substitutions L13E, K32E or E99K 
demonstrates that V84 seems to specifically improve defects conferred by E99 mutations, 
above the enhancements it confers in the context of wild-type MA. The results from each 
clone analyzed in this chapter are summarized in Table 4.2. 
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Table 4.2 Summary of Results from Chapter 4 
 
The different viruses analyzed in this chapter are listed in the left hand column. 
The assays performed and individual findings relative to results from the wild-
type parental virus are indicated. Single-cycle infectivity was determined 24 hours 
post-infection, unless indicated otherwise. Relative Env incorporation was 
approximated by Western blot using anti-gp41 mAb (Chessie 8). * results from 48 
hours 
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Both NMR and X-ray crystallographic techniques have determined that residue 84 
falls within the fourth helix of MA, a region almost entirely buried inside the tightly 
packed globular core of the MA protein (31, 93, 124). This fourth helix makes up part of 
a hydrophobic pocket, created by the N-terminus of MA Helix V packing alongside 
residues of Helix IV (30, 93). It has been suggested that instability of this pocket, which 
includes residues V84, Y86, I92, V94, A100, and K103, might compromise the overall 
structure of the MA core domain (30). Based on these residues and the determined 
structure of MA, I recognized that E99 also appears to fall in the vicinity of the pocket. I 
speculated that this region may have a role in Env incorporation, and that in addition to 
V84, E99 may be necessary for its stabilization. However, as a polar amino acid, E99 is 
unlikely to contribute to the hydrophobicity of this domain. Therefore, it seems unlikely 
that maintaining the Env incorporation function of this C-terminal MA hydrophobic 
pocket may necessitate either an interaction between the side chains of residues 84 and 
99, or possibly between these residues and a host or viral bridging protein. It is also 
possible that these two residues somehow compensate for the overall changes, in pocket 
stability or function, incurred by mutations at either position. 
It is worth noting that I consistently found a valine at residue 84 to be more 
conducive to viral replication compared to a threonine. Since this was observed in the 
context of an otherwise wild-type virus, it was not surprising that marginal improvement 
in infectivity correlated to the introduction of V84 in both the LAI-K32E and LAI-L13E 
mutants. However, it is apparent that the rescues observed when T84V is expressed 
alongside the E99V or E99K mutations were notably more conspicuous. Specifically, 
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while V84 improved the K32E- or L13E-imposed infectivity defects by 1- or 2- fold, V84 
enhanced the infection of viruses containing E99K or E99V by about 35- and 32-fold. 
The overall improvements seen in each virus when residue 84 is a valine is consistent 
with the hypothesis that this residue is critical for stabilization of the hydrophobic pocket. 
However the specific improvement observed with the E99 mutations suggest that either 
E99 is also critical for the stabilization of this pocket, or V84 improves E99 mutations by 
a mechanism independent of this hydrophobic pocket stabilization.  
Although a valine at residue 84 correlates with enhanced infectivity, I was 
surprised to find that a threonine is present more frequently at this position in MA. 
Sequence alignment of >1100 MA proteins from HIV-1 Group M, subtypes A through K, 
reveals a threonine and a valine in this position in 82% and 17% of the strains, 
respectively. I also find it interesting that two amino acids associated with vastly different 
polarities and sizes could be present at one position 99% of the time. Also curious is that 
the residue correlated with enhanced infectivity (V84) is present less frequently than the 
amino acid linked to inferior replication kinetics (T84). In considering this, I reasoned 
that enhanced infectivity, as measured with laboratory assays using cells in culture, may 
not confer an advantage in virus replication in vivo. For example, if a valine at residue 84 
does vastly enhance single-cycle infectivity in vivo, then the incidence of super-infection 
(defined here as multiple viruses infecting a single cell) may occur too frequently.  It is 
possible that super-infection events are more easily detected by the host cell, in 
comparison to the recognition of a single virus entering into a cell. In turn, apoptosis may 
be triggered before nascent particles are ready for release, which would negatively affect 
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the fitness of that virus. Alternatively, V84 may cause an overall structural change in 
MA, and while this may be advantageous for infectivity in cell culture, it may establish 
an epitope more easily neutralized by host immunity.  
The E99V-associated defects observed with V84 in NL4.3-derived particles, but 
not in LAI, reveal a greater degree of complexity between these two residues in Env 
incorporation, virus-cell fusion and infectivity. Data gathered from single-cycle and 
spreading infection assays of NL4.3-E99V suggest a delay in the replication kinetics of 
this virus. Consistent with this possibility, a considerable defect in virus-cell fusion was 
evident for NL4.3-E99V at each of the time points analyzed (Figure 4.5, lower graph), 
despite a relatively modest Env incorporation defect, as assessed by Western blot (Figure 
4.4, upper panel). Observing a greater level of BLaM activity in cells after extended 
incubation with NL4.3-E99V, but not with LAI-E99V, would provide more evidence for 
a delay in virus-cell fusion. The phenotypic variation observed between LAI- and NL4.3- 
derived viruses containing valines at both positions 84 and 99 might be the result of 
additional amino acid dissimilarities between the two strains. For example, positions 28, 
124 and 125 also differ in LAI-MA and NL4.3-MA, and these non-conservative amino 
acid differences may contribute to the dissimilar phenotypes (Figure 4.1A). Alternatively, 
variations encoded within other viral proteins could also be responsible for the observed 
phenotypes. 
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CHAPTER V: IDENTIFICATION OF AN ADDITIONAL DEFECT 
IMPOSED BY E99 MA MUTATIONS AT AN EARLY, POST-
FUSION STEP 
5.1 Introduction 
As discussed in Chapter 1, the incorporation of full-length Env into HIV-1 
particles seems to be dependent upon an interaction between the viral gp41 cytoplasmic 
tail (CT) and the MA domain of Gag. In contrast, the packaging of heterologous viral 
envelopes into HIV-1 seems to occur through a MA-independent mechanism. Many 
believe that this discrepancy is linked to the unusually long CT of HIV-1 Env, as it has 
been suggested that the extraordinary length of HIV-1 gp41 may sterically hinder its 
incorporation into virus particles in a way that only the HIV-1 MA can accommodate (71, 
93). In general, extended cytoplasmic domains are a unique property of many lentiviral 
envelope glycoproteins, when compared to those of other retroviruses. For example, most 
simple retroviruses have CTs of 20 to 50 amino acids in length, whereas the lentiviruses 
HIV-1, HIV-2 and SIV all have cytoplasmic domains of about 150 residues (53). 
Previously, it has been observed that the Env incorporation defects in HIV-1 MA 
mutants can be overcome by pseudotyping particles with heterologous envelopes bearing 
shorter CTs (14, 43, 52, 69, 71, 104, 214). The glycoprotein of the Vesicular Stomatitis 
Virus (VSV-G) is commonly used in such pseudotyping experiments, as its short CT 
permits packaging into many different viruses, and its use of a common receptor confers 
a broad cellular tropism to the pseudotyped particle. To facilitate virus entry, the VSV 
glycoprotein binds to a phospholipid receptor at the surface of a target cell (10, 210). This 
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interaction promotes the formation of clathrin-coated pits, which enables the virus to be 
internalized via endocytosis. Fusion activity of the glycoprotein is then activated within 
the endosome by the eventual decrease in pH inside the vesicle. This process deposits the 
viral core into the cytoplasm of the cell, often at a site proximal to the nuclear periphery 
(2).   
Although VSV-G pseudotyping can be a useful way to restore fusion in a mutant 
virus, this endocytic entry can obscure analyses regarding the nature of the initial 
impairment. This is because it not only overcomes a fusion block, but also may bypass a 
post-entry restriction that would be encountered if fusion were to take place at the PM. 
To mimic the normal mode of HIV-1 entry, and in turn examine the presence of an early 
post-entry block, many studies have relieved Env incorporation defects in MA mutants 
through truncation of the HIV-1 gp41 CT (14, 43, 69, 71, 104, 118, 142). Thus, the 
truncated Env is packaged via a MA-independent mechanism, in a manner similar to the 
incorporation of other glycoproteins bearing shorter CTs. It is believed that in vivo, the 
extended length of the Env CT is beneficial for HIV-1 replication (70, 180). This 
hypothesis is based on the fact that very few primary isolates have been found with 
extensive deletions in the gp41 CT (180). However, its importance for infection in cell 
culture has been questioned, since many cell lines, such as MT-4 and those derived from 
HeLa cells, can support productive infections of HIV particles containing gp41 
truncations (118, 142, 205). In this chapter, I used the Env truncation and VSV-G 
pseudotyping methods to further characterize the infectivity defects imposed by the E99V 
and E99K MA mutations. 
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5.2 Results 
5.2.1 HIV-1 Env truncation restores fusion but not infectivity of viruses with 
mutations at MA E99 
 
To examine whether the fusion and infectivity defects imposed by MA mutations 
E99V and E99K can be reversed by truncating sequences within the long cytoplasmic 
domain of HIV-1 gp41, PCR-based site-directed mutagenesis was used to introduce two 
consecutive stop codons into the gp41 coding sequences of pLAI-WT, pLAI-E99V, 
pLAI-E99K, pLAI-K32E or pLAI-L13E. The gp41 proteins generated from transfection 
of the resulting proviral clones (pLAI-∆144, pE99V-∆144, pE99K-∆144, pK32E-∆144, 
and pL13E-∆144, respectively) contain an abbreviated CT that is six residues in length, 
instead of the normal 150 amino acids. Each mutant proviral clone, or pLAI-∆Env, was 
individually transfected into 293T cells. Viruses in culture supernatants were harvested 
48 hours post-transfection, and then normalized by RT content for subsequent analysis.  
The Beta-Glo assay system was used to monitor single-cycle infectivity of 
viruses with either full length or truncated HIV-1 gp41. Four serial dilutions of each virus 
were used to infect TZM-bl cells, and their relative infectivities were analyzed 24 hours 
post-infection. Upon comparison of the raw data, I found that the LAI-∆144 particles 
were more infectious than LAI-WT, at each dilution (data shown in Appendix B, Tables 
B.1 and B.2). This result was consistent with previous studies (205, 208), and is likely 
due to the removal of a tyrosine-based endocytic motif normally present in the gp41 
cytoplasmic domain. In the absence of this signal, Env expression is increased at the 
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surface of producer cells, which likely favors more efficient packaging of Env into 
particles (173).  
To evaluate virus infection across the four dilutions, I assigned the infectivity 
values of the LAI-WT or LAI-∆144 infections to represent 100%, and then infections 
with the other viruses were adjusted accordingly at each titer. These normalized values 
for each virus bearing either full-length or truncated gp41 are presented in Tables 5.1 and 
5.2, respectively. Adjusted in this way, it is evident that the truncated Env augmented 
infectivity of each MA mutant consistently across the different titers. However, it was 
also apparent that the extent of rescue varied among the different MA mutations. The 
presence of a short gp41 CT rescued the infectivity defects associated with each of the 
L13E and K32E MA mutations to levels comparable to the WT-∆144 infection. By 
contrast, only a modest enhancement was observed with viruses bearing the E99V or 
E99K mutations. Therefore, I concluded that truncation of the gp41 CT was not able to 
reverse the infectivity defects associated with either of the E99 MA substitutions. 
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Table 5.1 Relative infectivities of LAI-derived viruses bearing single amino 
substitutions in MA
The data shown are normalized from the RLU values presented in Table 8-2, and 
represent averages of four independent Beta-­‐Glo infectivity assays analyzed 24 
hours after TZM-bl cells were infected with four serial dilutions of the indicated 
virus. The normalized values are based on results from the LAI-WT infection, 
which represents 100% infectivity at each titer. 
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Table 5.2 Relative infectivities of LAI-derived double mutants bearing gp41 
cytoplasmic domain truncation and individual substitutions in MA
 
The data shown are normalized from the RLU values presented in Table 8-3, and 
represent averages of four independent Beta-­‐Glo infectivity assays analyzed 24 
hours after TZM-bl cells were infected with four serial dilutions of the indicated 
virus. The normalized values are based on results from the WT-∆144 infection, 
which represents 100% infectivity at each titer. 
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Since the data demonstrate that LAI-∆144 was more infectious than equal RT 
units of LAI-WT, I decided to compare dilutions of the two viruses that resulted in 
similar values, which would likely correspond to a comparable MOI in each infection. I 
determined that the average RLU value from infection with 5K RTU of LAI-WT was 
similar to the RLU values from the 2.5K RTU LAI-∆144 infection, and the relative 
infectivities of each virus are shown in Figure 5.1A.  
Although low levels of infection were detected in TZM-bl cells inoculated with 
E99V-∆144 and E99K-∆144, the possibility remained that these viruses might still have 
the capacity to initiate a spreading infection. To examine this, equal RT units of LAI-
∆144, E99V-∆144 or LAI-ΔEnv were used to infect MT-4 cells in a 24-well plate. The 
cells were washed after four hours, and then replated in fresh media. Small aliquots of the 
culture supernatants were collected every other day for two weeks, and then analyzed for 
RT activity. The data, shown in Figure 5.1B demonstrates that robust levels of virus 
replication were detected in cells incubated with LAI-∆144, but not in LAI-ΔEnv. 
Overall, spreading infection was markedly reduced with particles bearing the E99V MA 
substitution, compared to the cells inoculated with LAI-∆144. However, after 11 days, 
some RT activity was detectable in the E99V-∆144 infected cultures. Supernatant from 
the E99V-∆144 day 15 culture was then used to infect fresh MT-4 cells. Minimal RT 
activity was detected after a week (data not shown), and the cells were harvested at that 
time. Total cellular DNA was extracted and proviral DNA was sequenced using primers 
specific for the MA region. Although the E99V mutation was still present, the 
continuously low levels of infection led me to conclude that overall, particles bearing the 
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E99V MA substitution had a reduced capacity to initiate single–cycle and spreading 
infections, even with the gp41 truncation.  
Since the impairments in single-cycle infectivity associated with the L13E and 
K32E MA mutations were both rescued by Env truncation, I concluded that functional 
Env trimers were indeed expressed and incorporated into these particles. However, since 
the possibility remained that the MA mutations were somehow reducing expression or 
packaging of truncated Env, I decided to analyze Env incorporation in the E99V-∆144 or 
E99K-∆144 particles. Pseudotyped viruses with truncated CTs were generated through 
transient transfection of HeLa cells. After 48 hours, viruses and producer cells were 
harvested and processed for immunoblot analysis, as descried earlier. I found that the 
Chessie 8 antibody used in previous experiments could not detect the truncated 
glycoproteins, probably due to the loss of a required epitope. Two different antibodies 
directed against gp120 (Clone VT-21 and Chessie 6, both from NIH AIDS Research & 
Reference Reagent Program), and serum from an HIV-seropositive patient (a gift from K. 
Luzuriaga), were also used to detect Env in producer cells and viral lysates. 
Unfortunately, the Env glycoproteins with short cytoplasmic tails were not detected in 
any of the particles or producer cells, even though the infectivity data indicated proper 
expression and packaging into LAI-∆144 particles. Since an antibody to detect the 
truncated form of gp41 was unavailable, I was unable to determine whether truncated 
Env was expressed and incorporated into E99V-∆144 or E99K-∆144 particles. 
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Figure 5.1 Effects on infectivity by Env truncation in LAI-derived particles 
bearing individual MA mutations. (A) Single-cycle infectivities of LAI-derived 
viruses, containing either full length (blue bars, inoculated at 5K RTU/well) or 
truncated (red bars, inoculated at 2.5K RTU/well) HIV-1 Env, were monitored in 
  
120 
TZM-bl cells 24 hours post-infection using the Beta-Glo reporter assay. The 
assessment of infectivity for each mutant virus was based on the levels in LAI-
WT or LAI-∆144 infections, which represented 100% infectivity. The data shown 
is the average of four independent experiments performed in duplicate. (B) Equal 
RT units of the indicated viruses were used to infect MT-4 cells, and virus 
replication kinetics were monitored every other day for two weeks, as described 
in Figure 3.5. Fresh cells and media were added to each culture on day seven. A 
representative graph of two independent experiments, performed in duplicate, is 
shown.  
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Next, the fusion capacity of these particles were analyzed, using the BLaM assay 
described previously. Each proviral clone with a truncated Env, or pLAI-∆Env, was co-
transfected into 293T cells with an expression vector for BLaM-Vpr. Equal amounts of 
each virus were used to infect TZM-bl cells, and virus-cell fusion was monitored, as 
described for Figure 3.6. The data from this virus-cell fusion assay is shown in Figure 
5.2. Supporting my infectivity results, I found that BLaM activity was comparable in 
cells incubated with particles containing truncated Env and MA mutations K32E or 
L13E, or WT MA. Remarkably, the levels of BLaM activity in cells treated with E99V-
∆144 or E99K-∆144 were also comparable to the LAI-∆144 infection at each time point 
analyzed. Therefore, despite an inability to monitor Env packaging by Western blot, the 
high capacity to initiate virus-cell fusion, as detected with this assay, suggests that 
truncated Env was indeed incorporated into E99V-∆144 and E99K-∆144 particles at 
levels comparable with WT-∆144. Most important, these results suggest that although 
Env truncation could not rescue their infectivity defects, this modification was able to 
reverse the diminished fusion capacity imposed by the E99V and E99K MA 
substitutions.  
The incongruity between my fusion and infectivity data for the E99V-∆144 and 
E99K-∆144 particles suggests that in addition to disruptions in Env incorporation, the 
E99V and E99K MA mutations might also impose a post-entry restriction to productive 
infection. To evaluate the early step for which E99V-∆144 particles might be defective, 
early products (EP) were analyzed in target cells incubated with E99V-∆144. EPs are the 
first part of the viral genome to be reverse transcribed, and they are used as a marker for 
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reverse transcription initiation. Prior to infection, equal amounts of LAI-∆144 or E99V-
∆144 viruses (as determined by RT analysis) were treated with DNase, to eliminate any 
contaminating DNA carried over from the transfection procedure. MT-4 cells were then 
challenged with the DNase-treated viruses in a 12-well plate, and equal volumes of cells 
were harvested from each well at 1, 5, 8 or 24 hours post-infection. When cells from each 
time point were collected, total DNA was extracted using the DNeasy kit (Qiagen). 
Primers that target a region within the R and U5 portions of the HIV-1 LTR were used to 
amplify and quantitate EPs (minus-strand strong stop viral DNA) by qPCR. To normalize 
the cell counts in each sample, an additional set of primers were used to quantify copies 
of the cellular CCR5 gene, which is present in two copies of each cell. The data, 
presented as EPs per million cells is shown in Figure 5.3. Significant levels of EPs were 
detected in cultures infected with LAI-∆144, and these levels increased with time. 
However, an 8-fold reduction in EP synthesis was observed in the E99V-∆144 infection 
at 24 hours, compared to those produced by LAI-∆144. Thus, although E99V-∆144 
particles were competent for fusion with target cells, they were markedly impaired for the 
production of EPs. These results suggest that the E99V-∆144 particles were unable to 
overcome a post-entry block that occurs at, or prior to, the initiation of reverse 
transcription.  
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Figure 5.2 Effects of Env truncation on virus-cell membrane fusion capacity 
in LAI-derived viruses bearing MA substitutions. Virus-cell membrane fusion 
events were assayed in TZM-bl cells as described in Figure 3.7. The data shown is 
representative of three independent experiments performed in duplicate.  
 
 
  
124 
5.2.2 VSV-G pseudotyping can partially rescue the post-entry block 
In the previous section, I showed that the E99V and E99K MA mutations 
conferred an infectivity defect, even when fusion was permitted at the plasma membrane 
of target cells. To determine whether endosomal entry could rescue the infectivity defect 
of these particles, I next decided to analyze particles that were pseudotyped with the 
glycoprotein from the Vesicular Stomatitis Virus (VSV-G). To create proviral clones 
encoding the MA mutations but lacking the ability to make HIV-1 Env, mutagenic 
primers were used to introduce individual MA substitutions E99V, E99K, K32E or L13E 
into the proviral clone pLAI-∆Env, to produce pE99V-∆Env, pE99K∆Env, pK32E∆Env 
and pL13E∆Env, respectively. The individual clones, or pLAI-∆Env, were cotransfected 
into 293T cells with an expression vector encoding VSV-G. Virus-containing 
supernatants were harvested 24 and 48 hours post-transfection, and then normalized by 
RT assay.  
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Figure 5.3 Early reverse transcription products in cells infected with LAI-
derived virus containing truncated HIV-1 Env with and without the E99V MA 
substitution. MT-4 cells were infected with equal RT units of the indicated virus. At 
1, 5, 8 or 24 hours post-infection, cells were lysed and EPs were quantified directly 
by real-time PCR using primers specific for strong-stop viral DNA. Data was 
normalized by quantification of the cellular CCR5 gene in each sample. Data shown 
is the mean of two separate experiments performed in duplicate.  
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To determine whether the pseudotyped viruses were competent for a single round 
of infection, 2-fold serial dilutions were incubated with TZM-bl cells and analyzed with 
the Beta-Glo assay system at 24 hours. In parallel, similar infections were performed 
using viruses with wild-type HIV-1 Env. Non-pseudotyped LAI-∆Env particles were 
used as a negative control. In analyzing the average raw RLU values from four separate 
experiments, it is apparent that each dilution of the VSV-G-pseudotyped particles 
containing wild-type MA (VSV-G-LAI-∆Env) was substantially more infectious than 
LAI-WT (presented in Appendix B Table B.3).  
To normalize the data, an infectivity value of 100 was assigned to the VSV-G-
LAI-∆Env infection, as done in the analyses of viruses bearing a truncated Env. The 
normalized data for infections with VSV-G-pseudotyped viruses is presented in Table 
5.3. It was apparent that overall, pseudotyping with VSV-G enhanced infection of each 
virus, however, the degree of enhancement varied depending on the MA mutation. VSV-
G pseudotyping rescued infectivities of viruses bearing the L13E or K32E MA mutations, 
to at least 50% of the levels achieved using VSV-G-LAI-∆Env. 
Across each titer, I observed a partial rescue for both the VSV-G-E99V-∆Env and 
VSV-G-E99K-∆Env infections (Table 5.3). However, the raw data suggests that the 
VSV-G-LAI-∆Env virus was saturating at higher titers. For this reason, I concluded that 
the 20K RTU or 10K RTU viral inputs might not represent accurate enhancement for 
infections with a-VSV-G-E99V-∆Env or a-VSV-G-E99K-∆Env. Nevertheless, the data 
for the VSV-G-LAI-∆Env infections at dilutions of 5K RTU and less declined linearly in 
relation to the titer. With saturation unlikely at these intermediate titers, the data suggests 
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that VSV-G pseudotyping improved infectivities of viruses with E99V or E99K MA 
mutations from less than 2% of infection of LAI-WT when bearing HIV-1 Env, to levels 
of around 40% or 22% of VSV-G-LAI-∆Env when pseudotyped with VSV-G, 
respectively. 
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Table 5.3 Relative infectivities of LAI-derived MA mutants 
pseudotyped with VSV-G Env
The data shown are normalized from the RLU values presented in Table 8-4, and 
represent averages of four independent Beta-­‐Glo infectivity assays analyzed 24 
hours after TZM-bl cells were infected with four serial dilutions of the indicated 
virus. The normalized values are based on results from the VSV-G-LAI-∆Env 
infection, which represents 100% infectivity at each titer. 
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To analyze the rescues observed with comparable MOIs (as determined by the 
titers of LAI-WT and VSV-G-LAI-∆Env that resulted in similar raw RLU values), I 
evaluated the normalized data using virus with WT HIV-1 Env at 10K RTU per well, to 
the infections with VSV-G pseudotyped particles at 2.5K RTU per well. With this data, 
shown in Figure 5.5, I concluded that VSV-G pseudotyping facilitates moderate 
improvements in infectivity in viruses containing MA substitutions E99V or E99K.  
Next, I sought to analyze the fusion capacities of these VSV-G pseudotyped 
particles. Proviral clones pLAI-∆Env, pE99V-∆Env, pE99K∆Env, pK32E∆Env or 
pL13E∆Env were cotransfected into 293T cells, along with the BLaM-Vpr expression 
construct, and the VSV-G vector, as described in Materials and Methods. At 24 hours and 
48 hours after the transfection, virus-containing supernatants were harvested and 
normalized according to RT content. Equal titers of each virus were used to infect TZM-
bl cells, and virus-cell fusion was monitored as described previously in Figure 3.7.  
Results from this fusion assay are shown in Figure 5.6. Despite only a partial 
rescue in infectivity, I found that the fusion capacity for VSV-G-E99V-∆Env or VSV-G-
E99K-∆Env with target cells was completely restored. In fact, BLaM activity in cells 
infected with VSV-G-E99V-∆Env or VSV-G-E99K-∆Env was markedly higher than 
cells challenged with VSV-G-LAI-∆Env at each time point. Interestingly, I found that 
BLaM activity in cells challenged with VSV-G-K32E-∆Env or VSV-G-L13E-∆Env, 
while consistently above background, did not reach the levels observed in cells 
challenged with VSV-G-LAI-∆Env. However, the fusion capacity for VSV-G-L13E-
∆Env was improved when compared to that of LAI-L13E particles. By contrast, the 
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virus-cell fusion for VSV-G-K32E-∆Env particles was not augmented when compared to 
that of LAI-K32E. Most important, these results reveal that although VSV-G 
pseudotyping could not fully rescue the E99V- and E99K- associated infectivity defects, 
it was able to completely reverse the E99V- and E99K- associated fusion defects. These 
findings were consistent with my Env truncation data, as they suggest the existence of a 
post-fusion restriction to particles bearing the E99V or E99K MA mutations. 
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Figure 5.4 Single-cycle infectivities of LAI-derived MA mutants, containing 
either WT HIV-1 Env, or pseudotyped with VSV-G. Pseudotyped virus was 
generated by co-transfection of a pLAI-based Env deficient proviral clone and an 
expression plasmid encoding the VSV-G heterologous envelope. Infectivity was 
monitored 24 hours post-infection using the Beta-Glo reporter assay, as 
described in Figure 3.4. The assessment of infectivity for each mutant virus is 
based on the level of LAI-WT (blue bars, 10K RTU/well) or VSV-G-LAI-∆Env 
(red bars, inoculated at 2.5 RTU/well), which represents 100% infectivity. Data 
is the average of four independent experiments performed in duplicate.  
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Figure 5.5 Effects of VSV-G pseudotyping on virus-cell membrane fusion 
capacity in LAI-derived viruses bearing MA substitutions. Fusion events of 
VSV-G-pseudotyped particles were assayed in TZM-bl cells as described in 
Figure 3.7. The data shown is representative of three independent experiments 
performed in duplicate.  
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To further analyze the post-entry step that may be interrupted by the E99 MA 
mutations, I investigated the extent to which the VSV-G-E99V-∆Env particles were 
competent for reverse transcription. Proviral clones pLAI-∆Env and pE99V-∆Env were 
individually transfected into 293T cells with an expression vector encoding VSV-G. 
Virus-containing supernatants were harvested 24 and 48 hours post-transfection as 
before, and then normalized by RT content. DNase-treated virus was then used to infect 
MT-4 cell cultures. At the indicated time points, cells were harvested, and total DNA was 
extracted. Specific primers were used to quantify EPs and CCR5 copy number, as in the 
PCR analysis of the previous section. The data, shown in Figure 5.7A, is presented as 
copies of EP per million cells. EPs were detected in both cultures, and while the levels 
were lower in the VSV-G-E99V-∆Env infected cells compared to those from the VSV-G-
LAI-∆Env infections, the values increased over time. These data agree with the partial 
rescue observed with the infectivity assays.  
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Figure 5.6 Analysis of reverse transcription products in cells infected with 
VSV-G-pseudotyped MA mutants. MT-4 cells were infected with equal RT 
units of LAI-derived MA mutants containing WT HIV-1 Env, or pseudotyped 
with VSV-G. At the specified times post-infection, cells were lysed and total 
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DNA was extracted. (A) EPs were directly quantified by real-time PCR, using 
primers specific for strong-stop viral DNA. Data was normalized by 
quantification of the cellular CCR5 gene in each sample. Data shown are the 
mean of two separate experiments performed in duplicate.  (B) 2LTR circles were 
directly quantified by real-time PCR, using primers specific for the HIV-1 LTR-
LTR junction. Data was normalized by quantification of the cellular CCR5 gene 
in each sample. Data shown are the mean of two separate experiments performed 
in duplicate.  
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Next I analyzed the production of 2LTR circles in infected cells. 2LTR circles are 
a form of viral DNA found only in the nucleus of cells. Although they are dead-end 
products of reverse transcription and cannot be integrated into the host cell genome, their 
detection in infected cells is a useful marker for the successful completion of reverse 
transcription and nuclear import (23, 27). MT-4 cells were incubated with LAI-WT, LAI-
E99V, LAI-∆Env, VSV-G-LAI-∆Env and VSV-G-E99V-∆Env particles. Infected cells 
were collected at 2, 8 and 24 hours and then total DNA was extracted from each sample. 
Q-PCR was performed, using primers to specifically amplify the LTR-LTR junction used 
to identify 2LTR circles. The data was normalized according to CCR5 copy numbers, and 
is presented in Figure 5.7B as 2LTR circles per million cells. By 24 hours, cells from the 
LAI-∆Env or LAI-E99V infections gave no signal, while significant levels of 2LTR 
circles were detected in the LAI-WT infection, findings that correlate with my previous 
infectivity data. Most important, 2LTR circles were also present in the VSV-G-E99V-
∆Env infection at levels that correlate to the partial rescue observed with the single-cycle 
reporter assay. Overall, the detection of both EPs and 2LTR circles in cells infected with 
VSV-G-E99V-∆Env supports my hypothesis that VSV-G pseudotyping confers a partial 
rescue of the post-fusion block imposed by the E99V MA mutation. 
5.3 Discussion 
Here, I employed single-cycle infectivity, fusion, and PCR assays to determine 
whether restoring the incorporation of a functional envelope is sufficient to reverse the 
infectivity defects conferred by the E99V or E99K MA mutations in HIV-1 particles. My 
results from the BLaM fusion assays indicate that truncation of the HIV-1 gp41 CT, or 
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pseudotyping with VSV-G were sufficient methods to restore the fusion capacities of 
HIV-1 viruses containing the E99V or E99K MA substitutions. However, my infectivity 
data suggests that the specific route of entry utilized by the virus is critical for reinstating 
infectivity in these viruses. I found that when particles were permitted to fuse at the PM 
of a target cell, the infectivity defects imposed by the E99V or E99K MA mutations were 
not reversed. By qPCR, I determined that E99V-∆144 particles were unable to initiate 
reverse transcription, which suggests the presence of an early, post-fusion restriction 
inside cells. Conversely, my results demonstrated that this putative post-entry block was 
partially bypassed when virus entry was shunted through an endosomal route, as 
facilitated by VSV-G pseudotyping. It has been speculated that this alternate delivery 
method could protect the virus from certain entry- and post-entry restrictions that would 
be encountered if fusion were to occur at the PM. Indeed, this partial rescue was 
confirmed with detection of early products and 2LTR circles in VSV-G-E99V-∆Env 
infected cells. Since VSV-G-mediated fusion would not bypass a restriction at nuclear 
import or integration, I speculate that this post-entry defect must be encountered soon 
after fusion with the PM.  
My results were validated with parallel studies analyzing rescues of previously 
characterized MA mutations. Consistent with earlier reports, I observed that Env 
truncation and VSV-G pseudotyping were sufficient modes of restoring infectivity 
defects imposed by L13E or K32E MA mutations (72, 111). This suggests that a 
disruption in Env incorporation during particle assembly is the only, or at least the most 
prominent, defect imposed by the L13E and K32E MA mutations. However, since these 
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methods failed to completely restore the infectivity defects associated with the E99V and 
E99K substitutions, I conclude that in addition to a role in Env incorporation, the 
glutamate at MA residue 99 is critical for an early, post-fusion function of MA. A 
summary of the findings from this chapter are shown in Table 5.4. 
MA has previously been implicated in a number of post-entry steps, including 
uncoating, reverse transcription, PIC migration, nuclear import and even integration (23, 
31, 72, 88, 101, 104, 166, 198, 213). It is possible that MA E99 has a specific role in 
facilitating one or more of these early steps, such as engaging with a cellular cofactor or a 
virally encoded protein in the HIV core. Another possibility is that E99 could be 
important for the dissociation of MA molecules from the PM, either by a direct 
mechanism or through an indirect one, such as promoting a MA conformation that 
sequesters the myristoyl moiety. Such a disruption in MA membrane detachment during 
early events could have several consequences that might prevent productive infection of 
the particle. For example, MA has been shown to associate with the viral core, and failing 
to dissociate from the PM could tether the complex to the membrane, and in turn inhibit 
proper trafficking of the reverse transcription complex (RTC) towards the nucleus. Such 
membrane adherence may prevent critical interactions with the cytoskeleton, which could 
be detrimental for efficient nuclear migration. Moreover, an association between the RTC 
and actin filaments has been linked to efficient reverse transcription (21). Another 
possibility is that proper capsid uncoating could be linked to the location of the complex 
within the cell, and membrane tethering of the viral core might impair the uncoating step. 
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Finally, one might imagine that such sequestration at the cell’s periphery could expose 
the viral core to cellular degradative pathways. 
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Table 5.4 Summary of Results from Chapter 5 
 
The different viruses analyzed in this chapter are listed in the left hand column. 
The assays performed and individual findings relative to results from the wild-
type parental virus are indicated. Single-cycle infectivity was determined 24 hours 
post-infection. Relative Env incorporation was approximated by Western blot 
using anti-gp41 mAb (Chessie 8). Spreading infection was analyzed in MT-4 
cells. EP and 2LTR circle data represents the 24-hour time point. ND = assay not 
done. NS = assay performed but results not shown.  
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Indeed, it has been suggested that the membrane affinity of MA must be precisely 
balanced to facilitate its roles in early and late phases of the HIV-1 life cycle (151, 170).  
One study speculated that in particular, the N-terminal region of the MA fifth helix exerts 
a negative affect on the overall membrane affinity of MA (151). Structural studies have 
suggested that the N-terminal region of this C-terminal helix lies in proximity with the 
PM (4, 93). Therefore, I propose that the polar, negatively charged glutamate at residue 
99, which happens to lie within this precise location of the molecule, may be critical in 
antagonizing this membrane affinity. In agreement with this hypothesis is the finding that 
both valine and lysine substitutions disrupt this post-fusion role for MA. It is likely that 
valine, a large hydrophobic amino acid, would enhance the overall hydrophobicity of the 
MA C-terminal helix and thereby promote membrane affinity. Similarly, the positively 
charged lysine could increase membrane association by interacting with negatively 
charged phospholipids embedded in the cell’s PM. In Chapter 3 (section 3.2.2), I also 
showed that substitution of this glutamate with aspartate, glycine or alanine (mutations 
E99D, E99G and E99A) did not reduce virus infectivity. These findings might be 
explained by the presence of other residues in the MA C-terminal helix that are also 
important in antagonizing MA membrane affinity, and these substitutions (E99D, E99G 
or E99A) may either be too conservative or not strong enough to negate the membrane 
disassociation properties of proximal residues. Based on these speculations, I would 
propose that other substitutions of residue 99, such as glutamate for arginine, 
phenylalanine, isoleucine or leucine (E99R, E99F, E99I or E99L), would also impart a 
post-entry defect in viruses that have an Env truncation.  
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CHAPTER VI: DEVELOPMENT OF AN ASSAY  
TO MONITOR RTC TRAFFICKING IN INFECTED CELLS 
6.1 Introduction 
In Chapter 5, I demonstrated that in addition to an Env incorporation defect, the 
E99V and E99K MA mutations might also confer post-entry blocks to productive 
infection. My results using a mutant with a truncated Env (E99V-∆144) suggested that 
this defect likely occurs prior to the reverse transcription step (refer to Figure 5.2.1). 
Interestingly, a similar phenotype was observed when wild-type virus was incubated with 
H9 cells expressing siRNAs that knockdown the Arp2/3 actin-nucleator complex, a 
structure necessary for the polymerization of actin microfilaments (107). This result is 
consistent with another study, which indicated that virus interaction with the actin 
microfilaments alone might stimulate efficient reverse transcription (21). In addition, 
fluorescent imaging techniques have indicated that the RT complex (RTC) likely uses 
microtubules to move long distances within the cell (129). Thus, it appears that an 
association with the cytoskeleton during early events might be crucial for the productive 
infection of HIV-1. Although the viral proteins that interact with host-cell transport 
machinery at this step are unknown, MA is a candidate (21, 201). Therefore, it is possible 
that the E99V and E99K MA mutations might interrupt RTC interaction with the host 
cytoskeletal system, thwarting proper intracellular trafficking of the complex. The 
accumulation of these mutant RTCs at the PM, or inside a subcellular compartment, may 
then inhibit viral DNA synthesis, ultimately blocking infection.  
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A variety of techniques have been established to monitor the progress of many 
early events of the retroviral life cycle. However, a standard assay for evaluating whether 
retroviral RTCs are competent for migration through the cell to the nucleus is lacking. As 
a result, the pathways that nucleoprotein complexes follow after virus-cell fusion are not 
clearly defined. Such a technique might be useful for identifying viral proteins or cellular 
factors involved in the putative interaction between the RTC and the host cytoskeletal 
system. To address this, and to characterize the early block encountered by the E99V-
∆144 mutant virus, I sought to develop and validate a PCR-based method that would 
allow for the investigation of a possible defect in RTC nuclear trafficking.  
6.2 Results 
6.2.1 Experimental rationale and overview of the methods 
The processes of HIV-1 reverse transcription and nuclear translocation are 
thought to proceed concurrently. However, nucleoprotein complexes can arrive at the 
host cell nucleus as early as 1 hour after infection (21), while reverse transcription of the 
viral RNA genome into DNA is generally completed in 8 to 12 hours (59). Therefore, it is 
likely that a vast majority of nuclear RTCs are undergoing reverse transcription (21). I 
reasoned that if viral RNA genomes (gRNA) could be extracted and quantified from 
different subcellular compartments within infected cells, then it would be possible to 
distinguish between normal and aberrant RTC trafficking based on different levels of 
RTCs over time.  
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My proposed methods are outlined in Figure 6.1.  Cells are first incubated with 
equal amounts of virus at 4° C, which allows viral binding to the cellular receptors but 
not internalization. Next, the cells are moved to 37° C to permit synchronized entry of 
bound particles into the cells. Cells are then harvested and subjected to fractionation. 
Total RNA is extracted from each of the fractions containing different cellular 
components, and then HIV-1 gRNAs are reverse transcribed into cDNA using a primer 
specific for the full-length HIV-1 genome. Finally, quantitative PCR is used to quantify 
the cDNA copies in each sample.  
6.2.2 Optimization of fractionation techniques 
Originally, I intended to analyze RTC migration by comparing the quantity of 
gRNA in membranous, cytoskeletal, cytosolic and nuclear components of the cell. 
However, early attempts to do this consistently were unsuccessful, and it became clear 
that clean separation of these fractions would be critical to ensure the accuracy of my 
results. Therefore, I compared additional methods used for isolating nuclei from 
cytoplasmic extracts. For these experiments, I used the CD4+ HeLa-derived MAGI cell 
line as target cells, since their adherent nature would allow for uniform infection. 
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Figure 6.1 Schematic representation of the proposed RTC migration assay. 
Equal amounts of virus are added to cells, and virus-cell fusion events are 
synchronized by a one-hour pre-incubation at 4° C before moving the flasks to a 
37° C incubator. After specified times, cells are harvested and fractionated. Total 
RNA is isolated from each of the cellular components, and then HIV-1 gRNAs 
are reverse transcribed into cDNA using a primer specific for the full-length viral 
genome. Finally, quantitative PCR is used to quantify the cDNA copies in each 
sample.  
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Initially, I compared mechanical disruption to chemical disruption of the cell. 
Both protocols called for an initial swelling of cells in hypotonic media. The mechanical 
protocol then involved 10-15 strokes with mini-dounce homogenizers to disrupt plasma 
membranes. The chemical technique used the nonionic detergent digitonin, which is 
reported to permeabilize cell membranes and mitochondria while preserving nuclei and 
most other organelles (134). After swelling, cell permeabilization was initiated upon 
exposure to a diluted digitonin solution. After thirty minutes on ice, the reaction was 
stopped by the addition of casein.  
Nuclei were pelleted using centrifugation, and the cytoplasmic supernatants were 
carefully removed and transferred to another tube. Total protein content was calculated 
for each fraction using the BCA Protein Assay kit (Pierce) as directed, and extract 
purities were analyzed by Western blot. To distinguish between the two cellular 
components, a polyclonal antibody for Sam68 was used as a nuclear marker, and 
monoclonal antibodies specific for β-actin and pyruvate kinase were used as cytoplasmic 
determinants. In addition, I determined the integrity of the nuclear membrane with a 
monoclonal antibody directed against Nup62, a protein normally associated with the 
nuclear pore complex. In the resulting blots (Figure 6.2A), I found that nuclear extracts 
from both methods were enriched for Sam68, but only the pyruvate kinase antibody 
seemed to show specificity for the digitonin-derived cytoplasmic fraction. Although a 
significant amount of Nup62 was also detected in this extract, I cannot exclude the 
possibility that this was newly synthesized protein not yet inserted into the nuclear 
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envelope. Neither method was successful in isolating pure cellular components, however, 
since β-actin was detected in all samples.  
Next, I tested a chemical-based protocol that used the nonionic, non-denaturing 
detergent Nonidet P-40 (NP-40). Although higher concentrations of NP-40 are often used 
to lyse both cellular and nuclear membranes, more dilute solutions are reported to 
permeabilize plasma membranes while keeping nuclear membranes intact (56). Cells 
were incubated in a 0.63% solution of NP-40 on ice with periodic vortexing. In parallel, I 
repeated the digitonin lysis protocol, using two different concentrations of digitonin. In 
the Western blot analysis of the resulting fractions, I used antibodies directed against 
HSP90 and GAPDH as cytoplasmic markers.  The results, shown in Figure 6.2B, 
indicated that the NP-40 method generated cleaner fractions than either dilution of 
digitonin. 
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Figure 6.2 A comparison of the efficiencies of fractionation procedures 
designed for separating cytoplasm from intact nuclei. MAGI cells were 
subjected to dounce homogenization, digitonin treatment, or NP-40 exposure, and 
then centrifuged to separate the nuclei from cytoplasm, as described in the text. 
Equal µg of protein from each fraction, or from whole cell lysates, were separated 
by SDS-PAGE. Extract purity was analyzed by immunoblotting. (A) Comparison 
of dounce homogenization and digitonin treatment. Antibodies were directed 
against Sam68 (nuclear), Nup62 (nuclear envelope), pyruvate kinase 
(cytoplasmic), or β-actin (cytoplasmic). (B) Comparison of 40µg/mL or 80µg/mL 
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digitonin treatment, or 0.63% NP-40 exposure. Antibodies were directed against 
Sam68 (nuclear), HSP90 (cytoplasmic), or GAPDH (cytoplasmic).  
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To further optimize the NP-40 method, fractionations made with a variety of 
dilutions of NP-40 were compared. Western blot analysis indicated that each of the 
cellular component fractions were pure using all but the GAPDH-specific antibodies 
(Figure 6.3A). The GAPDH blot suggested that some cytoplasmic proteins were 
contaminating the nuclei pellets. This experiment was unable to distinguish whether the 
contaminating GAPDH was due to small amounts of cytoplasm that had carried over 
after the centrifugation step, or incompletely lysed cells that had been pelleted down with 
the nuclei. To distinguish between these two possibilities, I repeated the experiment using 
the 0.6% and 0.9% NP-40 solutions and compared the purities of washed and unwashed 
nuclei at each concentration. As shown in Figure 6.3B, washing the intact nuclei in 1X 
PBS reduced cytoplasmic contamination, as indicated by the markers HSP90  
and GAPDH, without significantly lowering Sam68 levels. These results demonstrated 
that contamination of the nuclear fractions was due to carry over of soluble cellular 
components, and not inefficient cell lysis. 
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Figure 6.3 Optimization of the NP-40 fractionation method. MAGI cells were 
treated with the indicated concentrations of NP-40, and then nuclear and 
cytoplasmic fractions were prepared as described in the text. Equal µg of protein 
were separated by SDS-PAGE and analyzed by immunoblotting with antibodies 
directed against Sam68 (nuclear), HSP90 (cytoplasmic), GAPDH (cytoplasmic) 
or β-actin (cytoplasmic). (A) Cells were exposed to 0.3%, 0.6%, 0.9%, or 1.2% 
NP-40 solutions. (B) Cells were exposed to 0.6% or 0.9% NP-40 solutions, and 
then intact nuclei were isolated and either washed with 1X PBS (lanes 3 and 7) or 
left unwashed (lanes 1 and 5).  
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6.2.3 Characterization of positive and negative controls 
Although VSV-G pseudotyping is known to enable a more efficient infection of 
HIV-1 particles than those with wild-type HIV Env, I wanted to ensure the physiological 
relevance of HIV particle trafficking observed with this assay. Therefore, I decided to use 
non-pseudotyped LAI-WT as my positive control. For negative controls, I used LAI-
∆Env, as well as exogenously-added soluble CD4 (sCD4) to inhibit LAI-WT infection.  
During HIV-1 infection, the majority of viral particles are internalized into cells 
via endocytosis. Although a portion of these endocytosed particles may indeed fuse and 
be competent for infection (133), I decided that limiting endocytic internalization was 
necessary to reduce any background from the non-specific recycling of particles in and 
out of the cells. Therefore, I chose to perform the infections in media containing 0.45 M 
sucrose, which is known to block endocytosis of ligands and receptors (159). 
MAGI cells were cultured in T-25 flasks until about 80-90% confluency. The 
media was removed and cold virus was added to each culture, one flask for each time 
point. Virus-receptor binding, but not internalization, was permitted by the pre-incubation 
of cells at 4°C for one hour. Every 5 minutes, the flasks were manually rocked back and 
forth, to enhance virus-cell binding efficiency. After one hour, the supernatant was 
removed and fusion events were synchronized with the addition of pre-warmed, sucrose-
containing media. The flasks were then placed in a 37° C incubator. Because sucrose can 
be toxic to cells upon sustained exposure (159), I replaced the hypertonic media with 
normal media after 20 minutes. Cells were further incubated at 37° C for either 25 or 160 
minutes.  
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Cells were harvested, washed and divided into two aliquots. One aliquot was 
stored for subsequent extraction of total cellular DNA. The other aliquot was fractionated 
using 0.6% NP-40. Total cellular RNA was isolated from the nuclear and cytoplasmic 
extracts using the RNeasy kit (Qiagen) as directed. RNA from each sample was then 
subjected to RT-PCR using the Superscript 1st Strand System kit (Invitrogen), and a 
primer specific for the 5’ end of the viral genome (primer BB).  This region was targeted 
because it is the last portion to be destroyed by RNase H during reverse transcription in 
the cell. To validate the specificity of the PCR, I also set up reactions omitting the RT 
enzyme. I quantified the cDNA products with qPCR, using primers W and LA17/r, and a 
probe that targeted a region between these qPCR primers. The data was then normalized 
by quantifying CCR5 gene copy number in the total DNA extracted from the aliquot of 
unfractionated cells. The primers and probe that targeted the HIV-1 genome are depicted 
in Figure 6.4. 
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Figure 6.4 A schematic representation of the locations in the HIV-1 genome 
targeted by the RT-PCR and qPCR steps. Primer BB, located in Gag was used 
to generate cDNA from HIV-1 gRNA. Since this region is the last part of the 
genome to be degraded by the RNase H activity of RT, window of detection is 
maximized. Primers W and LA17/r, targeting sequences in R and Gag 
respectively, were used to amplify and quantitate cDNA molecules from each 
sample. The probe selectively binds to a region in U5.  
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The results from this experiment are shown in Figure 6.5. The lack of detectable 
cDNA in any of the no-RT controls, demonstrated that the quantified cDNA copies in 
other samples represented gRNA extracted from cells. As expected, cells infected with 
the LAI-∆Env virus had fewer gRNA copies than infection with WT virus. Addition of 
sCD4, however, did little to inhibit infection by WT-LAI. Control experiments indicated 
that, by 2LTR circle analysis, sCD4 was effective in inhibiting WT-LAI infection in  
MAGI cells (data not shown). Therefore, it is unclear why efficient entry and migration 
events occurred in the LAI-WT/sCD4 samples in this assay.  
A significantly greater number of gRNA was detected in the cytoplasmic fraction 
compared to the nuclear preparation from each infection condition. This finding may be 
evidence of the limited number of viral cores that successfully reach the nucleus after 
fusion into the cell. I also detected an increase in cytoplasmic-associated gRNA, and a 
reduction in nuclear-associated gRNA, over time, which may indicate incomplete 
synchronization of fusion events. It was also possible that delayed fusion was an 
unintended consequence of the sucrose exposure. I also considered that the decrease in 
nuclear gRNA at the later time point might be from its degradation by RNase H activity. 
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Figure 6.5 Analysis of potential positive and negative controls in the RTC 
migration assay. Distribution of RTCs in nuclear (top graph) or cytoplasmic 
(bottom graph) fractions of MAGI cells infected with equal RT units of LAI-
WT, LAI-WT in the presence of soluble CD4 (sCD4), or LAI-∆Env.  Cells were 
incubated for 1 hour at 4 °C, followed by 45 or 180 minutes at 37 °C. Endocytosis 
was inhibited with 0.45 M sucrose added to the cell culture media for the first 20 
minutes of the 37 °C incubation. Cells were harvested, washed and then exposed 
to 0.6% NP-40 before centrifugation at 6500 RPM. Intact nuclei were washed 
after separation from the cytoplasmic supernatant. RNA from each sample was 
then subjected to standard RT-PCR using primer BB. Control reactions were 
performed in parallel in the absence of reverse transcriptase. The cDNA product 
was quantified in duplicate wells by qPCR using primers W and LA17/r. +RT = 
reaction performed in the presence of reverse transcriptase, -RT = control reaction 
performed in the absence of reverse transcriptase. 
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Although fewer gRNA copies were detected in LAI-∆Env infected cells than in 
those infected with LAI-WT, I still detected a substantial amount of viral RNA in the 
nuclei of LAI-∆Env infected cells. 2LTR analysis had determined that LAI-∆Env was not 
competent for a productive infection (data not shown), but incomplete washing of the 
cells after harvesting may have lead to contamination by residual free or receptor-bound 
virus. 
6.2.4 Effectiveness of endocytosis inhibition 
To evaluate the degree to which 0.45 M sucrose prevented endocytosis, I 
compared both LAI-WT and LAI-∆Env infections in the presence or absence of sucrose. 
Higher amounts of gRNA were detected in the cytoplasmic fractions of cells not exposed 
to sucrose, compared to those exposed to sucrose (Figure 6.6), consistent with the known 
ability of sucrose to limit entry of endocytosed virus (159). In the LAI-WT infection, the 
peak number of cytoplasmic gRNA was occurred at 90 minutes post-infection in the 
presence of sucrose, whereas peak cytoplasmic gRNA was detected at 30 minutes post-
infection when endocytosis was permitted. These results suggest that sucrose may confer 
a delay in fusion, which may reflect the time needed by cells to recover from hypertonic 
media exposure. Conversely, it may indicate that the majority of endocytic entry events 
occur prior to membrane fusion, at which time other processes required for efficient 
membrane fusion, such as specific intracellular signaling, might also be taking place. 
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Figure 6.6 The effect of sucrose exposure on blocking virus endocytosis. 
Distribution of RTCs in nuclear (top graph) or cytoplasmic (bottom graph) 
fractions of cells infected with LAI-WT or LAI-∆Env, as described above, with or 
without the 20-minute sucrose incubation. Cells were harvested at 30 minutes, 90 
minutes, or 3 hours post-infection.  
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Nuclear-associated gRNA peaked at 90 minutes in the presence of sucrose but 
was highest at 3 hours without sucrose during LAI-WT infection (Figure 6.6). This 
suggests that limiting endocytosis may enhance the efficiency of RTC trafficking, despite 
the corresponding delay in membrane fusion.  
Since prolonged sucrose exposure can be toxic to cells, I also used dynasore 
(Sigma) to inhibit endocytosis. Dynasore is a small molecule GTPase inhibitor that 
blocks dynamin-dependent endocytosis, and its use is associated with less cytotoxicity 
than observed with other reagents (106). Cells were infected with LAI-WT virus in the 
presence of either 0.45 M sucrose, or 80 µM dynasore, and then harvested 45 or 180 
minutes post-infection. The qPCR data suggested that dynasore was far more effective 
than sucrose in limiting endocytic entry of virus (Figure 6.7), however the use of 
dynasore also reduced cell recovery during harvesting. I therefore concluded that sucrose 
was less toxic and therefore better suited than dynasore in this assay. 
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Figure 6.7 Comparison of two methods for inhibiting endocytosis. 
Distribution of RTCs in nuclear (top graph) or cytoplasmic (bottom graph) 
fractions of cells infected with equal RT units of LAI-WT, in the presence of 
either 0.45 M sucrose or 80 µM dynasore, at two time points. Sucrose was washed 
away after 20 minutes whereas the dynasore concentration was kept constant 
throughout the infection. Cells were harvested 45 or 180 minutes post-infection.  
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6.2.5 RTC trafficking in the absence of reverse transcription 
While previous studies have demonstrated that efficient reverse transcription is 
dependent on cytoskeletal interactions (21), it is unclear whether efficient trafficking 
events require reverse transcription. I therefore tested whether intracellular RTC 
migration could proceed in the absence of efficient reverse transcription, using the RT 
inhibitor AZT. As a thymidine analog, AZT is incorporated into cDNA by the viral RT 
enzyme. Its insertion prevents further strand synthesis as the compound lacks the 3’OH 
group required for cDNA elongation. I incubated MAGI cells with media containing 10 
µM AZT for two hours before the addition of virus, after which the infection protocol 
preceded as above. The trafficking profile of cytoplasmic RTCs was similar with and 
without AZT (Figure 6.8), consistent with its inhibitory effects occurring independently 
of virus entry. On the other hand, in the absence of AZT, nuclear gRNA quantities 
reached a high point at 90 minutes and its peak at 24 hours. The two peaks likely 
reflected RTC migration to the nucleus and the synthesis of new viral genomes, 
respectively. Reduced gRNA detected in the cytoplasmic fraction at 24 hours, suggested 
that the majority of unspliced viral RNA is translated and degraded by this time, as 
opposed to being stabilized for packaging into nascent particles. In contrast, gRNA 
decreased over time in the nuclear fraction of cells infected in AZT-containing media. 
This observation is consistent with a role for the central DNA flap in nuclear targeting 
and likely represents reduced efficiency of RTC nuclear entry in the absence of reverse 
transcription. 
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Figure 6.8 Analysis of RTC migration in the absence of efficient reverse 
transcription. Distribution of RTCs in nuclear (top graph) or cytoplasmic 
(bottom graph) fractions of cells infected with LAI-∆Env, or LAI-WT virus in 
the presence or absence of 10 µM AZT. Cells were harvested at 30 minutes, 90 
minutes, 3 hours or 24 hours post-infection.  
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6.3 Discussion 
The development of additional techniques for identifying and characterizing the 
post-entry steps required for a productive retroviral infection is crucial for the 
advancement of HIV research. My efforts in developing a technique to monitor RTC 
trafficking is one important step in addressing this technical gap, though further 
optimization is required.  
In addition to the experiments described above, I also evaluated various cell 
harvesting techniques. I found that trypsin exposure was the safest and most consistent 
way to harvest intact cells, compared to scraping with a plastic or rubber scraper. As 
small differences in cell recovery could confound my results, and I also tested ways to 
normalize the data. In one experiment, I analyzed gRNA in the unfractionated cells, 
instead of CCR5 copy number. cDNA copies in each fraction were then compared to the 
total number of cDNA copies quantified in whole cell lysates. Final gRNA equivalent 
numbers were then reported as a percentage of total cDNA per cell. Unfortunately, my 
results were inconsistent and in some cases total cDNA content from the fractionated 
samples far exceeded that extracted from unfractionated cells. 
I also recognize fundamental limitations of the experimental design, as described 
here. This study was conceived of prior to 2009, when it was widely believed that 
endocytosed virus was unable to fuse and productively infect cells. I therefore found it 
appropriate to inhibit endocytic internalization events. However, a study published by 
Miyauchi and colleagues in 2009 demonstrated that productive infection does in fact 
occur by HIV-1 fusion within endosomes, and that this may even be the predominant 
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mode of entry in some cell types (133). Considering my data in light of these recent 
findings, I speculate that reducing endocytosis may have diminished the efficiency of 
infections, which could minimize the validity of my results. While RTC migration defects 
may certainly arise in some mutants, a mutation that prevents proper mobility through the 
cortical actin layer at the cell periphery might be overcome by delivery of the viral core 
within an endosome.  
Finally, another limitation that might confound interpretation of the data is the 
RNase H function of RT. Since RNase H degrades the viral RNA during reverse 
transcription, viral genomic RNA may not be a proper marker for RTC migration in this 
assay. It is likely that many RTCs in the nucleus are still undergoing reverse transcription 
at earlier time points, however the inevitable destruction of gRNA obscures the analysis 
of low cDNA copies from cells harvested at later time points. For example, the detection 
of low nuclear-associated gRNA at later time points may reflect aberrant nuclear 
trafficking of complexes, or more efficient reverse transcription. Therefore, more 
rigorous testing is needed to define the optimal times post-infection for analyzing 
migration. The ideal window would be after a high number of RTCs reach the nucleus, 
but before RNase H activity degrades a significant portion of the nuclear associated 
gRNAs. To define this window, one might analyze the RTC migration of an RNase H 
mutant virus. A 1999 study identified the P236L mutation in the RNase H domain of RT 
in inhibiting RNase H activity in HIV-1 particles (79). However, one must determine 
whether defective RNase H activity negatively impacts RTC trafficking. 
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CHAPTER VII: DISCUSSION 
7.1 Summary of results 
The results from this thesis implicate E99, a glutamate residue located in the C-
terminal helix of the HIV-1 MA protein, in Env incorporation during particle assembly as 
well as early post-entry steps. I demonstrated that virus particles bearing a substitution of 
this glutamate by either a valine (E99V) or lysine (E99K) are devoid of Env proteins and 
unable to fuse with target cell membranes. More conservative substitutions of this 
residue, such as aspartate, glycine or alanine (E99D, E99G or E99A) do not confer any 
substantial changes in Env incorporation or infectivity. Comparing the extent of 
infectivity defects in particles bearing the E99V or E99K substitutions to previously 
published MA mutants L13E, L21K or K32E, suggested that residue E99 plays a more 
important role in virus infection. I used a genetic approach to identify a second-site 
mutation in MA, T84V, which successfully rescued the Env incorporation, fusion, and 
infectivity impairments associated with the E99V or E99K substitutions. However, the 
degree to which a valine at position 84 rescued mutations at position 99 depended on the 
particular residue that replace E99 and the particular virus strain in which it was 
expressed. I also utilized a MA-independent method to facilitate the incorporation of 
various envelope proteins into virus particles that contained the E99V or E99K MA 
mutations. Although one approach, truncation of the HIV-1 gp41 protein, successfully 
restored virus-cell fusion at the cell’s plasma membrane, it was not sufficient to reverse 
the infectivity defects incurred by the E99V or E99K MA mutations. A lack of viral DNA 
in these cells indicated that HIV-1 cores were unable to initiate reverse transcription after 
  
166 
entry. Interestingly, pseudotyping E99V- or E99K- containing particles with VSV-G, 
which mediates virus-cell fusion events by a pH-dependent endosomal route, was able to 
partially rescue the reverse transcription and infectivity impairments. Therefore, in 
addition to mediating Env incorporation during nascent HIV particle assembly, MA 
residue E99 is also critical in early, post-entry functions of the protein. Finally, I 
addressed the lack of methods available for analyzing early events of the retroviral life 
cycle. Specifically, I developed a novel technique for distinguishing between aberrant 
and successful trafficking of reverse transcription complexes (RTCs) after entry. 
7.2 Potential mechanism for E99 in Env incorporation 
The mechanism for HIV-1 Env incorporation into nascent particle assembly has 
not yet been fully defined. However, it remains clear that the MA domain of Gag 
somehow mediates this process, which is required for the production of infectious HIV-1 
particles. It has been hypothesized that MA might somehow accommodate packaging of 
the lengthy C-terminal tail of gp41 into particles. Previous reports have identified specific 
residues in the N-terminal portion of MA that are required for this process, however 
deletion studies suggest that additional regions outside of the MA N-terminal domain are 
also utilized in Env incorporation (43, 52, 53, 69, 116, 118, 141, 142, 162, 200, 214). To 
my knowledge, this thesis is the first study to identify a specific residue in the C-terminal 
helix of MA required for nascent particles to acquire Env glycoproteins. I considered 
both direct and indirect mechanisms by which the E99V or E99K MA mutations might 
confer a defect in Env incorporation.  
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First, residue 99 may directly contribute to Env incorporation via a specific 
interaction with viral glycoproteins. The glutamate residue typically at this MA position 
may be critical for MA-Env binding, and a non-conservative valine or lysine substitution 
could therefore abolish an association between the two proteins. X-ray crystallographic 
studies of HIV-1 and SIV MA structures suggest that MA trimers may form a hexameric 
lattice with an arrangement of spaces large enough to accommodate the cytoplasmic tails 
of gp41 trimers (4, 93, 165). While the precise residues that make up the putative MA- 
Env binding site have yet to be defined, it has been suggested that any solvent-exposed 
amino acids are candidates (93). Indeed, antibody mapping studies suggested that E99 is 
present at the surface of MA molecules, and therefore it may be available as a potential 
binding site for the C-terminal tail of gp41 (124, 157). Alternatively, this residue may 
directly interact with cellular or other viral proteins that are essential for stabilizing 
Gag:Env complexes. For example, the human protein TIP47 has been reported as a 
cellular cofactor required for Env incorporation during HIV-1 assembly, as it interacts 
with both Gag and gp41, and its expression is necessary for Env packaging into particles 
(116). It was speculated that TIP47 might interact with Env inside endosomes during its 
retrograde transport from the PM, and that a TIP47-MA interaction might redirect Env 
from this endosome to the Golgi pathway back to the PM (116). Although this study 
identified MA residues L12, W15 and E16 as binding sites for TIP47, the authors noted 
that additional sites on MA may also be involved in TIP47 binding. Gag has also been 
implicated in facilitating viral particle budding through the recruitment of the host cell’s 
ESCRT machinery, and so host proteins within this complex could also be considered as 
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factors that might interact with MA E99 (99). Finally, recent siRNA screens have 
implicated new cellular proteins in HIV-1 particle assembly, and these studies may 
provide other candidate factors for mediating or stabilizing an interaction between MA 
and Env (18, 108).  
It is also possible that residue 99 is indirectly providing support for the structure 
of MA that is required for Env incorporation. For example, certain E99 mutations could 
result in local or global misfolding of MA, preventing the formation of a functional 
domain required for Env packaging into HIV-1 particles. E99 is located in close 
proximity to a C-terminal hydrophobic pocket in MA, created by the N-terminus of Helix 
V packing alongside Helix IV (30, 93). It has been suggested that mutation of particular 
residues within this pocket, particularly V84, Y86, I92, V94, A100, and K103, might 
compromise the overall structure of the MA core domain (30). While it is unlikely that 
E99 contributes to the hydrophobicity of this pocket, it may be necessary to stabilize the 
region. Since I demonstrated that a valine at MA position 84 (V84) rescued the E99V- 
and E99K-associated Env incorporation defects, I propose that V84 stabilizes the 
hydrophobic pocket, such that it prevents or mitigates any structural distortions made by 
a valine or lysine at position 99.  
7.3 Potential mechanisms for E99 in membrane dissociation of MA 
My results demonstrated that in addition to conferring an Env incorporation 
defect, the E99V and E99K mutations also imposed a post-fusion impairment, 
specifically at a step prior to reverse transcription. Previous studies have shown that the 
glutamate at position 99 is located in a region of MA that likely associates with the PM 
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(93, 124, 174). Despite the physical proximity, the hydrophilic nature and negative 
charge of this amino acid suggests that E99 is not involved in a direct association with the 
PM. Although certain residues at this membrane-proximal side of the C-terminal MA 
helix may associate with the cellular membrane- such as K95, T97 and K98- it has been 
proposed that this region exerts an overall negative effect on membrane binding (150). 
The hydrophilic and basic properties of glutamate, together with the vital role for position 
99 in MA function demonstrated in these studies, suggest that E99 might be involved in 
antagonizing the membrane association of MA.  
The many functions of HIV-1 MA require it to have both a high affinity for the 
plasma membrane, but also the ability to dissociate from it. The strong membrane 
binding properties of MA have been well established, and are attributed to the attachment 
of a myristate moiety and the clustering of basic residues at the surface of the protein’s 
globular core. On the other hand, particular MA residues that are involved in detachment 
from the PM have not been well characterized. Dissociation from the membrane during 
early entry events is critical for MA association with the viral core, as well as its potential 
roles in uncoating, reverse transcription, nuclear localization and integration. Failure to 
detach from the PM, while binding to the viral core, would cause MA to tether the 
complex to the membrane and prevent proper trafficking required for productive 
infection. 
The ability of MA to reduce its affinity for the PM has been related to possible 
sequestration of the myristoyl group inside the hydrophobic core of MA (90, 191, 206, 
217). Consistent with this hypothesis is the observation that MA monomers that associate 
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with the viral core seem to adopt a “tense” conformation (191, 206, 217). The 
concealment of the hydrophobic moiety may then allow exposure of basic residues on the 
outside of MA that account for its karyophilicity (217). Such a scenario suggests that 
residues within MA that are involved in sequestering the myristate group are critical for 
membrane dissociation. I hypothesize that E99 is critical in facilitating the membrane 
dissociation of MA monomers during early events in HIV infection. This residue could 
promote the sequestration of myristate, which may lead to a reduced membrane binding, 
as detailed above. Alternatively, E99 could act prior to the myristoyl switch, initiating 
membrane detachment through a different mechanism altogether.  
Considering both possibilities, my initial analysis of the E99V and E99K 
mutations indicated that either a large hydrophobic or a basic residue at MA position 99 
was sufficient to cause the post-fusion defects. However, I also found that the phenotype 
caused by the E99K MA substitution was more severe than that of the E99V mutant. For 
example, the T84V secondary mutation compensated for the Env incorporation, fusion 
and infectivity defects of the E99V mutation to a greater extent than those of the E99K 
substitution. Similarly, facilitating MA-independent fusion was consistently more 
effective in restoring the replication defect of E99V than that of E99K. Somewhat 
surprising was my finding that several other amino acids could be tolerated at position 
99, despite the high conservation of a glutamate at this position in primary HIV isolates. 
Specifically, I found that virus containing the E99A substitution demonstrated 
comparable levels of infection as the wild-type virus, despite the uncharged, hydrophobic 
nature of alanine. I reasoned that the difference between an alanine substitution at 
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position 99 and a valine substitution is that the former is considerably smaller than the 
latter, which could potentially minimize negative effects on viral infection. Regardless, 
position 99 appears to tolerate neutral and hydrophobic substitutions while disallowing 
the likes of lysine. As positively charged amino acids such as lysine enable interaction 
with membrane phospholipids, I hypothesize that E99 is more important for destabilizing 
the membrane affinity of MA than for mediating the myristoyl switch. 
7.4 Future Studies 
This thesis identified a single conserved residue in the MA protein of HIV that is 
multifunctional, and utilized at both early and late stages of the viral life cycle. Several 
mechanisms through which this residue might act are proposed here, and my results 
suggest that the reduced infectivity of viruses bearing the E99V or E99K MA mutations 
are due to the cumulative effects of several disrupted MA functions. Further functional 
and structural analyses of this residue and others in the MA C-terminal helix are 
necessary to more fully understand the pleiotropic roles of this region in MA.  
In my experiments, I observed that E99V-associated Env incorporation and 
infectivity defects were evident in the NL4.3 strain, even in the presence of a valine at 
MA position 84. Since a valine at this position was sufficient to completely rescue the 
E99V phenotype in LAI, these results may reflect an additional amino acid difference 
between LAI-MA and NL4.3-MA. I identified other non-conservative differences 
between the two strains at MA positions 28, 124 and 125. In addition to residues 84 and 
99, these amino acids could also be critical for stabilizing a structure in MA that is 
required for the protein to facilitate Env incorporation during assembly, or influence its 
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membrane affinity. Additionally, sequence differences within the second α-helix of the 
NL4.3 and LAI gp41 C-terminal tails may be important, as this particular region has been 
implicated in an interaction with MA (141).  
To further characterize a role for E99 in Env incorporation, one could analyze the 
stability and persistence of gp41 or gp120 at the surface of LAI-E99V or LAI-E99K 
producing cells by labeling cells with specific antibodies and monitor surface expression 
of Env with FACS. A previous study demonstrated that certain MA residues could affect 
the non-covalent association of gp120 and gp41 on the surface of particles, possibly by 
changing the structure of the gp41 ectodomain (43). Another method to analyze E99 in 
Env packaging is to examine the ability of Gag to associate with lipid rafts of virus 
producing cells. Previous studies have shown that the association of Gag with lipid 
microdomains is important for Env incorporation during virus assembly (15, 50, 60). Gag 
association with detergent resistant membrane domains can be analyzed using membrane 
flotation assays, as described in a 2003 study by Feng, et. al (60). In this technique, 
cytoplasmic lysates are obtained from cells transfected with mutant proviral clones, and 
treated with or without detergent. The lysates are then separated through sucrose 
gradients, and the association of Gag with lipid rafts can be determined by Western 
blotting fractions of the gradient (14, 60).   
 My data suggested that the E99V or E99K substitutions might alter the overall 
structure of MA. To investigate this possibility, one might compare changes in the 3D 
solution structure of recombinant mutant MA proteins to that of the wild-type MA 
  
173 
protein. Major or slight shifts detected by NMR spectroscopy, or X-ray crystallography 
could help identify changes in biochemical properties or structure. 
Finally, to further characterize the post-entry defect conferred by E99 mutations, 
one could use a previously published method that has potential for monitoring virus 
uncoating, which is thought to precede the reverse transcription step (187). This 
technique involves pelleting particulate capsid proteins from newly infected cells through 
a sucrose gradient. By removing the middle sucrose layer, one can separate out capsid 
found within endosomes and lysosomes. The top layer and the resulting pellet can then be 
analyzed by Western blot to measure the relative levels of soluble and particulate capsid 
molecules, respectively.  This technique could be performed on cells infected with HIV 
bearing a gp41 CT truncation, and either a wild type- or E99V/K-containing- MA coding 
region. Comparing differences in the fates of capsid between these viruses could reflect 
accelerated or restricted uncoating of the viral core, and would support the potential role 
of MA E99 in the viral core uncoating process. 
7.5 Implications for the development of a novel anti-HIV therapeutic  
Today, there are no approved drugs that target Gag or any aspect of the virus 
assembly pathway. However, small molecule compounds targeting the putative MA 
nuclear localization signal are currently being developed to inhibit HIV-1 nuclear import 
(87). While the importance of its nuclear localization function has been disputed (48, 63, 
120, 209), the Env incorporation or other post-entry functions of MA could represent 
another class of anti-MA targets. Considering the results of this study, drugs that mimic 
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the defects conferred by the E99V or E99K MA mutations would likely display 
significant antiviral activity.  
In addition to small molecule inhibitors, gene therapy is another approach to 
designing novel antiviral agents. For example, dominant negative forms of an HIV 
protein or cellular cofactor expressed in a lentiviral vector may be effective in hindering 
HIV replication. An attractive feature of such an approach is that the introduction of 
multiple mutations would limit the emergence of resistance, and their co-expression may 
have cumulative effects on their potency (61, 97). Indeed, the oligomeric property of Gag 
makes it a promising candidate for use in a gene therapy vector, and certain amino acid 
substitutions in MA and CA have already been shown to act in a dominant negative 
fashion by inhibiting production of wild type virus (34, 102, 139, 179, 195). Although it 
is currently unknown whether the E99V or E99K MA substitutions act in a dominant 
negative fashion, a 1998 study demonstrated that viral replication can proceed in the 
absence of MA (168). Since virus replication can proceed in the absence of MA, and I 
show here that mutation of a single amino acid in MA can inhibit replication, the E99V 
or E99K MA mutations may have the potential to act in a dominant negative fashion.  
7.6 Conclusions 
Great strides have been made in the management of HIV disease since the first 
cases were reported thirty years ago. Yet, current estimates report that there are still about 
34 million people living with HIV worldwide. Unfortunately, the majority of these 
individuals do not have access to existing treatments. On the other hand, many of those 
who do receive antiviral therapy must endure the debilitating side effects of treatment. In 
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addition, poor adherence to strict treatment schedules combined with the rapidly mutating 
nature of the virus has led to the emergence of drug resistant strains. Thus, the 
development of better anti-retroviral drugs, ones with fewer side effects and that use 
novel mechanisms of action, is critical in the ongoing fight against HIV. 
The studies in this thesis demonstrate that a highly conserved glutamate residue at 
position 99 in HIV-1 MA is essential for both early and late steps in the virus life cycle. 
Although the precise mechanisms by which this residue carries out these pleiotropic 
functions are unknown, future studies will lead to a greater understanding of MA-
dependent processes that are required for productive HIV infection. Most important, this 
critical residue in the viral MA protein may prove to be an effective drug target, and its 
identification, presented here, could bring the world one step closer to a cure.
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APPENDIX A: a-MLV Pseudotyping Studies 
In addition to the VSV-G pseudotyping studies (presented in Chapter 5 section 
5.2.2), the effects of pseudotyping mutant particles with the envelope from amphotropic 
Murine Leukemia Virus (a-MLV env) were also evaluated. Similar to VSV-G, the 
transmembrane protein of a-MLV env has a short cytoplasmic domain, and thus it is 
easily incorporated into HIV particles (119). Also, a-MLV env utilizes a common 
receptor for entry into cells, which confers broad tropism to particles that acquire it (128). 
In contrast to VSV-G, a-MLV env facilitates virus-cell fusion at the PM through a pH 
independent mechanism (128). This mode of virus entry deposits the viral core into the 
cytoplasm at the periphery of the cell. Thus a-MLV pseudotyped HIV-1 particles remain 
vulnerable to restrictions in the cytoplasm that may have been bypassed by endosomal 
fusion.  
To produce a-MLV pseudotyped virus, the pLAI-∆Env, pE99V-∆Env, pE99K-
∆Env, pK32E-∆Env and pL13E-∆Env proviral clones were co-transfected into 293T cells 
with an expression vector encoding the amphotropic Murine Leukemia Virus strain 4070 
A glycoprotein (a-MLV). Virus was harvested 24 and 48 hours post-transfection, and 
then normalized by RT content. To determine whether the a-MLV-pseudotyped viruses 
were competent for a single round of infection, 2-fold serial dilutions of virus were 
incubated with TZM-bl cells and analyzed 24 hours post-infection with the Beta-Glo 
assay system. In parallel, similar infections were also performed using viruses with wild-
type HIV-1 Env. Non-pseudotyped LAI-∆Env particles were used as a negative control.  
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I found that the a-MLV-pseudotyped particles with wild-type MA (a-MLV-LAI-
∆Env) were markedly less infectious than equivalent RT units of LAI-WT. However, 
considerable infection levels in TZM-bl cells by a-MLV-LAI-∆Env virus were observed 
in comparison to the non-pseudotyped LAI-∆Env control. The raw data from these 
infections, presented in Table B.4, indicate that a-MLV-LAI-∆Env particles were 
generated and infectious. The RLU values from each infection were normalized using the 
a-MLV-LAI-∆Env values at the corresponding titer to represent 100% infectivity. These 
normalized values are presented in Table A.1. This data demonstrates that pseudotyping 
with a-MLV env augmented the infections of virus with each MA mutation. However, 
the degree of enhancement varied depending on the MA mutation. Overall, a-MLV env 
was able to rescue infectivities of viruses bearing the L13E and K32E MA mutations. In 
contrast, this heterologous envelope could not substantially rescue infectivities of viruses 
containing either E99V or E99K MA mutations. The raw data suggests that a-MLV-LAI-
∆Env was saturating at higher titers, as the values at 80K and 40K were very similar. 
Therefore, I suspect that the infectivity data observed for a-MLV-E99V-∆Env or a-MLV-
E99K-∆Env at these viral inputs may not represent accurate improvements. Even at these 
high titers, a-MLV pseudotyping only improved the infectivity defects imposed by the 
E99V or E99K MA substitutions from less than 2%, to 18% or 11% of particles 
containing wild-type MA, respectively.  
Because a-MLV-WT-∆Env was markedly less infectious than equal RT units of 
WT-LAI, I decided to compare infections between viral titers that generated similar raw 
values, as was done earlier. Shown in Figure A.1, normalized values of virus with WT 
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HIV-1 Env at 5K RTU per well were compared to infections with a-MLV pseudotyped 
particles at 40K RTU per well. Again, I found that the infectivity defects imposed by the 
L13E or K32E MA mutations were rescued by a-MLV pseudotyping, while the a-MLV-
E99V-∆Env and a-MLV-E99K-∆Env viruses were markedly impaired for single-cycle 
infection. This data suggested that a-MLV pseudotyping was not able to significantly 
rescue the infectivity defects imposed by MA substitutions E99V or E99K.  
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Table A.1 Relative infectivities of LAI-derived MA mutants pseudotyped 
with a-MLV Env.
The data shown are normalized values from the raw RLU values from Table 8-5, 
which presented averages from four independent Beta-­‐Glo infectivity assays 
analyzed 24 hours after TZM-bl cells were infected with individual LAI-derived 
viruses (as indicated in the left column) at four serial dilutions (indicated in the 
top row as RT units of virus per well). The normalized values are based on the 
level of a-MLV-LAI-∆Env, which represents 100% infectivity at each dilution.  
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Figure A.1 Single-cycle infectivities of LAI-derived MA mutants containing 
WT HIV-1 Env or pseudotyped with a-MLV Env. Infectivity was monitored 
24 hours post-infection using the Beta-Glo reporter assay, as described in 
Figure 3.4. The assessment of infectivity for each mutant virus is based on the 
level of LAI-WT (blue bars, inoculated at 5 RTU/well) or a-MLV-LAI-∆Env 
(red bars, inoculated at 40 RTU/well), which represents 100% infectivity. 
Pseudotyped virus was generated by co-transfection of a pLAI-based Env 
deficient proviral clone and an expression plasmid encoding the a-MLV 
heterologous envelopes. Data is the average of four independent experiments 
performed in duplicate.  
 
  
211 
Next, I sought to determine whether a-MLV-env pseudotyped particles with the 
position 99 substitutions could fuse with TZM-bl cells. Proviral clones pLAI-∆Env, 
pE99V-∆Env, pE99K-∆Env, pK32E-∆Env or pL13E-∆Env were cotransfected into 293T 
cells with the BLaM-Vpr expression construct and the a-MLV env vector, as described in 
Materials and Methods (Chapter 2, section 2.4). At 24 hours and 48 hours after the 
transfection, virus-containing supernatants were harvested and normalized by RT content. 
Unfortunately, the production of a-MLV pseudotyped particles in the presence of the 
BLaM-Vpr chimeric proteins was inefficient. This was evidenced by the RT contents of 
a-MLV-LAI-∆Env transfected cell supernatants, which were consistently lower than 
those generated in parallel transfections by LAI-WT or VSV-G pseudotyped particles 
(data not shown).  
Equal RT units of each virus were used to infect TZM-bl cells, and virus-cell 
fusion was monitored as described previously for Figure 3.7. Since high titers of virus 
were required to detect BLaM activity in cells challenged with virus, BLaM activity in 
cells challenged with a-MLV-LAI-∆Env could only be observed at levels above 
background when the virus was concentrated by centrifugation through a sucrose 
cushion. Interestingly, the Beta-Glo assay was able to detect significant infectivity with 
equivalent titers of the a-MLV-LAI-∆Env (BLaM) virus, demonstrating the differences in 
sensitivity between the two assay systems. Figure A.2 shows results from the fusion 
assay, using the concentrated a-MLV pseudotyped particles. I was able to detect BLaM 
activity in cells challenged with a-MLV-LAI-∆Env, a-MLV-L13E-∆Env and a-MLV-
K32E-∆Env, confirming the infectivity results suggesting a rescue. However, the fusion 
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capacities of a-MLV-E99V-∆Env or a-MLV-E99K-∆Env particles were only slightly 
better than LAI-∆Env particles, my negative control.  
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Figure A.2 Effects of a-MLV pseudotyping on virus-cell membrane fusion 
capacity in LAI-derived viruses bearing MA substitutions. Fusion events of a-
MLV Env-pseudotyped particles were assayed in TZM-bl cells as described in 
Figure 3.7. The data shown is representative of three independent experiments 
performed in duplicate.  
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Next I wanted to determine whether the E99V and E99K MA mutations disrupted 
a-MLV Env expression in producer cells, or incorporation into particles. Virus particles 
were generated in HeLa cells through co-transfecting the a-MLV expression vector and 
the pLAI-∆Env, pE99V-∆Env, pE99K-∆Env, pK32E-∆Env or pL13E-∆Env proviral 
clones. As before, virus was harvested 24 and 48 hours post-transfection, and then 
normalized by RT content. Transfected HeLa cells were also harvested. I attempted to 
performed immunoblot analysis on particles made from transfected HeLa cells, as well as 
the cell lysates, using the 83A25 monoclonal antibody, kindly provided by Leonard 
Evans. However, I was unable to detect a-MLV env in any particles or cells, even in 
particles that demonstrated significant infectivity. These results suggest that the antibody 
did not efficiently recognize the protein. Therefore, I was unable to determine whether 
low fusion and infectivities of the a-MLV-env pseudotyped virus bearing the E99V or 
E99K MA mutations was a result of inefficient incorporation of a-MLV env into these 
particles or a specific fusion defect imposed by the E99V or E99K MA mutations. 
Although I could not determine the efficiency of a-MLV-env incorporation into 
particles, I did examine reverse transcription products in cells challenged with a-MLV-
E99V-∆Env. Proviral clones pLAI-∆Env and pE99V-∆Env were individually transfected 
into 293T cells with expression vectors encoding a-MLV. In parallel, the pLAI-WT, 
pLAI-E99V and pLAI-∆Env proviral clones were also transfected. Virus-containing 
supernatants were harvested 24 and 48 hours post-transfection, and normalized by RT 
content. Equal amounts of each virus were treated with DNase to eliminate possible 
contamination from transfected DNA. The DNase treated a-MLV pseudotyped virus was 
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used to infect MAGI cells. At the indicated time points, cells were harvested, and total 
DNA was extracted. Specific primers were used to quantify EPs and then the data was 
normalized by CCR5 copy number. The data was analyzed to determine the copies of EP 
per million cells, and is shown in Figures A.3.  
Significant levels of EPs in MAGI cells infected with LAI-WT or a-MLV-LAI-
∆Env were detected, and these quantities increased over time. By contrast, only minimal 
quantities of EPs were detectable in cells challenged with LAI-∆Env. Similarly, EPs 
detected in the MAGI cultures challenged with LAI-E99V or a-MLV-E99V-∆Env were 
only at levels just above background. With this data, I remain unable to conclude whether 
the E99V-∆Env particles were generated, or whether they could successfully fuse with 
target cells.  
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Figure A.3 Analysis of early products in cells infected with pseudotyped 
HIV-1 MA mutants. MAGI cells were infected with equal RT units of LAI-
derived MA mutants containing WT HIV-1 Env, or pseudotyped with a-MLV. At 
the specified times post-infection, cells were lysed and EPs were directly 
quantified by real-time PCR, using primers specific for strong-stop viral DNA. 
Data was normalized by quantification of the cellular CCR5 gene in each sample. 
Data shown are the mean of two separate experiments performed in duplicate.  
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APPENDIX B: Single-Cycle Infectivity Data  
 
Table B.1 Relative Luciferase Units from TZM-bl cell infections with LAI-
derived viruses bearing single amino substitutions in MA
TZM-bl cells were infected with the indicated LAI-derived virus at four serial 
dilutions. Data shown are the average relative luciferase units (RLU) of four 
independent Beta-­‐Glo infectivity assays performed in duplicate and analyzed 
with a luminometer 24 hours post-infection.  
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Table B.2 Relative Luciferase Units from TZM-bl cell infections with LAI-
derived double mutants bearing gp41 cytoplasmic domain truncation and 
individual substitutions in MA 
 
TZM-bl cells were infected with the indicated LAI-derived viruses at four serial 
dilutions. Data shown are the average relative luciferase units (RLU) of four 
independent Beta-­‐Glo infectivity assays performed in duplicate and analyzed 
with a luminometer 24 hours post-infection. 
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Table B.3 Relative Luciferase Units from TZM-bl cell infections with LAI-
derived MA mutants pseudotyped with VSV-G 
 
TZM-bl cells were infected with the indicated LAI-derived viruses at eight serial 
dilutions. Data shown are the average relative luciferase units (RLU) of four 
independent Beta-­‐Glo infectivity assays performed in duplicate and analyzed 
with a luminometer 24 hours post-infection.   
 
  
220 
Table B.4 Relative Luciferase Units from TZM-bl cell infections with LAI-
derived MA mutants pseudotyped with a-MLV env 
 
TZM-bl cells were infected with the indicated LAI-derived viruses at four serial 
dilutions. Data shown are the average relative luciferase units (RLU) of four 
independent Beta-­‐Glo infectivity assays performed in duplicate and analyzed 
with a luminometer 24 hours post-infection.  
